CA2742954A1 - Aminoalcohol lipidoids and uses thereof - Google Patents

Aminoalcohol lipidoids and uses thereof Download PDF

Info

Publication number
CA2742954A1
CA2742954A1 CA2742954A CA2742954A CA2742954A1 CA 2742954 A1 CA2742954 A1 CA 2742954A1 CA 2742954 A CA2742954 A CA 2742954A CA 2742954 A CA2742954 A CA 2742954A CA 2742954 A1 CA2742954 A1 CA 2742954A1
Authority
CA
Canada
Prior art keywords
compound
unsubstituted
substituted
unbranched
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2742954A
Other languages
French (fr)
Other versions
CA2742954C (en
Inventor
Kerry Peter Mahon
Kevin Thomas Love
Christopher G. Levins
Kathryn Ann Whitehead
Robert S. Langer
Daniel Griffith Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to CA3006395A priority Critical patent/CA3006395C/en
Publication of CA2742954A1 publication Critical patent/CA2742954A1/en
Application granted granted Critical
Publication of CA2742954C publication Critical patent/CA2742954C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/42—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having etherified hydroxy groups and at least two amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/14—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0238—Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
    • B01J2531/0241—Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
    • B01J2531/0252—Salen ligands or analogues, e.g. derived from ethylenediamine and salicylaldehyde
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84—Metals of the iron group
    • B01J2531/845—Cobalt
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Provided are: a pH-sensitive carrier for a physiologically active substance, which can respond to a weakly acidic environment to promote a membrane-disrupting function; a method for producing the carrier; a pH-sensitive medicine and a pH-sensitive pharmaceutical composition, each containing the carrier; and a corresponding culture method. A pH-sensitive carrier which can exhibit an effect of promoting a membrane-disrupting function, comprising: at least one pH-sensitive compound selected from the group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, a higher bile acid, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof; and at least one amphipathic substance selected from the group consisting of a phosphatidylcholine having 10 to 12 carbon atoms, a polyoxyethylene sorbitan mono-fatty acid ester having 12 to 18 carbon atoms, a sorbitan fatty acid ester having 16 to 18 carbon atoms, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol d'oleate, polyoxyethylene castor oil and u-tocopherol.

Description

2 PCT/US2009/006018 AMINOALCOHOL LIPIDOIDS AND USES THEREOF

RELATED APPLICATIONS
[0001] The present application claims priority under 35 U.S.C. 119(e) to U.S.
provisional applications, USSN 61/112,414, filed November 7, 2008, and USSN
61/166,518, filed April 3, 2009; each of which is incorporated herein by reference.

GOVERNMENT SUPPORT
[0002] This invention was made with U.S. Government support under grant numbers 2-R37-EB000244-29, 5-U54-CA119349-03, and 5-R01-EB000244-27, awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.

BACKGROUND OF THE INVENTION
[0003] Despite promise in the laboratory, the potential of genetic therapies for the treatment of disease has yet to be realized. Initial attempts to translate genetic materials into cures led to cancer and, in some cases, death to patients involved in the clinical trials. Such deleterious outcomes were attributed not to the genetic material, but to the viral delivery systems utilized in these trials. As a result, there has been intense interest in developing synthetic materials that have the delivery efficiencies of viral vectors but circumvent the mutagenesis that led to the observed side effects (e.g., cancer).
[0004] Synthetic materials, or nonviral delivery vectors, come in a variety of forms that work in unique ways. Polymeric materials such as polyethylenimine or poly(beta-amino ester)s have been shown to efficiently complex DNA for delivery into the cell.
Polymers in these classes of delivery agents typically contain amine functionalities that serve to electrostatically bind to DNA to form nanoparticles that are then taken up by the cell via endocytosis. Once in the cell, these amine groups serve to buffer the endosome and cause an influx of ions due to the proton-sponge mechanism. The resulting burst of the endocytic vesicle leads to the release of the payload of the particle, which is then free to travel to the nucleus where the DNA is expressed.
[0005] While the mechanism of RNA-based therapies is different, the objective of the delivery system remains the same. The RNA must be complexed and internalized by the cell in order to exhibit activity. In many cases, polymeric materials do not work as efficiently for RNA
delivery. This is likely due to the difference in chemical structure of the therapeutic RNA being delivered, which are generally short, linear fragments containing additional hydroxyl moieties on each ribose ring. These differences necessitate an alternative nonviral approach that is suited for complexation with short RNA strands. Promising results have been achieved with materials that form liposomes or lipoplexes that entrap the RNA or form nanoparticles, which are efficiently internalized by the cell.
[00061 The materials utilized to form a lipid-based delivery system generally consist of a positively charged headgroup and a hydrophobic tail. The charged portion serves to electrostatically bind the negatively charged RNA, while the hydrophobic tail leads to self-assembly into lipophilic particles. Such cationic lipids are promising but still fall short of the transfection efficiency achieved by viral vectors.
[0007) Few advances have been made in the field, in part due to the limited structural diversity of these lipid-like molecules, which is a result of the difficult synthetic procedures required to access these structures. Therefore, in order to push the area of nonviral lipid particle delivery systems forward, it is necessary to investigate chemical transformations that can lead to diverse molecules capable of complexing RNA and shuttling the material across the cell membrane. The most successful approach to date has been the contribution by Anderson and coworkers, who generated a library of lipid-like materials using straightforward simple chemical transformations. This set of materials was based on the well-known and efficient reaction known as the Michael addition of an amine to an acrylamide or acrylate to yield a beta-amino amide or a beta-amino ester, respectively. These structures consist of an amine core linked to long, hydrophobic alkyl chains. Starting with a set of amines and Michael acceptors, the team generated over 1000 compounds that were tested for their ability to complex and deliver RNA in a high throughput assay. This screen led to the identification of a number of lead compounds that were more efficient in vitro than the current industry standard, Lipofectamine 2000, and are currently being tested in vivo for potential use in therapeutic applications (Akinc et al., Nat.
Biotech. 2008, (26) 561).

[0008] There exists a continuing need for a new set of lipid-like molecules that feature similar properties to the existing amine-containing lipidoid materials, but accessed through an entirely different chemical reaction and having the ability to deliver RNA as well as other nucleic acids and other diagnostic, therapeutic, and prophylactic agents to cells.

SUMMARY OF THE INVENTION
[0009] The present invention originates from the discovery that aminoalcohol lipidoid compounds for drug delivery may be prepared by reacting an amine with a terminal epoxide or an aldehyde.

R-NH2 + yR HO(R1 + HN(OH
HN,R R Ri R-NH2 + O HO(Rt HN,-~OH
R1 HN.R + R Rt R-NH2 + L~ HOR1 + HN(OH
Rt H N, R R Rt 0 OPG 1. (mine formation 2. Reduction OH
R-NH2 + HN~
3. Deprotection I
H R, R Rt The inventive lipidoid compounds are particularly useful in the administration of polynucleotides. The aminoalcohol lipidoid compounds of the present invention are amenable to combinatorial synthesis and screening to generate libraries of compounds for use as nonviral drug delivery agents. The inventive compounds may be used for other purposes as well such as, for example, coatings, additives, excipients.
[0010] In one aspect, the present invention provides novel aminoalcohol lipidoid compounds of the formulae:

R1 R2 R, R3 -ly HO Rc HO R~ /RC R2 N-A---N HO,-tyR1 R3~OH
N-A-N\ X RD /N ^^AwNN

Ri R3 R, R3 HO R1 R3 OH HO I R1 OH p R2 N.^^^^^A.,,~õ^,N R4 N-As^^^^N R3 RA -N N RF
RD

R2 OH R4 OH m and RA
I
RAC N
RA
x Y
I
RA
[0011] These aminoalcohol lipidoid compounds may be prepared by reacting an amine with an epoxide-terminated compound. In certain embodiments, the epoxide is stereochemically pure (e.g., enantiomerically pure). In certain embodiments, the amine is stereochemically pure (e.g., enantiomerically pure). In certain embodiments, the lipidoid is prepared from the reductive amination of an imine which is derived from the condensation of an amine and an aldehyde. In R~
R, R, certain embodiments, each HO ' is independently HO or HO c . In certain R, R1 R, embodiments, each is independently or ^^^" . In certain embodiments, R2 R2 R2 each HO is independently HO or HO . In certain embodiments, each is A N N-independently or In certain embodiments, each HO is independently N
HOB or HO In certain embodiments, each ^^^^ is independently or A N
n "^ ^ In certain embodiments, each HO ' is independently HO or HO~ . In A N N N
certain embodiments, and each 4" is independently or . In certain embodiments, an amine and an epoxide-terminated compound are reacted at elevated temperatures in the absence of solvent to prepare the inventive aminoalcohol lipidoids as shown in Figure 1. In certain embodiments, the aminoalcohol lipidoid compounds include a hydrophilic portion resulting from the opening of the epoxide by the amine and a hydrophobic aliphatic tail.
[0012] Typically, the amines chosen contain between two and five amine moieties and the epoxide-terminated compounds include a tail of varying chain lengths and optionally feature various functional groups and varying degrees of saturation. The inventive aminoalcohol lipidoid compounds may be used in the delivery of therapeutic agents (e.g., polynucleotide, small molecule, protein, peptide) to a subject. The inventive aminoalcohol lipidoid compounds are particularly useful in delivering negatively charged agents given the tertiary amines available for protonation thus forming a cationic moiety. For example, the aminoalcohol lipidoid compounds may be used to delivery DNA, RNA, or other polynucleotides to a subject or to a cell. As would be appreciated by one of skill in the art, the above reaction may result in a mixture with lipidoid compounds having one tail, some having two tails, some having three tails, and yet others having four or more tails. Also, two different epoxide compounds may be used in the reaction mixture to prepare an aminoalcohol lipidoid compound with two different tails.
[0013] In another aspect, novel aminoalcohol lipidoid compounds for drug delivery may be prepared by reacting a polyamine with a terminal epoxide.

O~R, + RZ,N-R3N-R4 D RA N"R3N"R4 or RA N"R3N"R2 [N-1]epoxide N=a+2b equivalents a = # secondary amines in starting material b = # primary amines in starting material wherein, R1 represents alkyl chains of varying lengths, while R2 through R4 generally represent various combinations of alkyl chains, polyamines, and hydrogen atoms.
Reactions are set up by adding [N - I] equivalents of epoxide to polyamine (where N is the number of 2 amines plus 2 x number of 1 amines in the polyamine starting material). This generates a mixture enriched in compounds with [N - 1] tails. Typically, these compounds are a mixture of various constitutional isomers, are usually isolable by chromatography on silica gel; the identity and purity of the products may be confirmed through 1H/13C NMR spectroscopy and/or by MALDI-MS
(with 2,5-dihydroxybenzoic acid matrix). As described herein, the epoxide, the amine, or both the epoxide and the amine may be stereochemically pure.
[0014] These inventive lipidoid compounds are also particularly useful in the administration of polynucleotides. The aminoalcohol lipidoid compounds of the present invention are amenable to combinatorial synthesis and screening to generate libraries of compounds for use as nonviral drug delivery agents. The inventive compounds may be used for other purposes as well such as coatings, additives, materials, and excipients.
[0015] In one aspect, the present invention provides a novel aminoalcohol lipidoid compound of the formula:

as described herein. In another aspect, the present invention provides a novel aminoalcohol lipidoid compound of the formula:
RA
I
RAC N
N k""W RA
x Y
RA
as described herein.
[0016] In one aspect, the present invention provides novel aminoalcohol lipidoid compounds based upon reacting a polyamine with a suitable terminal epoxide as described herein. In certain embodiments, the polyamine is "amine 111" of the formula:
6/248 H
H2N'/-'NN'-/-'NNH2 H H
amine 111 . In certain embodiments, the polyamine is "amine 200" of H
the formula: amine 200 . In certain embodiments, the polyamine is H2N--\-NH

HN-\
N / NH
tL ~~ amine 205 amine 205" of the formula: . In certain embodiments, the H
Me'NNH2 polyamine is "amine 96" of the formula: amine 96 Materials based on amine 96 are generated through systematic variation around the amine 96 core structure (see Example 15, Part 2). Aminoalcohol lipidoid compounds based upon amine 111 resulted from performing MALDI-MS analyses on the products of the amine 111 and epoxide reaction (see Example 14, Part 1).
[0017] In one aspect of the invention, the inventive aminoalcohol lipidoid compounds are combined with an agent to be delivered to a cell or a subject to form microparticles, nanoparticles, liposomes, or micelles. The agent to be delivered by the particles, liposomes, or micelles may be in the form of a gas, liquid, or solid, and the agent may be a polynucleotide, protein, peptide, or small molecule. The inventive aminoalcohol lipidoid compounds may be combined with other aminoalcohol lipidoid compounds, polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, lipids, etc. to form the particles. These particles may then optionally be combined with a pharmaceutical excipient to form a pharmaceutical composition.
[0018] The invention also provides methods of preparing the inventive aminoalcohol lipidoid compounds. One or more equivalents of an amine are allowed to react with one or more equivalents of an epoxide-terminated compound under suitable conditions to form an aminoalcohol lipidoid compound of the present invention. In certain embodiments, all the amino groups of the amine are fully reacted with the epoxide-terminated compound to form tertiary amines. In other embodiments, all the amino groups of the amine are not fully reacted with the
7/248 epoxide-terminated compound to form tertiary amines thereby resulting in primary or secondary amines in the aminoalcohol lipidoid compound. These primary or secondary amines are left as is or may be reacted with another electrophile such as a different epoxide-terminated compound.
As will be appreciated by one skilled in the art, reacting an amine with less than excess of epoxide-terminated compound will result in a plurality of different aminoalcohol lipidoid compounds with various numbers of tails. Certain amines may be fully functionalized with two epoxide-derived compound tails while other molecules will not be completely functionalized with epoxide-derived compound tails. For example, a diamine or polyamine may include one, two, three, or four epoxide-derived compound tails off the various amino moieties of the molecule resulting in primary, secondary, and tertiary amines. In certain embodiments, all the amino groups are not fully functionalized. In certain embodiments, two of the same types of epoxide-terminated compounds are used. In other embodiments, two or more different epoxide-terminated compounds are used. The synthesis of the aminoalcohol lipidoid compounds is performed with or without solvent, and the synthesis may be performed at higher temperatures ranging from 30 C - 100 C, preferably at approximately 50 C - 90 C. The prepared aminoalcohol lipidoid compounds may be optionally purified. For example, the mixture of aminoalcohol lipidoid compounds may be purified to yield an aminoalcohol lipidoid compound with a particular number of epoxide-derived compound tails. Or the mixture may be purified to yield a particular stereo- or regioisomer. The aminoalcohol lipidoid compounds may also be alkylated using an alkyl halide (e.g., methyl iodide) or other alkylating agent, and/or they may be acylated.
[0019] The invention also provides libraries of aminoalcohol lipidoid compounds prepared by the inventive methods. These aminoalcohol lipidoid compounds may be prepared and/or screened using high-throughput techniques involving liquid handlers, robots, microtiter plates, computers, etc. In certain embodiments, the aminoalcohol lipidoid compounds are screened for their ability to transfect polynucleotides or other agents (e.g., proteins, peptides, small molecules) into the cell.

DEFINITIONS
[0020] Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance
8/248 with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75"' Ed., inside cover, and specific functional groups are generally defined as described therein.
Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito : 1999, the entire contents of which are incorporated herein by reference.
[0021] Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis-and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
[0022] Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are all contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
[0023] If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
[0024] The "enantiomeric excess" of a substance is a measure of how pure a desired enantiomer is relative to the undesired enantiomer. Enantiomeric excess is defined as the absolute difference between the mole fraction of each enantiomer which is most often expressed as a percent enantiomeric excess. For mixtures of diastereomers, there are analogous definitions and uses for "diastereomeric excess" and percent diastereomeric excess.
[0025] For example, a sample with 70% of R isomer and 30% of S will have an enantiomeric excess of 40%. This can also be thought of as a mixture of 40%
pure R with 60% of
9/248 a racemic mixture (which contributes 30% R and 30% S to the overall composition).
[0026] One of ordinary skill in the art will appreciate that the synthetic methods, as described herein, utilize a variety of protecting groups. By the term "protecting group," as used herein, it is meant that a particular functional moiety, e.g., 0, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound. In certain embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group should be selectively removable in good yield by readily available, preferably non-toxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction.
As detailed herein, oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized.
Hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, l -[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-l-methoxyethyl, 1.-methyl-I-benzyloxyethyl, 1-methyl-l-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, ally], p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-Iris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(imidazol- l -
10/248 yl)bis(4',4"-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-l'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-l-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, (methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, a-naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1,2- or 1,3-diols, the protecting groups include methylene acetal, ethylidene acetal, I -t-butyl ethyl idene ketal, I -phenylethylidene ketal, (4-methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, I-
11/248 methoxyethylidene ortho ester, 1-ethoxyethylidine ortho ester, 1,2-dimethoxyethylidene ortho ester, a-methoxybenzylidene ortho ester, 1-(N,N-dimethylamino)ethylidene derivative, a-(N,N'-dimethylamino)benzylidene derivative, 2-oxacyclopentylidene ortho ester, di-t-butylsilylene group (DTBS), 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra-t-butoxydisiloxane-1,3-diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate. Amino-protecting groups include methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1, 1 -dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1, 1 -dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-l-(4-biphenylyl)ethyl carbamate (Bpoc), 1.-(3,5-di-t-butylphenyl)- 1-methylethyl carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adanmantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (lpaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, phenothiazinyl-(10)-carbonyl derivative, N'-p-toluenesulfonylaminocarbonyl derivative, N'-phenylaminothiocarbonyl derivative, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate,
12/248 cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxycarbonylvinyl carbamate, o-(NN-dimethylcarboxamido)penzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-l-cyclopropylmethyl carbamate, 1-methyl-I-(3,5-dimethoxyphenyl)ethyl carbarnate, 1-methyl-l-(p-phenylazophenyl)ethyl carbamate, 1-methyl-l-phenylethyl carbamate, .1-methyl-l-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxycarbonylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, I-substituted 3,5 -dini tro-4-pyrid one, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N- 1, 1 -dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, NN'-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-
13/248 hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentacarbonylchromium- or tungsten)carbonyllamine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphorarnidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenyhnethylsulfenamide, 3-nitropyridinesulfenamide (Npys), p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), fI-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide. Exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the method of the present invention.
Additionally, a variety of protecting groups are described in Protective Groups in Organic Synthesis, Third Ed. Greene, T.W. and Wuts, P.G., Eds., John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.
[00271 It will be appreciated that the compounds, as described herein, may be substituted with any number of substituents or functional moieties. In general, the term "substituted"
whether preceded by the term "optionally" or not, and substituents contained in formulas of this invention, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible
14/248 substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. Furthermore, this invention is not intended to be limited in any manner by the permissible substituents of organic compounds. Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment of diseases or disorders. The term "stable", as used herein, preferably refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
[0028] The term "aliphatic," as used herein, includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, acyclic, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, "aliphatic" is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.
Thus, as used herein, the term "alkyl" includes straight, branched and cyclic alkyl groups.
An analogous convention applies to other generic terms such as "alkenyl," "alkynyl," and the like.
Furthermore, as used herein, the terms "alkyl," "alkenyl," "alkynyl," and the like encompass both substituted and unsubstituted groups. In certain embodiments, as used herein, "lower alkyl"
is used to indicate those alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.
[0029] In certain embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-4 carbon atoms.
Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH2-cyclopropyl, vinyl, ally], n-butyl, sec-butyl, isobutyl, tert-
15/248 butyl, cyclobutyl, -CH2-cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, cyclopentyl, -CH2-cyclopentyl, n-hexyl, sec-hexyl, cyclohexyl, -CH2-cyclohexyl moieties and the like, which again, may bear one or more substituents. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-l-yl, and the like.
Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), I -propynyl, and the like.
[0030] The term "alkyl" as used herein refers to saturated, straight- or branched-chain hydrocarbon radicals derived from a hydrocarbon moiety containing between one and twenty carbon atoms by removal of a single hydrogen atom. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, and dodecyl.
[0031] The term "alkenyl" denotes a monovalent group derived from a hydrocarbon moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom.
Alkenyl groups include, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like.
[0032] The term "alkynyl" as used herein refers to a monovalent group derived form a hydrocarbon having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Representative alkynyl groups include ethynyl, 2-propynyl (propargyl), I-propynyl, and the like.
[0033] The term "alkoxy," or "thioalkyl" as used herein refers to an alkyl group, as previously defined, attached to the parent molecule through an oxygen atom or through a sulfur atom. In certain embodiments, the alkyl, alkenyl, and alkynyl groups contain 1-20 alipahtic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups contain 1-4 aliphatic carbon atoms.
Examples of alkoxy, include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy, and n-hexoxy. Examples of thioalkyl include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, and the like.
[0034] The term "alkylamino" refers to a group having the structure -NHR', wherein R' is aliphatic, as defined herein. In certain embodiments, the aliphatic group contains 1-20 aliphatic
16/248 carbon atoms. In certain other embodiments, the aliphatic group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the aliphatic group employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the aliphatic group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the aliphatic group contains 1-4 aliphatic carbon atoms. Examples of alkylamino groups include, but are not limited to, methylamino, ethylamino, n-propylamino, iso-propylamino, cyclopropylamino, n-butylamino, tert-butylamnino, neopentylamino, n-pentylamino, hexylamino, cyclohexylamino, and the like.
[0035] The term "carboxylic acid" as used herein refers to a group of formula -CO2H.
[0036] The term "dialkylamino" refers to a group having the structure -NRR', wherein R
and R' are each an aliphatic group, as defined herein. R and R' may be the same or different in an dialkyamino moiety. In certain embodiments, the aliphatic groups contains 1-20 aliphatic carbon atoms. In certain other embodiments, the aliphatic groups contains 1-10 aliphatic carbon atoms. In yet other embodiments, the aliphatic groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the aliphatic groups contains 1-6 aliphatic carbon atoms. In yet other embodiments, the aliphatic groups contains 1-4 aliphatic carbon atoms. Examples of dialkylamino groups include, but are not limited to, dimethylamino, methyl ethylamino, diethylamino, methylpropylamino, di(n-propyl)amino, di(iso-propyl)amino, di(cyclopropyl)amino, di(n-butyl)amino, di(tert-butyl)amino, di(neopentyl)amino, di(n-pentyl)amino, di(hexyl)amino, di(cyclohexyl)amino, and the like. In certain embodiments, R
and R' are linked to form a cyclic structure. The resulting cyclic structure may be aromatic or non-aromatic. Examples of cyclic diaminoalkyl groups include, but are not Hinted to, aziridinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, imidazolyl, 1,3,4-trianolyl, and tetrazolyl.
[0037] Some examples of substituents of the above-described aliphatic (and other) moieties of compounds of the invention include, but are not limited to aliphatic; heteroaliphatic;
aryl; heteroaryl; arylalkyl; heteroarylalkyl; alkoxy; aryloxy; heteroalkoxy;
heteroaryloxy;
alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; Cl; Br; 1; -OH; -NO2;
-CN; -CF3; -CH2CF3;
-CHC12; -CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO',CH3; -C(O)Rx; -CO2(Rx); -CON(Rx)2;
-OC(O)Rx; -OCO2Rx; -OCON(Rx)2i -N(Rx)2; -S(O)2Rx; -NRx(CO)Rx wherein each occurrence of Rx independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted,
17/248 branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
[0038] In general, the terms "aryl" and "heteroaryl," as used herein, refer to stable mono-or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted. Substituents include, but are not limited to, any of the previously mentioned substitutents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound. In certain embodiments of the present invention, "aryl"
refers to a mono-or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. In certain embodiments of the present invention, the term "heteroaryl," as used herein, refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, 0, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from S, 0, and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl,oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
[0039] It will be appreciated that aryl and heteroaryl groups can be unsubstituted or substituted, wherein substitution includes replacement of one, two, three, or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl;
heteroarylalkyl; alkoxy;
aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; -F; -Cl;
-Br; -I; -OH; -NO2; -CN; -CF3; -CH2CF3; -CHCI2; -CH2OH; -CH2CH2OH; -CH,NH2; -CH2SO2CH3; -C(O)RX; -C02(R,.); -CON(R,,)2i -OC(O)RX; -OCO2Rx; -OCON(R,)2; -N(RX)2i -S(O)2R,;; -NR,;(CO)R,;, wherein each occurrence of R,, independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or
18/248 unsubstituted. Additional examples of generally applicable substitutents are illustrated by the specific embodiments shown in the Examples that are described herein.
[0040] The term "cycloalkyl," as used herein, refers specifically to groups having three to seven, preferably three to ten carbon atoms. Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of other aliphatic, heteroaliphatic, or hetercyclic moieties, may optionally be substituted with substituents including, but not limited to aliphatic; heteroaliphatic; aryl;
heteroaryl; arylalkyl;
heteroarylalkyl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio;
arylthio;
heteroalkylthio; heteroarylthio; -F; -Cl; -Br; -I; -OH; -N02; -CN; -CF3; -CH2CF3; -CHCI2; -CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO2CH3; -C(O)Rx; -C02(R,,); -CON(Rx)2; -OC(O)R,; -0002Rx; -OCON(Rx)2; -N(Rx)2; -S(0)2Rx; -NRx(CO)R,,, wherein each occurrence of R,;
independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substitutents are illustrated by the specific embodiments shown in the Examples that are described herein.
[0041] The term "heteroaliphatic," as used herein, refers to aliphatic moieties that contain one or more oxygen, sulfur, nitrogen, phosphorus, or silicon atoms, e.g., in place of carbon atoms. Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc.
In certain embodiments, heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl; heteroarylalkyl;
alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; -F; -Cl; -Br; -I; -OH; -NO2; -CN; -CF3; -CH2CF3; -CHCI2i -CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO2CH3; -C(O)R.; -C02(R.); -CON(Rx)2; -OC(O)R,,; -0002R,,; -OCON(Rx)2; -N(Rx)2; -S(0)2Rx; -NRx(CO)Rx, wherein each occurrence of Rx independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein
19/248 may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substitutents are illustrated by the specific embodiments shown in the Examples that are described herein.
[0042] The term "haloalkyl" denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.
[0043] The term "heterocycloalkyl" or "heterocycle," as used herein, refers to a non-aromatic 5-, 6-, or 7- membered ring or a polycyclic group, including, but not limited to a bi- or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to I double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally be oxidized, (iii) the nitrogen heteroato n may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to a benzene ring.
Representative heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl. In certain embodiments, a "substituted heterocycloalkyl or heterocycle" group is utilized and as used herein, refers to a heterocycloalkyl or heterocycle group, as defined above, substituted by the independent replacement of one, two or three of the hydrogen atoms thereon with but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; arylalkyl;
heteroarylalkyl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; -F; -Cl; -Br; -I; -OH; -NO2; -CN; -CF3; -CH2CF3; -CHC12; -CH2OH; -CH2CH2OH; -CH2NH2; -CH2SO2CH3; -C(O)RX; -CO2(R.); -CON(R,,)2; -OC(O)RX; -OCO2Rr; -OCON(RX)2; -N(R,,)2; -S(O)2Rr; -NRr(CO)RX, wherein each occurrence of RX independently includes, but is not limited to, aliphatic, heteroaliphatic, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein any of the aliphatic, heteroaliphatic, arylalkyl, or heteroarylalkyl substituents described above and herein may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and wherein any of the aryl or heteroaryl substituents described above and herein may be substituted or unsubstituted. Additional examples of generally applicable substitutents are illustrated by the specific embodiments shown in the Examples which are described herein.
20/248 [0044] "Carbocycle": The term "carbocycle," as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is a carbon atom.
[0045] "Independently selected": The term "independently selected" is used herein to indicate that the R groups can be identical or different.
[0046] "Labeled": As used herein, the term "labeled" is intended to mean that a compound has at least one element, isotope, or chemical compound attached to enable the detection of the compound. In general, labels typically fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes, including, but not limited to, 2H, 3H, 322P, 35S, 67Ga, 99mTC (Tc-99m), "'In, 1231, 1251 169Yb and'86Re; b) immune labels, which may be antibodies or antigens,which may be bound to enzymes (such as horseradish peroxidase) that produce detectable agents; and c) colored, luminescent, phosphorescent, or fluorescent dyes. It will be appreciated that the labels may be incorporated into the compound at any position that does not interfere with the biological activity or characteristic of the compound that is being detected. In certain embodiments of the invention, photoaffinity labeling is utilized for the direct elucidation of intermolecular interactions in biological systems. A variety of known photophores can be employed, most relying on photoconversion of diazo compounds, azides, or diazirines to nitrenes or carbenes (See, Bayley, H., Photogenerated Reagents in Biochemistry and Molecular Biology (1983), Elsevier, Amsterdam.), the entire contents of which are hereby incorporated by reference. In certain embodiments of the invention, the photoaffinity labels employed are o-, m-and p-azidobenzoyls, substituted with one or more halogen moieties, including, but not limited to 4-azido-2,3,5,6-tetrafl uorobenzoic acid.
[0047] The terms "halo" and "halogen" as used herein refer to an atom selected from fluorine, chlorine, bromine, and iodine.
[0048] The term "heterocyclic," as used herein, refers to a non-aromatic partially unsaturated or fully saturated 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size and bi- and tri-cyclic ring systems which may include aromatic six-membered aryl or aromatic heterocyclic groups fused to a non-aromatic ring. These heterocyclic rings include those having from one to three heteroatoms independently selected from oxygen, sulfur, and nitrogen, in which the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
[0049] The term "heteroaryl", as used herein, refers to a cyclic aromatic radical having
21/248 from five to ten ring atoms of which one ring atom is selected from sulfur, oxygen, and nitrogen;
zero, one, or two ring atoms are additional heteroatoms independently selected from sulfur, oxygen, and nitrogen; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
[0050] Specific heterocyclic and aromatic heterocyclic groups that may be included in the compounds of the invention include: 3-methyl-4-(3-methylphenyl)piperazine, 3 methylpiperidine, 4-(bis-(4-fluorophenyl)methyl)piperazine, 4-(diphenylmethyl)piperazine, 4-(ethoxycarbonyl)piperazine, 4-(ethoxycarbonylmethyl)piperazine, 4-(phenyl methyl)piperazine, 4-(I -phenylethyl)piperazine, 4-(1,1-dimethylethoxycarbonyl)piperazine, 4-(2-(bis-(2-propenyl) amino)ethyl)piperazine, 4-(2-(diethylamino)ethyl)piperazine, 4-(2-chlorophenyl)piperazine, 4-(2-cyanophenyl)piperazine, 4-(2-ethoxyphenyl)piperazine, 4-(2-ethylphenyl)piperazine, 4-(2-fluorophenyl)piperazine, 4-(2-hydroxyethyl)piperazine, 4-(2-methoxyethyl)piperazine, 4-(2-methoxyphenyl)piperazine, 4-(2-methylphenyl)piperazine, 4-(2-methylthiophenyl) piperazine, 4-(2-nitrophenyl)piperazine, 4-(2-nitrophenyl)piperazine, 4-(2-phenylethyl)piperazine, 4-(2-pyridyl)piperazine, 4-(2-pyrimidinyl)piperazine, 4-(2,3-dimethylphenyl)piperazine, 4-(2,4-difluorophenyl) piperazine, 4-(2,4-dimethoxyphenyl)piperazine, 4-(2,4-dimethylphenyl)piperazine, 4-(2,5-dimethylphenyl)piperazine, 4-(2,6-dimethylphenyl)piperazine, 4-(3-chlorophenyl)piperazine, 4-(3-methylphenyl)piperazine, 4-(3-trifluoromethylphenyl)piperazine, 4-(3,4-dichlorophenyl)piperazine, 4-3,4-dimethoxyphenyl)piperazine, 4-(3,4-dimethylphenyl)piperazine, 4-(3,4-methylenedioxyphenyl)piperazine, 4-(3,4,5-trimethoxyphenyl)piperazine, 4-(3,5-dichlorophenyl)piperazine, 4-(3,5-dimethoxyphenyl)piperazine, 4-(4-(phen ylmethoxy)phenyl)piperazine, 4-(4-(3, 1-dimethylethyl)phenylmethyl)piperazine, 4-(4-chloro-3-trifluoromethylphenyl)piperazine, 4-(4-chlorophenyl)-3-methylpiperazine, 4-(4-chlorophenyl)piperazine, 4-(4-chlorophenyl)piperazine, 4-(4-chlorophenylmethyl)piperazine, 4-(4-fluorophenyl)piperazine, 4-(4-methoxyphenyl)piperazine, 4-(4-methylphenyl)piperazine, 4-(4-nitrophenyl)piperazine, 4-(4-trifluoromethylphenyl)piperazine, 4-cyclohexylpiperazine, 4-ethylpiperazine, 4-hydroxy-4-(4-chlorophenyl)methylpiperidine, 4-hydroxy-4-phenylpiperidine, 4-hydroxypyrrolidine, 4-methylpiperazine, 4-phenylpiperazine, 4-piperidinylpiperazine, 4-(2-
22/248 furanyl)carbonyl)piperazine, 4-((1,3-dioxolan-5-yl)methyl)piperazine, 6-fluoro-1,2,3,4-tetrahydro-2-methylquinoline, 1,4-diazacylcloheptane, 2,3-dihydroindolyl, 3,3-dimethylpiperidine, 4,4-ethylenedioxypiperidine, 1,2,3,4-tetrahydroisoquinoline, 1,2,3,4-tetrahydroquinoline, azacyclooctane, decahydroquinoline, piperazine, piperidine, pyrrolidine, thiomorpholine, and triazole.
[0051] The term "substituted," whether preceded by the term "optionally" or not, and "substituent," as used herein, refer to the ability, as appreciated by one skilled in this art, to change one functional group for another functional group provided that the valency of all atoms is maintained. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. The substituents may also be further substituted (e.g., an aryl group substituent may have another substituent off it, such as another aryl group, which is further substituted with fluorine at one or more positions).

[0052] The following are more general terms used throughout the present application:
[0053] "Animal": The term animal, as used herein, refers to humans as well as non-human animals, including, for example, mammals, birds, reptiles, amphibians, and fish. Preferably, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig). An animal may be a transgenic animal.
[0054] "Associated with": When two entities are "associated with" one another as described herein, they are linked by a direct or indirect covalent or non-covalent interaction.
Preferably, the association is covalent. Desirable non-covalent interactions include hydrogen bonding, van der Waals interactions, hydrophobic interactions, magnetic interactions, electrostatic interactions, etc. In certain embodiments, an aninoalcohol lipidoid compound is associated with a polynucleotide through electrostatic interactions.
[0055] "Biocompatible": The term "biocompatible," as used herein is intended to describe compounds that are not toxic to cells. Compounds are "biocompatible" if their addition to cells in vitro results in less than or equal to 20% cell death, and their administration in vivo does not induce inflammation or other such adverse effects.
[0056] "Biodegradable": As used herein, "biodegradable" compounds are those that, when introduced into cells, are broken down by the cellular machinery or by hydrolysis into
23/248 components that the cells can either reuse or dispose of without significant toxic effect on the cells (i.e., fewer than about 20% of the cells are killed when the components are added to cells in vitro). The components preferably do not induce inflammation or other adverse effects in vivo.
In certain embodiments, the chemical reactions relied upon to break down the biodegradable compounds are uncatalyzed.
[0057] "Effective amount": In general, the "effective amount" of an active agent or composition refers to the amount necessary to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of an agent or device may vary depending on such factors as the desired biological endpoint, the agent to be delivered, the composition of the encapsulating matrix, the target tissue, etc. For example, the effective amount of microparticles containing an antigen to be delivered to immunize an individual is the amount that results in an immune response sufficient to prevent infection with an organism having the administered antigen.
[0058] "Peptide" or "protein": According to the present invention, a "peptide"
or "protein" comprises a string of at least three amino acids linked together by peptide bonds. The terms "protein" and "peptide" may be used interchangeably. Peptide may refer to an individual peptide or a collection of peptides. Inventive peptides preferably contain only natural amino acids, although non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and/or amino acid analogs as are known in the art may alternatively be employed. Also, one or more of the amino acids in an inventive peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. In certain embodiments, the modifications of the peptide lead to a more stable peptide (e.g., greater half-life in vivo). These modifications may include cyclization of the peptide, the incorporation of D-amino acids, etc.
None of the modifications should substantially interfere with the desired biological activity of the peptide.
[0059] "Polynucleotide" or "oligonucleotide": Polynucleotide or oligonucleotide refers to a polymer of nucleotides. Typically, a polynucleotide comprises at least three nucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside
24/248 analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methylated bases), intercalated bases, modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose), or modified phosphate groups (e.g., phosphorothioates and 5' -N-phosphoramidite linkages).
[0060] "Small molecule": As used herein, the term "small molecule" refers to organic compounds, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have relatively low molecular weight and that are not proteins, polypeptides, or nucleic acids.
Typically, small molecules have a molecular weight of less than about 1500 g/mol. In certain embodiments, the small molecule is uncharged. In certain embodiments, the small molecule is negatively charged. Also, small molecules typically have multiple carbon-carbon bonds.
Known naturally-occurring small molecules include, but are not limited to, penicillin, erythromycin, taxol, cyclosporin, and rapamycin. Known synthetic small molecules include, but are not limited to, ampicillin, methicillin, sulfamethoxazole, and sulfonamides.

BRIEF DESCRIPTION OF THE DRAWING
[0061] Figure 1 depicts a general synthetic scheme for preparing aminoalcohol lipidoids by combining amines and epoxides, and reacting them at approximately 90 T.
[0062] Figure 2 depicts exemplary amines containing between two and five amine functionalities and racemic epoxides of varying tails, unique functional groups and varying degrees of saturation that may be used for preparing aminoalcohol lipidoids.
[0063] Figure 3 depicts characterization data of aminoalcohol lipidoids derived from amine 114.
[0064] Figure 4 depicts thin layer chromatography (TLC) plates of selected compounds from the aminoalcohol lipidoid library. Plate "A" depicts fully substituted amines, while Plate "B" depicts n-I substituted amines.
[0065] Figure 5 depicts Firefly luciferase knockdown results relative to untreated cells from complexing RNA (50 ng) with various aminoalcohol lipidoids (at various wt/wt ratios) and incubated with HeLa cells.
25/248 [0066] Figure 6 depicts luciferase gene delivery results (Luciferase Expression, "RLU") in HepG2 cells for various epoxide lipidoid compounds in 10% serum and 0.3 pg of DNA per well.
[0067] Figure 7 depicts Factor VII Knockdown in vivo results and characterization of C57BIJ6 mice 48 hours after administration (via tail vein injection at a volume of 0.01 mug) of (a) phosphate buffered saline; (b) 1.75 mg/kg entrapped siRNA in lipidoid formulation; and (c) 4 mg/kg entrapped siRNA in lipidoid formulation.
[0068] Figure 8 depicts luciferase knockdown results (measured by relative luceriferase expression, % control) for a library of aminoalcohol lipidoid compounds wherein the ratio of aminoalcohol lipidoid compound to siRNA is 2.5: 1 (w/w).
[0069] Figure 9 depicts the luciferase knockdown results (measured by relative luceriferase expression, % control) for fifteen aminoalcohol lipidoid compounds having >90%
knockdown wherein the ratio of aminoalcohol lipidoid compound to siRNA is 2.5:1 (w/w).
[0070] Figure 10 depicts: (a) dose (mg/kg) response results (measured by Factor VII
knockdown in mice by aminoalcohol lipidoid C14-110 36 hours post-injection) wherein the ratio of aminoalcohol lipidoid compound to siRNA is 10:1 (w/w), the ratio of aminoalcohol lipidoid compound:cholesterol:PEG is 42:48:10, and 44% entrapment of 91 nm particles;
and (b) average of % BW change.
[0071] Figure 11 depicts in vitro screening results as luciferase knockdown in HeLa cells by 25 epoxide-based lipidoids at 5:1 w/w ratio.
[0072] Figure 12 depicts in vivo screening results as Factor VII knockdown 48 hours post-injection of formulated epoxide lipidoids in mice.
[0073] Figure 13a depicts dose response results for C16-96B as Factor VII
knockdown 48 hours post-injection of formulation C 16-96-B in mice.
[0074] Figure 13b depicts corresponding mice body weight loss and/or gain during the experimental that provided the results in Figure 13.
[0075] Figure 14a depicts dose response results for C14-110B as Factor VII
knockdown 72 hours post-injection of formulation C14-110-B in mice.
[0076] Figure 14b depicts corresponding mice body weight loss and/or gain during the experiment that provided the results in Figure 14a.
26/248 [0077] Figure 15 depicts C 16-96-B formulation optimization as Factor VII
knockdown 48 hours post-injection of formulation C16-96-B in mice at 1 mg/kg dose.
[0078] Figure 16 depicts C16-96-B dose response as Factor VII knockdown 48 hours post-injection of formulation C16-96-B in mice.
[0079] Figure 17a depicts additional in vivo screening and discovery of C12-200 and/or C12-205 as Factor VII knockdown 48 hours post-injection of formulated lipidoids in mice at 0.25 mg/kg dose.
[0080] Figure 17b depicts additional in vivo screening and discovery of C 12-200 and/or C12-205 and corresponding mice body weight loss and/or gain during the experiment that provided the results in Figure 17a.
[0081] Figure 18a depicts dose response results for C 12-200 and/or C 12-205 and ND98 comparison as Factor VII knockdown 48 hours post-injection of formulated C12-200 and/or C 12-205 in mice.
[0082] Figure 18b depicts corresponding mice body weight loss and/or gain during the experiment that provided the results in Figure 18a.
[0083] Figure 19 depicts formulation optimization of C12-200 and/or C12-205 as Factor VII knockdown 48 hours post-injection of formulated C12-200 and/or C12-205 in mice at 0.01 mg/kg dose.
[0084] Figure 20a depicts a MALDI-TOF mass spectra (intensity vs. m/z ratio) of the crude reaction mixture of technical grade 1.11 amine and C 12 epoxide.
[0085] Figure 20b depicts a MALDI-TOF mass spectra (intensity vs. inlz ratio) of the "purified" product from the crude reaction mixture of technical grade 111.
amine and C12 epoxide (from Figure 20a).
[0086] Figure 21a depicts a MALDI-TOF mass spectra (intensity vs. inlz ratio) of the crude reaction mixture of technical grade 111 amine and C 12 epoxide.
[0087] Figure 21b depicts a MALDI-TOF mass spectra (intensity vs. m/z, ratio) of the "purified" product from the crude reaction mixture of technical grade 111 amine and C12 epoxide (from Figure 21a).
[0088] Figure 22 depicts an 1H NMR (400 MHz) spectrum of C12-200 and/or C12-(chloroform, room temperature).
27/248 DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
[0089] The present invention provides novel aminoalcohol lipidoid compounds and drug delivery systems based on the use of such aminoalcohol lipidoid compounds. The system may be used in the pharmaceutical/drug delivery arts to delivery polynucleotides, proteins, small molecules, peptides, antigen, drugs, etc. to a patient, tissue, organ, cell, etc. These novel compounds may also be used as materials for coating, additives, excipients, materials, bioengineering, etc.
[0090] The aminoalcohol lipidoid compounds of the present invention provide for several different uses in the drug delivery art. The amine-containing portion of the aminoalcohol lipidoid compounds may be used to complex polynucleotides, thereby enhancing the delivery of polynucleotide and preventing their degradation. The aminoalcohol lipidoid compounds may also be used in the formation of picoparticles, nanoparticles, microparticles, liposomes, and micelles containing the agent to be delivered. Preferably, the aminoalcohol lipidoid compounds are biocompatible and biodegradable, and the formed particles are also biodegradable and biocompatible and may be used to provide controlled, sustained release of the agent to be delivered. These lipidoids and their corresponding particles may also be responsive to pH
changes given that these lipidoids are protonated at lower pH. The lipidoids may also act as proton sponges in the delivery of an agent to a cell to cause endosome lysis.

1. Aminoalcohol Lipidoid Compounds [0091] The aminoalcohol lipidoid compounds of the present invention are aminoalcohol lipidoid compounds containing primary, secondary, tertiary, and/or quaternary amines, and salts thereof. The amines may be cyclic or acyclic amines. In certain embodiments, the inventive aminoalcohol lipidoid compounds are relatively non-cytotoxic. In another embodiment, the inventive aminoalcohol lipidoid compounds are biocompatible and biodegradable.
In certain embodiments, the aminoalcohol lipidoids of the present invention have pK,s in the range of approximately 5.5 to approximately 7.5, more preferably between approximately 6.0 and approximately 7Ø In another embodiment, the aminoalcohol lipidoid compounds may be designed to have a desired pK, between approximately 3.0 and approximately 9.0, or between approximately 5.0 and approximately 8Ø The inventive aminoalcohol lipidoid compounds are particularly attractive for drug delivery for several reasons: 1) they contain amino groups for
28/248 interacting with DNA, RNA, other polynucleotides, and other negatively charged agents, for buffering the pH, for causing endosomolysis, for protecting the agent to be delivered, etc.; 2) they can be synthesized from commercially available starting materials; and/or 3) they are pH
responsive and can be engineered with a desired pK,.,.
[0092] In certain embodiments, the aminoalcohol lipidoid compound or composition containing aminoalcohol lipidoid compound(s), are those derived from terminated epoxides of 14 carbons or greater coupled with monomers of three or more amine functional groups. In certain embodiments, the composition containing an aminoalcohol lipidoid compound is about 40-60%
lipidoid, about 40-60 % cholesterol, and about 5-20% PEG. In certain embodiments, the composition containing an aminoalcohol lipidoid compound is about 50-60%
lipidoid, about 40-50 % cholesterol, and about 5-10% PEG. In certain embodiments, the composition containing an aminoalcohol lipidoid compound is 52% lipidoid, 48% cholesterol, and 10% PEG.
In certain embodiments, the composition containing an aminoalcohol lipidoid is about 50-75% lipidoid, about 20-40% cholesterol, and about 1-10% PEG. In certain embodiments, the composition containing an aminoalcohol lipidoid compound is about 60-70% lipidoid, about 25-35%
cholesterol, and about 5-10% PEG.
[0093] In certain embodiments, the aminoalcohol lipidoid compounds may be prepared by reacting an amine with a terminal epoxide or an aldehyde according to the following schemes.
R-NH2 + L. HO(R1 + HN(OH
R, I
HN,R R R, R-NH2 + HO----R~ HN--,,_,,OH
R1 HN.R + R Rt R-NH2 + L HO(Rj HN OH
R, HN,R R Ri 0 OPG 1. Imine formation 2. Reduction OH
R-NH2 + HN
H 3. Deprotection I
H Rt R R, In certain embodiments, the epoxide is stereochemically pure (e.g., enantiomerically pure). In certain embodiments, the amine is stereochemically pure (e.g., enantiomerically pure). In certain
29/248 embodiments, the lipidoid is prepared from the reductive amination of an imine which derived from the condensation of an amine and an aldehyde. In certain embodiments, the aminoalcohol lipidoid compounds of the present invention are of one of the formulae:
R, R, R, R, R3 --~ HO Rc HO R~ /Rc R2 Ns^^^^A.,, , N HO~y R3--~OH
N-A-N\ X RD Nw~^^rA'N
RB RD , R2 OH RB RD

R R3 R, R3 R3 R, R3 HO~R, OH HO OH P
R2 N-A---,N Rz:)~N ^^^^ A ,, N R4 RA N N RF
X RD
\ \~~
R2 OH Rz OH R4 OH m RA
I

RAC N N k---W RA
x I
and RA
wherein each occurrence of A, R1, R2, R3, R4, RB, Rc, RD, RA, RF, m, p, x, and y are as defined herein. As will be appreciated by one of skill in the art, the amine may be reacted with an excess of epoxide to form a fully functionalized aminoalcohol lipidoid compound. Or, the lipidoid may have fewer epoxide-derived tails than when fully functionalized. In certain embodiments, Ri R, R2 R2 i~ JI~ i~
each HO is independently HO/ or HO 'J' ; each HO--' is independently HO/ or HHO-Ty ; each HO "f is independently HO /or HOJ/ ; and each HOJ~
is -ly independently HO^/ or HO

[00941 In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:
30/248 R, R, R
HO / c N-A-N
RB RD
wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2-2o alkylene, optionally interrupted by 1 or more heteroatoms independently selected from 0, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
R, is hydrogen, a substituted, unsubstituted, branched or unbranched Ci_20-aliphatic or a substituted, unsubstituted, branched or unbranched CI-20 heteroaliphatic, wherein at least one occurrence of Ri is hydrogen;
RB, Rc, and RD are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1.20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1_20-heteroaliphatic or -CH2CH(OH)RE;
RB and RD together may optionally form a cyclic structure;
Rc and RD together may optionally form a cyclic structure; and RE is a substituted, unsubstituted, branched or unbranched CI-20 aliphatic or a substituted, unsubstituted, branched or unbranched CI-20 heteroaliphatic; or a pharmaceutically acceptable salt thereof.
[0095] In certain embodiments, A is an unsubstituted, unbranched, and acyclic C2.20 alkylene. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.20, alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments, A is a substituted, unbranched, and acyclic C2,1o alkylene, optionally interrupted, ss~~N'- ~\

by 1 oxygen atom. In certain embodiments, A is of the formula CH3 . In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.20 alkylene, optionally interrupted, by 1 or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by I or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by 2 oxygen atoms. In certain embodiments, A
is of the formula
31/248 In certain embodiments, A is of the formula wherein n is an integer between I and 10, inclusive. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.20 alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by 2 nitrogen atoms. In certain embodiments, A is of the H
N N
formula H In certain embodiments, A is of the formula n wherein n is an integer between I and 10, inclusive.
[0096] In certain embodiments, A is selected from the following formulae:
S

H
N
H N
H

N N
H H

H

[0097] In certain embodiments, R, is hydrogen. In certain embodiments, R, is an unsubstituted and unbranched, C120-aliphatic or C,_20 heteroaliphatic moiety.
In some embodiments, R1 is an unsubstituted and unbranched, Cul_12-aliphatic group. In some embodiments, RI is In some embodiments, R, is an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, is as` . In some embodiments, R, is an unsubstituted and unbranched, C14 heteroaliphatic group. In some embodiments, R, is In certain embodiments, R, is selected from the following formulae:

[0098] In certain embodiments, R, is a CI-20 alkenyl moiety, optionally substituted. In certain embodiments, R, is selected from the following formulae:

/~
It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.

i~
--~ -jy [0099] In certain embodiments, each HO is independently HO ' or HO
[00100] In certain embodiments, R, is:

or [00101] In certain embodiments, R, is selected from the following formulae:

O'v [00102] In certain embodiments, R, is selected from the following formulae:

F F ~FF F F F F F F F F

F F F F F FF F F F F F F F F F

F F F F F F ~FFF F F F <F F F F F^
F F F F F F F F F F F F
F F
F F F F F
F F F F F F F FFF F F F F F F
F F F F F F F ~
F F F F F F F F F F F F F F F F F F F F
F F F F F F F F F F F F F F F

F F F F F F F F F F F F F
F F F F FFF F F F F F F F F
F~X~~~> F F FFF F F F F F F F F F F F
F F F F F F F F F
F F F F F F F YFFFKF FF F F F F ~FF F F F F
F F FF F F F FF FF FF FF FF F
F F
F FF FF FF F ~FF
F F F F F F F F F FFF F F FFF F F F F F F F F F F F F F F F F F F F F

F F F F F F F F F F , F F F F FFF F <F F F FFFF F F F F F F F F F F F F
F F jF FF F F F FFFF F F F F F F F
F F F F F F F F F F F
F F F F F F F F ~FF
F F F F F F F F F F FF~FF F F F' F
F
FFF F F F F F F F F

[00103] In certain embodiments, R, is fluorinated. In certain embodiments R, is a fluorinated aliphatic moiety. In certain embodiments R, is perfluorinated. In certain embodiments R, is a perfluorinated aliphatic moiety. In certain embodiments, R, is a perfluorinated C, 20 alkyl group. In certain embodiments, R, is selected from the following formulae:
[00104]

FF F F F F F F FC\

O^` F F F F F F F F F F
F F F F F F F

F
F F F F F F F F

[00105] In certain embodiments, RI is selected from the following formulae:
and [00106] In certain embodiments, RB is hydrogen. In certain embodiments, RB is an unsubstituted and unbranched C1 20-aliphatic. In certain embodiments RB is C1-6-alkyl. In certain embodiments RB is methyl. In certain embodiments RB is ethyl. In certain embodiments RB is propyl. In certain embodiments RB is butyl. In certain embodiments, RB
is an unsubstituted and unbranched CI-2o-heteroaliphatic. In certain embodiments RB
is CI-6-heteroalkyl. In certain embodiments, RB is -CH2CH(OH)RE.
[00107] In certain embodiments, Rc is hydrogen. In certain embodiments, Rc is an unsubstituted and unbranched C1-2o-aliphatic. In certain embodiments Rc is C1-6-alkyl. In certain embodiments Rc is methyl. In certain embodiments Rc is ethyl. In certain embodiments Rc is propyl. In certain embodiments Rc is butyl. In certain embodiments, Rc is an unsubstituted and unbranched Ci-20-heteroaliphatic. In certain embodiments Rc is C1-6-heteroalkyl. In certain embodiments, Rc is -CH2CH(OH)RE.
[00108] In certain embodiments, RD is hydrogen. In certain embodiments, RD is an unsubstituted and unbranched CI20-aliphatic. In certain embodiments RD is CI-;-alkyl. In certain embodiments RD is methyl. In certain embodiments RD is ethyl. In certain embodiments RD is propyl. In certain embodiments RD is butyl. In certain embodiments, RD
is an unsubstituted and unbranched CI_ZO-heteroaliphatic. In certain embodiments RD
is C1-6-heteroalkyl. In certain embodiments, RD is -CH2CH(OH)RE.

[00109] In certain embodiments, RB, RC, and RD are all the same. In certain embodiments, RB, Rc, and RD are all hydrogen or all CI-C6 alkyl. In certain embodiments, RB, RC, and RD are all hydrogen. In certain embodiments, RB, Rc, and RD are all C1-C6 alkyl. In certain embodiments, RB, Rc, and RD are all hydroxyalkyl. In certain embodiments, RB, Rc, and RD are all aminoalkyl. In certain embodiments, RB, Rc, and RD are hydrogen or methyl.
In certain embodiments, at least two of RB, RC, and RD are the same. In certain embodiments, RB, RC, and RD are all different.
[00110] In certain embodiments, RE is hydrogen. In certain embodiments, RE is an unsubstituted and unbranched Q-20-aliphatic. In certain embodiments RE is C1.6-alkyl. In certain embodiments RE is methyl. In certain embodiments RE is ethyl. In certain embodiments RE is propyl. In certain embodiments RE is butyl. In certain embodiments, RE is an unsubstituted and unbranched C, 20-heteroaliphatic. In certain embodiments RE is Ci-6-heteroalkyl.
[00111] Particular exemplary compounds include:
CH3-(CH2)1 1'~~ OH CH3-(CH2)13 OH
,H /H
~~O O
Obi ,H H/N N
H N N
/~ ,H
CH3-(CH2)11 OH CH3-(CH2)11 OH
H /H H
N~Ilc N N N
N~i N-~ N H/ Ni \H
H H H and CH3 [00112] In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:

I Ri HO /RC

RD

A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_20 alkylene, optionally interrupted by 1 or more heteroatoms independently selected from 0, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;

R1 and R2 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1='0-aliphatic or a substituted, unsubstituted, branched or unbranched Ci_20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen and at least one occurrence of R2 is hydrogen;
Rc and RD are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1.2U-aliphatic, or a substituted, unsubstituted, branched or unbranched C1.20-heteroaliphatic or -CHZCH(OH)RE;
RC and RD together may optionally form a cyclic structure; and RE is a substituted, unsubstituted, branched or unbranched C1_20 aliphatic or a substituted, unsubstituted, branched or unbranched C1_20 heteroaliphatic; or a pharmaceutically acceptable salt thereof.
[00113] In certain embodiments, A is an unsubstituted, unbranched, and acyclic C2_20 alkylene. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_20 alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments A is a substituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by /- N"~z, 1 oxygen atom. In certain embodiments, A is of the formula CH3 . In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2-2o alkylene, optionally interrupted by 1 or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.10 alkylene, optionally interrupted by 1 or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by 2 oxygen atoms. In certain embodiments, A
is of the formula In certain embodiments, A is of the formula , wherein n is an integer between 1 and 10, inclusive. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.20 alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by 2 nitrogen atoms. In certain H
N "~ N
embodiments, A is of the formula H . In certain embodiments, A is of '__4 H -4N

the formula , wherein n is an integer between I and 10, inclusive.
[00114] In certain embodiments, A is selected from the following formulae:

H
N N N
H H

NN
H H

PN
H
[00115] In certain embodiments, R1 and R2 are hydrogen. In certain embodiments, R, and R2 are, independently, an unsubstituted and unbranched, CI-20-aliphatic or C,_20 heteroaliphatic moiety. In some embodiments, R, and R-, are, independently, an unsubstituted and unbranched, C1o_12-aliphatic group. In some embodiments, R, and R2 are r``j. In some embodiments, R1 and R2 are, independently, an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, R, and R2 In some embodiments, R1 and R2 are, independently, an unsubstituted and unbranched, C14 heteroaliphatic group. In some embodiments, R1 and R2 are. In certain embodiments, R, and R2 are, independently, selected from the following formulae:

[00116] In certain embodiments, R1 and R2 are, a Ci_2o alkenyl moiety, optionally substituted. In certain embodiments, R, and R2 are, independently, selected from the following formulae:

[00117] It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.
[00118] In certain embodiments, R, and R2 are:

or [00119] In certain embodiments, R, and Rs are, independently, selected from the following formulae:

[00120] In certain embodiments, R, and R2 are fluorinated. In certain embodiments R, and RZ are a fluorinated aliphatic moiety. In certain embodiments R, and R2 are perfluorinated. In certain embodiments R, and R2 area perfluorinated aliphatic moiety. In certain embodiments, R, and R2 are a perfluorinated C,_20 alkyl group. In certain embodiments, R, and R2 are selected from the following formulae:

F F ~FF F F F F F F F F

F F F F d`s F F F E F F E E E E
~FFF F F F ~FF FF F F F F F F F

F F F F F F F F F F F F F F F
F F F F F
F F F F FFFF F F F F F F F
F F F F F F <J~^
F
F F F F F F F F F F F
F F F F F F F F F
F F F F F F F F F F F F F F
F/ i ~''s F
i~~y F F F F F F F F F F F F
F F F F F FFF F F F F F F F F
F~x\ F F F F F F F F F
F FF FF FFxF F
F F F F FF FF F FF FF F~FF
F FF FF FF FF FF F
FF~F~
F FF FF FF F F
F F F F F F F F FFF F F FFF F F F F F F F F
F F F F F F F F F. F F F F F F F
-A~~Worss F F F F F F F F F F F , F F FFFFF FF F FF F F FF FF FF F FF FF FF F
F4Y < J~~C! C~ ~O~ F F F V F F. F F FFFF F F F F. F F F
F F F F F F F F F F F
FFFF F F F F F F F F F F F F F FF F F F F F F F F F F
FFF F F ~FF F F
E ~FF F

[00121] In certain embodiments, R1 and R2 are, independently, selected from the following formulae:

F F F F F F F F F

O^` F F F F F F F F F F
F F F F F F F
F
F
F F F F F F F F

[00122] In certain embodiments, R, and R2 are both the same. In certain embodiments, each of R, and R2 are independently hydrogen or C1-C6 alkyl. In certain embodiments, R, and R2 are both hydrogen. In certain embodiments, R, and R2 are both C1-C6 alkyl.
In certain embodiments, R, and R2 are both hydroxyalkyl. In certain embodiments, R, and R2 are both aminoalkyl. In certain embodiments, R, and R2 are different.
[00123] In certain embodiments, Rc is hydrogen. In certain embodiments, RC is an unsubstituted and unbranched C1_20-aliphatic. In certain embodiments Rc is C,_6-alkyl. In certain embodiments Rc is methyl. In certain embodiments Rc is ethyl. In certain embodiments Rc is propyl. In certain embodiments Rc is butyl. In certain embodiments, RC
is an unsubstituted and unbranched Ci_20-heteroaliphatic. In certain embodiments Rc is C1.6-heteroalkyl. In certain embodiments, RC is -CH2CH(OH)RE.
[00124] In certain embodiments, RD is hydrogen. In certain embodiments, RD is an unsubstituted and unbranched C1 20-aliphatic. In certain embodiments RD is C1.6-alkyl. In certain embodiments RD is methyl. In certain embodiments RD is ethyl. In certain embodiments RD is propyl. In certain embodiments RD is butyl. In certain embodiments, RD
is an unsubstituted and unbranched C1.20-heteroaliphatic. In certain embodiments RD
is C1.6-heteroalkyl. In certain embodiments, RD is -CH,CH(OH)RE.
[00125] In certain embodiments, RC and RD are both the same. In certain embodiments, each of Rc and RD are independently hydrogen, or C1-C6 alkyl. In certain embodiments, RC and RD are both hydrogen. In certain embodiments, RC and RD are both C1-C6 alkyl.
In certain embodiments, Rc and RD are both hydroxyalkyl. In certain embodiments, Rc and RD are both aminoalkyl. In certain embodiments, Rc and RD are different.
[00126] In certain embodiments, RE is hydrogen. In certain embodiments, RE is an unsubstituted and unbranched CI.20-aliphatic. In certain embodiments RE is CI-6-alkyl. In certain embodiments RE is methyl. In certain embodiments RE is ethyl. In certain embodiments RE is propyl. In certain embodiments RE is butyl. In certain embodiments, RE is an unsubstituted and unbranched C1_20-heteroaliphatic. In certain embodiments RE is C1-6-heteroalkyl.
[00127] Particular exemplary compounds include:

CH3-(CH2)11 OH CH3-(CH2)13 OH

'H ~ O H
HO H HO

CH3 (CH2)11 CH3 (CH2)13 CH3-(CH2)11 CH3-(CH2)11 OH
I
H H H
NNNN NNN,\
HO HI H HO CH

CH3 (CH2)11 and CH3 /(CH2)11 , [00128] In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:

HO (OH
/N ^^^^^A ~ N \
RB RD
wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_20 alkylene, optionally interrupted by l or more heteroatoms independently selected from 0, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
RI and R3 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1_20-aliphatic or a substituted, unsubstituted, branched or unbranched CI-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen and at least one occurrence of R3 is hydrogen;
RB and RD are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1.20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1 2o-heteroaliphatic or -CH2CH(OH)RE;
RB and RD together may optionally form a cyclic structure; and RE is a substituted, unsubstituted, branched or unbranched C1.2o aliphatic or a substituted, unsubstituted, branched or unbranched C_20 heteroaliphatic; or a pharmaceutically acceptable salt thereof.

~ R1 [00129] In certain embodiments, each HOJ/ is independently H O ' / or HO f ;
and each HO"/ is independently HO / or HO

[00130] In certain embodiments, A is an unsubstituted, unbranched, and acyclic C2_20 alkylene. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C7_20 alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments A is a substituted, unbranched, and acyclic C2_io alkylene, optionally interrupted by N
1 oxygen atom. In certain embodiments, A is of the formula CH3 . In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_20 alkylene, optionally interrupted by 1 or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by 1 or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.]0 alkylene, optionally interrupted by 2 oxygen atoms. In certain embodiments, A
is of the formula \\ In certain embodiments, A is of the formula wherein n is an integer between I and 10, inclusive. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_20 alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.1o alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.10 alkylene, optionally interrupted by 2 nitrogen atoms. In certain H

N
embodiments, A is of the formula H . In certain embodiments, A is of _4H
N '4 N
the formula , wherein n is an integer between I and 10, inclusive.
[00131] In certain embodiments, A is selected from the following formulae:

H
N
H N
H

H ~,rr NH2 N
H H

H

[00132] In certain embodiments, R1 and R3 are hydrogen. In certain embodiments, R1 and R3 are, independently, an unsubstituted and unbranched, C1.20-aliphatic or CI-20 heteroaliphatic moiety. In some embodiments, R1 and R3 are, independently, an unsubstituted and unbranched, C1A_,2-aliphatic group. In some embodiments, R, and R3 are c. In some embodiments, R1 and R3 are, independently, an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, R, and R3 are In some embodiments, R, and R3 are, independently, an unsubstituted and unbranched, C14 heteroaliphatic group. In some embodiments, R, and R3 are In certain embodiments, R, and R3 are, independently, selected from the following formulae:

w\~
[00133] In certain embodiments, R, and R3 are, a CI-20 alkenyl moiety, optionally substituted. In certain embodiments, R, and R3 are, independently, selected from the following formulae:

[00134] It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.
[00135] In certain embodiments, R, and R3 are:

or [00136] In certain embodiments, R, and R3 are, independently, selected from the following formulae:

o^, [00137] In certain embodiments, R, and R3 are fluorinated. In certain embodiments R, and R3 are a fluorinated aliphatic moiety. In certain embodiments R, and R3 are perfluorinated. In certain embodiments R, and R3 area perfluorinated aliphatic moiety. In certain embodiments, R, and R3 are a perfluorinated CI-20 alkyl group. In certain embodiments, R, and R3 are selected from the following formulae:

F F F F F F F F F F F F
F~x` F ~ ,s''`
F F F F F FF F F F F F F F F F F F
F F F FF F F F F F F F F

F F F F F FFF F F F F F F F F
F FF F F
F F F F F F F F FFFFFF FFF
F F F F F F F
F F F F F F F F FFFF F F F F F F F F
F%~ iC\ F F F F F F F F F F F F F F
F F F F F F Fi~~l F F F F F F F F F F FFF F F F F F F F F
F, ~~ ~^r``f F F FFF F F F F F F F F F F F
F F F F F F F F F
F F F F F F F F F F F FF F F F F F F F F F F
F
F F FF FF FF FF FF F
F FF FF FF F FF
F F F FFF F F F F F F ~FF
F F F F F F. F ~FF F F F
FF F FF FF FF F F ,, F F F F F F
F F F F F F F F F F F F F FE F E

F-~\~~~ j'~FF F F FF F F FFFF F F F F F F F
F F F F F F F F F F F

F~FF F F F F F F F F FF F F FF F F F ~FF ~FF F ~FF
F ,s`
FFF F F ~FF F F

[00138] In certain embodiments, R1 and R3 are, independently, selected from the following formulae:

F F F F F F F F F

F ~<\
F F F F F F F F F F
F F FFFF F

F F F F F F F F

[00139] In certain embodiments, R1 and R3 are both the same. In certain embodiments, each of R, and R3 are independently hydrogen, or C1-C6 alkyl. In certain embodiments, R, and R3 are both hydrogen. In certain embodiments, R, and R3 are both C1-C6 alkyl.
In certain embodiments, R, and R3 are both hydroxyalkyl. In certain embodiments, R, and R3 are both aminoalkyl. In certain embodiments, R1 and R3 are different.
[00140] In certain embodiments, RB is hydrogen. In certain embodiments, RB is an unsubstituted and unbranched C1_20-aliphatic. In certain embodiments RB is C1_6-alkyl. In certain embodiments RB is methyl. In certain embodiments RB is ethyl. In certain embodiments RB is propyl. In certain embodiments RB is butyl. In certain embodiments, RB
is an unsubstituted and unbranched C1_20-heteroaliphatic. In certain embodiments RB
is C1-6-heteroalkyl. In certain embodiments, RB is -CH2CH(OH)RE.
[00141] In certain embodiments, RD is hydrogen. In certain embodiments, RD is an unsubstituted and unbranched C120-aliphatic. In certain embodiments RD is C1.6-alkyl. In certain embodiments RD is methyl. In certain embodiments RD is ethyl. In certain embodiments RD is propyl. In certain embodiments RD is butyl. In certain embodiments, RD
is an unsubstituted and unbranched C1.70-heteroaliphatic. In certain embodiments RD
is C1_6-heteroalkyl. In certain embodiments, RD is -CH2CH(OH)RE.
[00142] In certain embodiments, RB and RD are both the same. In certain embodiments, each of RB and RD are independently hydrogen, or C1-C6 alkyl. In certain embodiments, RB and RD are both hydrogen. In certain embodiments, RB and RD are both C1-C6 alkyl.
In certain embodiments, RB and RD are both hydroxyalkyl. In certain embodiments, RB and RD are both aminoalkyl. In certain embodiments, RB and RD are different.
[00143] In certain embodiments, RE is hydrogen. In certain embodiments, RE is an unsubstituted and unbranched Ci_2o-aliphatic. In certain embodiments RE is Ci_6-alkyl. In certain embodiments RE is methyl. In certain embodiments RE is ethyl. In certain embodiments RE is propyl. In certain embodiments RE is butyl. In certain embodiments, RE is an unsubstituted and unbranched Ci_20-heteroaliphatic. In certain embodiments RE is C,-6-heteroalkyl.
[00144] Particular exemplary compounds include:

CH3-(CH2)11 OH HO CH2)11 H N H

CH3-(CH2)13 OH HO ((;H2)13 N
H H

CH3-(CH2)11 OH HO v(CH2)ii H
N-,~ N,,,,-,N N,, H H H

CH3-(CH2) "~c OH HO CH2) /NN--~ N\H
and H CH3 (CH2)11CH3 (CH2)11CH3 ' [00145] In certain embodiments, each HO -J-/ is independently HO/ or (CH2)11CH3 HOJ/

[00146] In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:

R, R3 HO R, R3 OH
R2 N s^^^^ A---N
D
X \R

wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic alkylene, optionally interrupted by I or more heteroatoms independently selected from 0, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
R1, R2, and R3 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1_20-aliphatic or a substituted, unsubstituted, branched or unbranched C1.20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen, at least one occurrence of R2 is hydrogen and at least one occurrence of R3 is hydrogen;
RD is hydrogen, a substituted, unsubstituted, branched or unbranched C1_20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1_20-heteroaliphatic or -CH2CH(OH)RE; and RE is a substituted, unsubstituted, branched or unbranched C1.2() aliphatic or a substituted, unsubstituted, branched or unbranched C1.20 heteroaliphatic; or a pharmaceutically acceptable salt thereof.
R, [00147] In certain embodiments, each HO is independently HO or HO ; each HO~ is independently HO or HO - ` ; and each HO-,:s` is independently HO^ or HO-j/
[00148] In certain embodiments, A is an unsubstituted, unbranched, and acyclic C2.2o alkylene. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_2() alkylene, optionally interrupted by l or more nitrogen atoms. In certain embodiments A is a substituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by 1 oxygen atom. In certain embodiments, A is of the formula CH3 . In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.2o alkylene, optionally interrupted by I or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.10 alkylene, optionally interrupted by I or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.10 alkylene, optionally interrupted by 2 oxygen atoms. In certain embodiments, A
is of the formula In certain embodiments, A is of the `~^ rO a 0~~~, formula wherein n is an integer between I and 10, inclusive. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.20 alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2.1o alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by 2 nitrogen atoms. In certain H
N--~ N
embodiments, A is of the formula H . In certain embodiments, A is of N-'H
the formula n , wherein n is an integer between I and 10, inclusive.
[001491 In certain embodiments, A is selected from the following formulae:

N
H
NX"~
H H

N
H sH

H

[00150] In certain embodiments, R1, R2 and R3 are hydrogen. In certain embodiments, R1, R2 and R3 are, independently, an unsubstituted and unbranched, CI_20-aliphatic or CI-20 heteroaliphatic moiety. In some embodiments, R1, R2 and R3 are, independently, an unsubstituted and unbranched, C12-aliphatic group. In some embodiments, R1, R2 and R3 are . In some embodiments, R1, R2 and R3 are, independently, an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, R1, R2 and R3 In some embodiments, R1, R2 and R3 are, independently, an unsubstituted and unbranched, Q4 heteroaliphatic group. In some embodiments, R1, R2 and R3 are ". In certain embodiments, R1, R2 and R3 are, independently, selected from the following formulae:

[00151] In certain embodiments, R1, R,, and R3 are, a CI-20 alkenyl moiety, optionally substituted. In certain embodiments, R1, R,, and R3 are, independently, selected from the following formulae:

[00152] It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.
[00153] In certain embodiments, R1, R2, and R3 are:

or [00154] In certain embodiments, R1, R2, and R3 are, independently, selected from the following formulae:

[00155] In certain embodiments, R1, RZ and R3 are fluorinated. In certain embodiments R1, R2 and R3 are a fluorinated aliphatic moiety. In certain embodiments R1, R3 and R3 are perfluorinated. In certain embodiments R1, R2 and R3 are a perfluorinated aliphatic moiety. In certain embodiments, R1, R2 and R3 are a perfluorinated Ci_2o alkyl group. In certain embodiments, R1, R2 and R3 are selected from the following formulae:

F F F FFFF FFFF`FF F

F F F F F FF F F F F F F F F F
F F F F F F FFF F F F F F F <F
FW'. F ~FF ~ /~
F F F F
F F FFFF F F F F F F
F F F F F F F F F F F F F F
F F F F F F F
%~'>~C!<%~ /<\`'J
F F F F F F F F FFFF F F F F F F F F
F F F F F F F F F F F F F
F F F F F F F F
F. F F F F F F F F FFF F F F F F F F F
F ~~ >(~C ~~ ^+'``~ F F FFF FF FFFF F F F F F F F
F FF FF FF F F
IF C F F F F F F F' F F F F F F F F F
F FF F F F FF F F F F F F F F F
F~

4,, F F F F F. F F F F F F F F F FFF F F F F F F F F
F~~ ~~ F F F F. F F. F F F F F F F F F
FF F FFxFF FF F F , F F F F F FF F FF FFFF F F F F F F F F F F F F
F-~\~`~ j"FF F F FF F F FFFF F F F F F F F
F F F F F F F F F F F
F F F F F F F F F
FF F F F F F F F FF F F FF F F
F`
F F F F F F F F F F F

[00156] In certain embodiments, R1, R2, and R3 are, independently, selected from the following formulae:

F F F F F FF F F

O^` F F F F F F F F F F
F F F F F F F
F
F o+`s F F F F F F F F

[00157] In certain embodiments, R1, R2, and R3 are all the same. In certain embodiments, at least two of R1, R2, and R3 are the same. In certain embodiments, R1, R2, and R3 are all different.
[00158] In certain embodiments, RD is hydrogen. In certain embodiments, RD is an unsubstituted and unbranched CI_2D-aliphatic. In certain embodiments RD is CI-6-alkyl. In certain embodiments RD is methyl. In certain embodiments RD is ethyl. In certain embodiments RD is propyl. In certain embodiments RD is butyl. In certain embodiments, RD
is an unsubstituted and unbranched Ci_20-heteroaliphatic. In certain embodiments RD
is C,_6-heteroalkyl. In certain embodiments, RD is -CH2CH(OH)RE.
[00159] In certain embodiments, RE is hydrogen. In certain embodiments, RE is an unsubstituted and unbranched Cl_20-aliphatic. In certain embodiments RE is C,-6-alkyl. In certain embodiments RE is methyl. In certain embodiments RE is ethyl. In certain embodiments RE is propyl. In certain embodiments RE is butyl. In certain embodiments, RE is an unsubstituted and unbranched CI_20-heteroaliphatic. In certain embodiments RE is C,.6-heteroalkyl.
[00160] Particular exemplary compounds include:

CH3-(CH2)11 '*~~ OH HO (CH2)l1 O
HO H
CH3-(CH2)11 CH3-(CH2)13 OH HOACH2)13 O
Nei N,H
HO

z)~s CH3---(CH

CH3-(CH2)1N~\~ """OH Hp` (CH2) HJ( N-~ NN-~ N.H
HO H

CH3-(CH2)11 N""'c OH HO (CH2)ll NN--~N'H
HO CH

CH3 (CH2)11 and (CH2)11CH3 (CH2)11CH3 [001611 In certain embodiments, each HO--/ is independently HO'/ or (CH2)11CH3 HO'J'/

[00162] In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:

R, R3 R, R3 HO-1~ OH
R2 N.^^^^'A ^^^^^~I R4 wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C,_2o alkylene, optionally interrupted by 1 or more heteroatoms independently selected from 0, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring; and R1, R.,, R3, and R4 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched Q_20-aliphatic or a substituted, unsubstituted, branched or unbranched CI-20 heteroaliphatic, wherein at least one occurrence of Ri is hydrogen, at least one occurrence of R2 is hydrogen, at least one occurrence of R3 is hydrogen and at least one occurrence of R4 is hydrogen; or a pharmaceutically acceptable salt thereof.
R, R
R~
i~
[00163] In certain embodiments, each HO is independently HO or HO ; each HO"J', is independently HO or HO~ ; each HO~ is independently HO
or R3 R4 J~ R4 HO /; and each HO -1Y is independently H O ' / or HO

[00164] In certain embodiments, A is an unsubstituted, unbranched, and acyclic G_2o alkylene. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2-2o alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments A is a substituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by I oxygen atom. In certain embodiments, A is of the formula CH3 . In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2_20 alkylene, optionally interrupted by I or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1() alkylene, optionally interrupted by I or more oxygen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1o alkylene, optionally interrupted by 2 oxygen atoms. In certain embodiments, A
is of the formula In certain embodiments, A is of the formula wherein n is an integer between 1 and 10, inclusive. In certain embodiments, A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic C2.2O alkylene, optionally interrupted by 1 or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_1O alkylene, optionally interrupted by I or more nitrogen atoms. In certain embodiments A is an unsubstituted, unbranched, and acyclic C2_10 alkylene, optionally interrupted by 2 nitrogen atoms. In certain H
N--~ N
embodiments, A is of the formula H . In certain embodiments, A is of the formula ~n , wherein n is an integer between 1 and 10, inclusive.
[00165] In certain embodiments, A is selected from the following formulae:

H H
H H

NN~/~N~\/~, H H

H
[00166] In certain embodiments, R1, R2, R3 and R4 are hydrogen. In certain embodiments, R1i R2, R3 and R4 are, independently, an unsubstituted and unbranched, C1_20raliphatic or C1_20 heteroaliphatic moiety. In some embodiments, R1, R2, R3 and R4 are, independently, an unsubstituted and unbranched, C12-aliphatic group. In some embodiments, R1, R2, R3 and R4 are In some embodiments, R1, R2, R3 and R4 are, independently, an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, R1, R2, R3 and R4 are /. In some embodiments, R1, R2, R3 and R4 are, independently, an unsubstituted and unbranched, C14 heteroaliphatic group.
In some embodiments, R1, R2, R3 and R4 are . In certain embodiments, R1, R2, R3 and R4 are, independently, selected from the following formulae:

[00167] In certain embodiments, R1, R2, R3, and R4 are, a C1-2o alkenyl moiety, optionally substituted. In certain embodiments, R1, R2, R3, and R4 are, independently, selected from the following formulae:

[00168] It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.
[00169] In certain embodiments, R1, R2, R3, and R4 are:

or [00170] In certain embodiments, R1, R2, R1, and R4 are, independently, selected from the following formulae:

O"y o^~
[00171] In certain embodiments, R1, R2, R3, and R4 are fluorinated. In certain embodiments R1, R2, R3, and R4 are a fluorinated aliphatic moiety. In certain embodiments R1, R2, R3, and R4 are perfluorinated. In certain embodiments R1, R2, R3, and R4 are a perfluorinated aliphatic moiety. In certain embodiments, R1, R2, R3, and R4 are a perfluorinated CI-20 alkyl group. In certain embodiments, R1, R2, R3, and R4are selected from the following formulae:

F F VF F F F F F F F F F

F F F F F F F F F F FFFFF F F F F F F F

F F F F F F > F F F F
F. F F F F F F F F F F F F F
F F F F F F F
/~ F F FFFF F F F F F F F F
F F F F F '~F
F FFFF F F F F F F F
F
F%~ iC\ /~ ~ il F F F F F F F F F F F F F F F F FFF F F F F F F F F

F~x~~\ F F F~FF F F FFFF F F F F F F F
F FF FF FF F F ,r F F FF F F F F ~FF F F F F
F F F F F
F )~' FF F F F FF F F F F F F F F F
F F
F F F F F F F F
F FFF F F FFF F F F F F F F F
F F F F F. F F F F F F F F F F F
F F F F F F F F F F F
F F F F F F F FF F F F F F F F F F F F F F F F F F F
F-i`~~`~~\ <!C~ /\ `S j"F F F AFF F F ~FF FFFF F F F F F F F
F F F F F F F F F F F
FFFF F F F F F F F FFF F F F F F F ~FF F F
F F F F F F F F F F F

[00172] In certain embodiments, R1, R2, R3, and R4 are, independently, selected from the following formulae:

0'/-F F F F F F F F F

O^` FF F FF FF FF F
F F FF FFF

F F F F F F F F

[00173] In certain embodiments, R1, R2, R3, and R4 are all the same. In certain embodiments, at least two of R1, R2, R3, and R4 are the same. In certain embodiments, at least three of R1, R2, R3, and R4 are the same. In certain embodiments, R1, R2, R3, and R4 are all different.
[00174] Particular exemplary compounds include:

I -;,,-CH3-(CH2)11 OH HO (CHz)11 CH3 (CH2)13 OH HO (CH2)13 N i-'-'01-"-"0,-,,_,N N l HO HO (CH2)11 OH (CH2) 13 CH3 (CH2)11 CH3 CH3 (CH2)13 CH3 CH CH
CH3-(CH2)11 OH HO\J/(CH2)11 3-(2)11 OH HO(CH2)11 N Ji N~~ N--N--' N NN-\/ N

/OH CH3 )OH
(CH2) 11 (CH2)11 CH3 (CHz)11 I CH (CH2)11 I
CH3 and 3 CH3 (CH2)11CH3 (CH2)11CH3 [00175] In certain embodiments, each HO --1-j is independently HO'/ or (CH2) CH3 HO-J-/
[00176] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 120 with the epoxide-terminated compound C14. In certain embodiments, the aminoalcohol lipidoid compound C 14-120 is one of the formulae below:
CH3-(CH2) "~c OH
H
CH3-(CH2)11 OH HO NFi H
N N/
H H CH3 (CH2)11 CH3 CH3-(CH2)11 OH HO- -12)11 CH3-(CH2)11 OH HO (CH2)ii N'-~O~~N, HO H
~ O
H H CH' (CH2)11 CH3-(CH2)1 1 OH HO (CH2)il N N
HO
OH
(CH2) CH3 (CH2)i1 I
or CH3 (CH2)11CH3 (CH2) CH3 (CH2)11CH3 or HO~,s=`
In certain embodiments, each HO~ is independently HO' In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.

[00177] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 120 with the epoxide-terminated compound C 16. In certain embodiments, the aminoalcohol lipidoid compound C16-120 is of one of the formulae below:
CH3-(CH2)13 OH
H
Nei ' O~iNI
CH3-(CH2)1 H
OH HO
H

H/ N H CH3 (CH2)13 CH3-(CH2)13 OH HO CH2)13 H
CH3-(CH2)13OH HO7(CH2)13 HO

H"N H CH3 (CH2)13 CH3-(CH2)13 OH HO (CH2)13 O N
HO
OH
(CH2 I13 CH3 (CH2)13 CH3 or (CH2)13CH3 (CH2)13CH3 (CH2)13CH3 /\
In certain embodiments, each HO is independently HO or HO
In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00178] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 98 with the epoxide-terminated compound C14. In certain embodiments, the aminoalcohol lipidoid compound C 14-98 is of one of the formulae below:

CH3-(CH2)1 OH
H H
NNNN
CH3-(CH2)11 OH HO H \H
H H
NN~~ N N
H/ H H . CH3 (CH2)h1 CH3-(CH2) OH HO (CH2)ll CH H
s N N
I N~~ N 'H
CH3-(CH2)11 OH HO,(CH2)ii HO H
H
HN~i HH CH(CH2)i1 CH3-(CH2)11 OH HO~(CH2)11 H
NNNN
HO H
OH
(CH2)11 or CHs (CH2)11 CH3 (CH2)11CH3 (CH2)11CH3 (CH2)1iCH3 i\
In certain embodiments, each HO 1 is independently HO / or HO
In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00179] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 113 with the epoxide-terminated compound C14. In certain embodiments, the aminoalcohol lipidoid compound C 14-113 is of one of the formulae below:

CH3-(CH2)11 OH
H
CH3-(CH2) OH NNN~
/H HO H

N~/NN
H CH3 H CH3 (CH2)11 CH3-(CH2)>> OH HO (CH2)11 CH3-(CH2)1 OH HO (CHz)i~ NNFi HO CH

HCH3H CH3(CH' CH3-(CH2)1 (CHz)~i 1"'~ OH HO, I

N~/~N~~N
HO CH

CH
CH3 (CH2)11 ( 2C 11 or H3 (CH2)11CH3 (CH2)11CH3 (CH2)11CH3 n 11, z In certain embodiments, each HO / is independently HO / or HO
In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00180] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 96 with the epoxide-terminated compound C18. In certain embodiments, the aminoalcohol lipidoid compound is of one of the formulae below:

HO (CH2)15 H3C. iH CH3 H3C N N~ HO (CH2)15 N~~N
HO H ~ HO \H
H3C\ ~~
N N
CH3 (CH2)15 H/ \H ; CH3 (CH2)15 HO (CH2)15 HO (CH2)15 )"', H3C\ H3C\

N"~N N~~N
H HO
(CH2)15 OH (CH2)15 OH
CH CH3 (CH2)15 CH
3 or 3 (CH2)15CH3 (CH2)15CH3 (CH2)15CH3 In certain embodiments, each HO F is independently HO "'Y or HO
In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00181] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 96 with the epoxide-terminated compound C14. In certain embodiments, the aminoalcohol lipidoid compound C14-96 is of one of the formulae below:

HO (CH2)11 H3C. i~~ iH CH3 H3C\
N N\ HO (CH2)11 N~\N\
HO H HO H
H3C\NN T_j CH3 (CH2)11 H/ \H . CH3 (CH2)11 HO )""(Ctl2hl HO (CH2)11 H3C~ H3C~
,NN N'*-~ N
H ~ HO

(CH2) 11 OH (CH2)11 OH
CH CH3 (CH )11 3 ; or 3 CH
(CH2)11CH3 (CH2)11CH3 (CH2)11CH3 i~
In certain embodiments, each HO / is independently HO / or HO
In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00182] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 110 with the epoxide-terminated compound C 14. In certain embodiments, the aminoalcohol lipidoid compound C14-1.10 is of one of the formulae below:
CH3-(CH2)11 OH
CH3-(CH2)11 OH H
N,' /H N N
H~NNNH HO H
~(CHz)11 NH2 CH3-(CH2)11 OH HO (CH2)11 CH3-(CH2)11 OH HO (CH2)11 N--,_,N, N~/~NN~ " HO N H
H H
(CH2)11 NH2 CH3-(CH2)11 OH HO CH2)1 CH3-(CH2)11 OH HO (CH2)11 H~N\~\NN\H
NN N-H
HO HO
OH

CH3 (CH2)11 NH2 (CH2) 1 11 (CH2)11 CH3 CH3-(CH2)11 OH Hp CH2)11 CH3-(CH2)11 OH HO CH2)11 N~~
HO\ NN\H HO N
\I OH
~(CH2)11 N-H CH3 ,(CH2)11 N-H (CHz111 CH ~(CH2)11 CH ,(CH2)11 3 s ; or CH3-(CH2)11 OH HO (CH2)11 NN
HO
OH
CH3 (CH2)11 HON CH2111 (CH)11 H3C (CH3)11 (CH2)11CH3 (CH2)11CH3 (CH2)11CH3 i\
In certain embodiments, each HO / is independently HO / or HO
In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00183] In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:

~ ~P
RA N N RF
4--/ wherein:

p is an integer between I and 3, inclusive;
m is an integer between I and 3, inclusive;
RA is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched Co i_2aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C, 20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;

RZ

RY
"Zry \--,) \--- W R5 OH OH ; or x Y

RF is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted RZ

\--- W Rv heteroaryl; OH ; OH; or x Y

each occurrence of R5 is independently hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1_20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;

RS \--,) wherein, at least one of RA, RF, Ry, and Rz is OH or OH;

each occurrence of x is an integer between I and 10, inclusive;
each occurrence of y is an integer between I and 10, inclusive;
each occurrence of Ry is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-2o aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.20 heteroaliphatic; substituted or unsubstituted aryl;
substituted or unsubstituted R5 \--,) heteroaryl; OH or OH;
each occurrence of RZ is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1_20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1_20 heteroaliphatic; substituted or unsubstituted aryl;
substituted or unsubstituted R5 \--,) heteroaryl; OH or OH ;
or a pharmaceutically acceptable salt thereof.
[00184] In certain embodiments, RA is hydrogen. In certain embodiments, RA is hydrogen.
In certain embodiments, RA is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.20 aliphatic. In certain embodiments, RA is CI-C6 aliphatic. In certain embodiments, RA is C1-C6 alkyl. In certain embodiments, RA is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.20 heteroaliphatic. In certain embodiments, RA is substituted or unsubstituted aryl. In certain embodiments, RA is substituted or unsubstituted heteroaryl. In certain embodiments, RA is OH . In certain embodiments, R5 _V) - %R5 R5 each OH is independently OH or OH . In certain embodiments, RA

RZ

Ry is OH. In certain embodiments, RA is X Y In certain RZ

I
embodiments RA is In certain embodiments RA
Rz c, N Rz `ZL N

is Ry In certain embodiments RA
Rz Rz N N
RY
is RZ
[00185] In certain embodiments, RF is hydrogen. In certain embodiments, no RF
is hydrogen. In certain embodiments, RF is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C)_() aliphatic. In certain embodiments, RF is Cj-C6 aliphatic.
In certain embodiments, RF is C)-C6 alkyl. In certain embodiments, RF is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C, 2O heteroaliphatic. In certain embodiments, RF is substituted or unsubstituted aryl. In certain embodiments, RF is substituted or unsubstituted heteroaryl. In certain embodiments, RF is OH . In certain embodiments, `~-/R5 ='1 ,,.RS R5 \ yR5 each /'z OH is OH In certain embodiments, each OH is OH . in certain RZ

RY
embodiments, RF is OH. In certain embodiments, RF is wx y . In Rz I

RY
certain embodiments RF is In certain embodiments RF
Rz N / Rz N
is Ry In certain embodiments RF
Rz Rz N N N
RY
I
is RZ In certain embodiments RF
Rz Rz is RZ Ry In certain embodiments RF

H
O

N CloH21 7,`L N

O OH
is C10H21 [00186] In certain embodiments, no RA is hydrogen and no RF is hydrogen. In certain Rz R
embodiments, RA is Y and RF
Rz N Rz R5 is Ry . In certain embodiments, RA is OH
R5 Rz Rz c, N N
N RY

or OH ; and RF is Rz In NlY R5 _V _ 'R5 \ yR5 certain embodiments, each OH is OH . In certain embodiments, each OH is RS

OH , In ceratin embodiments, RA is OH and RF
Rz Rz N N
Rv I
is Rz In certain embodiments, Rs ,R5 yR5 R5 each OH is OH . In certain embodiments, each OH is OH . In certain embodiments, RA is OH and RF

RZ RZ

N N~
RY
I
is RZ In certain embodiments, RA is OH

C1oH21 ClOH21 H,O
N
OH N'/~N yClOH21 H.O\ OH
C10H21 and RF is C10H21 C1oH21 C10H21 "~
[00187] In certain embodiments, each HO is HO . In certain embodiments, ~oH21 C1oHz1 each HO is HOJJI\\/ . In certain embodiments, in is 1. In certain embodiments, in is 2.
In certain embodiments, in is 3.
[00188] In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
[00189] In certain embodiments, R5 is hydrogen. In certain embodiments, R5 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1_2o aliphatic.
In certain embodiments, R5 is C8-C16 aliphatic. In certain embodiments, R5 is C8-C16 alkyl. In some embodiments, R5 is an unsubstituted and unbranched, C10_12-aliphatic group. In some embodiments, R5 is In some embodiments, R5 is In some embodiments, R5 is In certain embodiments, R5 is selected from the following formulae:

~as [00190] In certain embodiments, R5 is a CI-20 alkenyl moiety, optionally substituted. In certain embodiments, R5 is selected from the following formulae:

/ f,ss In certain embodiments, R5 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 heteroaliphatic. In some embodiments, R5 is an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, R5 is an unsubstituted and unbranched, C14 heteroaliphatic group. In certain embodiments, R5 is:

O^,,r+'` Ora'` O^~
or [00191] In certain embodiments, RS is, independently, selected from the following formulae:

O'Y
[00192] It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.
[00193] In certain embodiments, R5 is substituted or unsubstituted aryl. In certain embodiments, R5 is or substituted or unsubstituted heteroaryl.
[00194] In certain embodiments, R5 is fluorinated. In certain embodiments RS
is a fluorinated aliphatic moiety. In certain embodiments R5 is perfluorinated. In certain embodiments R5 is a perfluorinated aliphatic moiety. In certain embodiments, R5 is a perfluorinated C) 2O alkyl group. In certain embodiments, R5 is selected from the following formulae:

F F F F F F F FF E F F F

F F F F F FF F F F F F F F F F F F
F FF F F F FFF FF FF FF F
F F F F
F F F F F F FFFF F F F F F F F F
X_-__F F F FFFF F F F F F F F
F\x` ~

F F F F F F F F F F F F F F F FFFF F F F F F F F F

F%~/ kKTh F F F F F F F F F F F F F F
F F F F F F F
F F F F F F F F F F FFF F F F F F F F F
F F F F F F F F F F FF FF FF F
F FF FF FF F F
F F FF F F F F FF FF F FF FF FF F
F F F FF FF FF FF FF F
FF FF F
F~
F I FF FF FF F , F F FEE F F FFF F F F F F F F F
F
F F F F F F F
F FF F F FF F F FF FF FF F
F F FF FF FF F F , F F F F F F F F F FFFFFFFFFFFFFFFFFF
F
F-~\~~`% F F F F F F F FFFF F F F F F F F
F F F F F F F F F F F
F F F F F F F F F FFF F F FF F F F F F F F F F F
F F F
F
FFF F F F F F F F F

[00195) In certain embodiments, R5 is selected from the following formulae:
O^/-F F FF FF F F F 4\!YC\~
O^` F F F F F F F F F F
F F FF F F F F

F F F F F F F F

[00196] In certain embodiments, each R5 is independently hydrogen, or C1-C6 alkyl. In certain embodiments, each R5 is hydrogen. In certain embodiments, R, and R3 each R5 is C1-C6 alkyl. In certain embodiments, each R5 is hydroxyalkyl. In certain embodiments, each R5 is aminoalkyl. In certain embodiments, two R5 variables are the same. In certain embodiments, three R5 variables are the same. In certain embodiments, each R5 variable is different from the other.
[00197] In certain embodiments, x is 1. In certain embodiments, x is 2. In certain embodiments, x is 3. In certain embodiments, x is 4. In certain embodiments, x is 5. In certain embodiments, x is 6. In certain embodiments, x is 7. In certain embodiments, x is 8. In certain embodiments, x is 9. In certain embodiments, x is 10.
[00198] In certain embodiments, y is 1. In certain embodiments, y is 2. In certain embodiments, y is 3. In certain embodiments, y is 4. In certain embodiments, y is 5. In certain embodiments, y is 6. In certain embodiments, y is 7. In certain embodiments, y is 8. In certain embodiments, y is 9. In certain embodiments, y is 10.
[00199] In certain embodiments, x is 1 and y is 2. In certain embodiments, x is I and y is 3.
In certain embodiments, x is I and y is 4. In certain embodiments, x is 1 and y is 5. In certain embodiments, x is 2 and y is 2. In certain embodiments, x is 2 and y is 3.
[00200] In certain embodiments, Ry is hydrogen. In certain embodiments, Ry is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C,_20 aliphatic.
In certain embodiments, Ry is is C1-C6 alkyl. In certain embodiments, Ry is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C,_20 heteroaliphatic. In certain embodiments, Ry is substituted or unsubstituted aryl. In certain embodiments, Ry is substituted or unsubstituted \--'~Y heteroaryl. In certain embodiments, Ry is OH . In certain embodiments, R5 .,%R5 R5 each OH is independently OH or OH . In certain embodiments, Ry is OH
[00201] In certain embodiments, Rz is hydrogen. In certain embodiments, Rz is substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 aliphatic.
In certain embodiments, Ry is is C1-C6 alkyl. In certain embodiments, Rz is substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 heteroaliphatic. In certain embodiments, Rz is substituted or unsubstituted aryl. In certain embodiments, Rz is substituted or unsubstituted heteroaryl. In certain embodiments, Rz is OH . In certain embodiments, \ yR5 ,,''R5 \ y#R5 each OH is independently OH or OH . In certain embodiments, RZ

is OH.

[00202] Particular exemplary compounds include:
C1oH21 HO~

NN`-N'--,rC1oHz1 N C1oH21~ ,NJ HOJ OH OH _,N`~NN~C1oH21 OH l OH C1oH21 HO\ J HO\ J OH
CC1oH21 and C1OH21 C1oH21 [00203] In certain embodiments, the aminoalcohol lipidoid compounds of the present invention comprises a mixture of formulae:
ClOH21 HO 1 CtoH21 rNII --iN`-N--,rC10H21 Ci0H2iON ~OH
CloHz1~N~, N HO C\ ) OH OH '/'NN`'N~-yCioH2i OH OH ClOH21 HO, J HO) OH
ClOH21 and ClOH21 ClOH21 [00204] In certain embodiments, each HO / is independently HO'/ or ClOH21 HO
[00205] In certain embodiments, the aminoalcohol lipidoid compound of the present invention is of the formula:
RA
I
RAC N
N k"W RA
I x y RA
wherein:
each occurrence of RA is independently hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1_20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; OH ; or OH; wherein at least one RA

R5 \--,) is OH or OH;

each occurrence of R5 is independently hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.2() heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
each occurrence of x is an integer between 1 and 10, inclusive;
each occurrence of y is an integer between I and 10, inclusive;
or a pharmaceutically acceptable salt thereof.
[00206] In certain embodiments, RA is hydrogen. In certain embodiments, no RA
is hydrogen. In certain embodiments, at least one RA is hydrogen. In certain embodiments, RA is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1_2() heteroaliphatic. In certain embodiments, RA is substituted or unsubstituted aryl. In certain embodiments, RA is substituted or unsubstituted heteroaryl. In certain embodiments, two RA's together may form a cyclic structure. In certain embodiments, at least one RA is OH . In certain N- RS
N-Y X- \R5 embodiments, each OH is OH . In certain embodiments, each OH is RS
Rs independently OH . In certain embodiments, at least one RA is OH. in certain embodiments, RA is substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI-20 aliphatic. In certain embodiments, at least one RA is an alkenyl group. In certain embodiments, at least one RAis In certain embodiments, at least one RA In certain embodiments, at least one RA is In certain embodiments, at least one RA is In certain embodiments, at least one RA is . In certain embodiments, at least one RA is . In certain embodiments, at least one RA is an alkynyl group. In certain embodiments, at least one RA In certain embodiments, at least one RA is a substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1.20 heteroaliphatic group. In certain embodiments, at least one RA is a R5 N,C J
heteroaliphatic group. In certain embodiments, at least one RA is H . In certain R5.NC s embodiments, at least one RA is H . In certain embodiments, at least one RA is R5 . In O
.
certain embodiments, at least one RA is R5. 0 . Cs'. In certain embodiments, two RA variables are the same. In certain embodiments, three RA variables are the same. In certain embodiments, each RA variable is different from the other.
[00207] In certain embodiments, R5 is hydrogen. In certain embodiments, R5 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched CI 20 aliphatic.
In certain embodiments, R5 is C8-C16 aliphatic. In certain embodiments, R5 is C8-C16 alkyl. In some embodiments, R5 is an unsubstituted and unbranched, C10_12-aliphatic group. In some embodiments, R5 is In some embodiments, R5 is In some embodiments, R5 is In certain embodiments, R5 is selected from the following formulae:

\~,sf [002081 In certain embodiments, R5 is a CI-20 alkenyl moiety, optionally substituted. In certain embodiments, R5 is selected from the following formulae:

[00209] In certain embodiments, R5 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1 20 heteroaliphatic. In some embodiments, R.
is an unsubstituted and unbranched, C13 heteroaliphatic group. In some embodiments, R5 is an unsubstituted and unbranched, C14 heteroaliphatic group. In certain embodiments, R5 is:

or [00210] In certain embodiments, R5 is, independently, selected from the following formulae:

woo^~
[00211] It will be appreciated by one of ordinary skill in the art that the above substituents may have multiple sites of unsaturation, and could be so at any position within the substituent.
[00212] In certain embodiments, R5 is substituted or unsubstituted aryl. In certain embodiments, R5 is or substituted or unsubstituted heteroaryl. In certain embodiments, R5 N--r R5 N-) IR5 is OH . In certain embodiments, each OH is independently OH or OH . In certain embodiments, R5 is OH.
[00213] In certain embodiments, R5 is fluorinated. In certain embodiments R5 is a fluorinated aliphatic moiety. In certain embodiments R5 is perfluorinated. In certain embodiments R5 is a perfluorinated aliphatic moiety. In certain embodiments, R5 is a perfluorinated C1 20 alkyl group. In certain embodiments, R5 is selected from the following formulae:

F F ~FF F F F F F F F F

F F F F F F FF F F F F F F F F F

F F E F F F ~FF F F F F F F F F^
F F F F F F F F F F F F F F F
F FF F F
F F F F F F F F F F F F F F
F F F F F F F'~/
F F F F F '~F ~\ F F FFFF F F F F F F F F
F) i ~1 /~ ,s`` F F F FFFF F F F F F F F
F F F F F F F F Fil F F F F F F F F FFF F F F F F F F F
F\~ F F FFF F F F F F F F F
F FF FF FF F F
F F `F F F F F FF F F F F F F F F F F
F F F F F F F F F F F F
F~
F F F ~FF
F F FF FF FF F F , F Fr FF
F F F F F F F F F
F~
F FF F F F F F F F F F F. F F F
FF F FF FF FF F F , -~ ~ ~ F F F F F F F F F FFFF F F F F F F F F F F F F F F

F FF F F F F F F F FFFF F F F F F F F
F F F F F F F F F F
F F F F F F F F F F F F FFF F F FF F F F F F F F F F F
F
FFF F F F F F F F F

[002141 In certain embodiments, R5 is selected from the following formulae:

F F F F F F F F F

F F F F F F F F F F
IF F F F F F F

F17\~~~<%
F F F F F F F F

[00215] In certain embodiments, each R5 is independently hydrogen, or C1-C6 alkyl. In certain embodiments, each R5 is hydrogen. In certain embodiments, R, and R3 each R5 is C1-C6 alkyl. In certain embodiments, each R5 is hydroxyalkyl. In certain embodiments, each R5 is aminoalkyl. In certain embodiments, two R5 variables are the same. In certain embodiments, three R5 variables are the same. In certain embodiments, each R5 variable is different from the other.
[00216] In certain embodiments, x is 1. In certain embodiments, x is 2. In certain embodiments, x is 3. In certain embodiments, x is 4. In certain embodiments, x is 5. In certain embodiments, x is 6. In certain embodiments, x is 7. In certain embodiments, x is 8. In certain embodiments, x is 9. In certain embodiments, x is 10.
[00217] In certain embodiments, y is 1. In certain embodiments, y is 2. In certain embodiments, y is 3. In certain embodiments, y is 4. In certain embodiments, y is 5. In certain embodiments, y is 6. In certain embodiments, y is 7. In certain embodiments, y is 8. In certain embodiments, y is 9. In certain embodiments, y is 10.
[00218] In certain embodiments, an aminoalcohol lipidoid compound or composition containing aminoalcohol lipidoid compound(s) is prepared by reacting an amine of one of the formulae:

62 H3C`NCH3 H2N'~~ N . NH2 114 H H H
96 H3C,N--------NH2 H2N NH2 H

100 H2N--~NH2 H2NNH2 120 H
103 HO~~N""--'N

H
H
109 H2N~,~N`OH

110 H2N~-'NNH2 H2N NH2 111 H2NN""~H~~N~"NH2 H N~~ NH2 H2N~~Ni~NH2 113 112 z H CH3 H2_] R :~R N
Me~C T~ N NHz I i N Y
~~NHz ~~NHz n=0-14 R Y R=H,OMe.N02 R = OMe, H, NO2 Y = CH, N
NNH2 CI lliz~
N""~N~~NH2 H NH I R = Me, Br, Cl, FA H
~~ z H R
N N,~,~NHz H R
N ,, - NH2 O H N R=Me, Et H N - NH2 N ~ I N - NH2 N~~,,NHz ~I ~O1 NH
/ N~~NHz Me,H
N~-N~/-NH2 H
J H
0 ~Cz-~T C~NH
H
z H3C s H2 8 HO~'N~~NH
H z NHz HO~~N~/~NH2 ~ HNH2 oH~,NH2 H

O NNH2 A r N-~NH2 Me0 OH H Me H
NNH2 Ni~/~N-,iNH2 Nzz N~\NH2 OH H H I X = CH, N

H X = CH, N HO'*'~ N NH2 I N'/~NH2 H R R = H, F, CH3, OMe HN

H X = CH, N McO~~N 2 O(Oal-,N'-~NH2 Y Y=H,CI /~HN I j N NH2 with an epoxide-containing compound of one of the formulae:

C8b O~O O C16 F F F F F F
ClOd F
F O
F F F F F F F F F F

C11f F F F F F F F F 0 0 F O CH CHnCH2L-~ F F F F F F F F 2 n=0-16 n n=0-16 In certain embodiments, the epoxide-terminated compounds are of the formula:

C6 ~' O O v C8b O
O Ci6 ClOd F~~FF F O
F F F F F F F F F F

C11f F O
F O CH CH3 L-~c n F F F F F F F F ~ L~ 2 n=0-16 n n=0-16 In certain embodiments, the epoxide-containing compound is of the formula:

C8 0 =110 C14 C8b O.0 0 C16 F F FF FF FF F
ClOd F
F F F F F F F F F F
F F F F F F F
C11f F O 0 rCHn = 0 16 CH2 n n=0-16 F 0 CH2n F F F F F F F F

[00219] In certain embodiments, the epoxide contains one or more chiral centers, such as those shown below for amine C8b:

C8b [00220] In certain embodiments, one equivalent of an amine is reacted with one equivalent of an epoxide-terminated compound. In certain embodiments, one equivalent of an amine is reacted with one, two, three, four, five, six or more equivalents of an epoxide-terminated compound. In certain embodiments, the amount of epoxide-terminated compound is limiting to prevent the functionalization of all amino groups. The resulting aminoalcohol lipidoid or aminoalcohol lipidoid composition in these instances contain secondary amino groups and/or primary amino groups. Aminoalcohol lipidoid compounds having secondary amines are particular useful in certain instances. In certain embodiments, amine-containing aminoalcohol lipidoid compounds that have not been fully functionalized are father reacted with another electrophile (e.g., terminal epoxide, alkyl halide, etc.). Such further functionalization of the amines of the aminoalcohol lipidoid compound results in aminoalcohol lipidoid compounds with different epoxide-compound derived tails. One, two, three, four, five, or more tails may be different from the other tails of the aminoalcohol lipidoid compounds.
[00221] In certain embodiments, it will be appreciated by one skilled in the art that the amine and the epoxide will react at the unsubstituted carbon of the epoxide resulting in an aminoalcohol lipidoid compound as shown in the following schemes.

co H+
C_ R, HN~ OH
NH R Ri R

H+
CO ,OH
Rt HN

R

CO H+
-~=
Rt HN OH
NH2 R Rt R

HO` OPG 1 imine formation OH
2. Reduction HN~
H , R 3. Deprotection R R1 R
[00222] In certain embodiments, the epoxide is stereochemically pure (e.g., enantiomerically pure). In certain embodiments, the amine is stereochemically pure (e.g., enantiomerically pure). In certain embodiments, the lipidoid is prepared from the reductive amination of an imine which derived from the condensation of an amine and an aldehyde. The compounds of the invention can have an enantiomeric excess or a diastereomeric excess up to and including 2%, 5%,10%,15%, 20%, 25%, 30%, 35%, 40%,45%,50%, 55%, 60%, 61%, 62%,63%,64%,65%,66%, 67%, 68%,69%,70%,71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,90%,90.5%,91%, 91.5%, 92%,92.5%,93%,93.5%, 94%,94.5%,95%,95.5%,96%,96.5%,97%, 97.5%,98%,98.5%, 99%, 99.5%, or 100%.
[00223] In other embodiments, it will be appreciated by one skilled in the art that the amine and the epoxide will react at the substituted carbon of the epoxide resulting in an aminoalcohol lipidoid compound as shown in the following scheme.

H+
HO(R1 .:, R1 ~ HN.R
NH

While the above reaction may be less preferred, it is likely to occur at least to some degree and may be more favored under certain reaction conditions. An aminoalcohol lipidoid compound may have amines that have reacted in one or both manners.
[00224] In certain embodiments, the amine and epoxide-terminated compound are reacted together neat. In other embodiments, the reaction is done in a solvent (e.g., THF, CH2C12, MeOH, EtOH, CHC13, hexanes, toluene, benzene, CCI4, glyme, diethyl ether, etc.). In certain embodiments, the reaction mixture is heated. In certain embodiments, the reaction mixture is heated to temperature ranging from 30 C-100 C. In another embodiment, the reaction mixture is heated to approximately 90 C. The reaction may also be catalyzed. For example, the reaction may be catalyzed by the addition of an acid, base, or metal (e.g., Lewis acid). The reaction may be allowed to proceed for hours, days, or weeks. In certain embodiments, the reaction is allowed to proceed for 1-7 days. In certain embodiments, the reactions were run from about 1 to about 3 days. The resulting composition may be used with or without purification. In certain embodiments, the lipidoids are subsequently subjected to an alkylation step (e.g., reaction with methyl iodide) to form quaternary amine salts. Optionally, various salt forms of the lipidoids may be prepared. In certain embodiments, the salts are pharmaceutically acceptable salts.
[00225] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of~aminoalcohol lipidoid compounds is prepared by reacting amine H2N"/-'NN
H
200 amine 200 with an epoxide-terminated compound. In certain embodiments, the amine 200-derived aminoalcohol lipidoid compounds (i.e., C12-200) and its various possible isomers are of the formulae below:
tails HO
N---N - N--yClOH21 C1oH21N ,, INJ HO \J OH

4 tails CH2CH(OH)C10H21 ^N N N,CH2CH(OH)C1OH21 C H21 HO) H
( CHZC,NJ CH2CH(OH)C1oH21 H

CH2CH(OH)C10H21 C10H21(HO)HCH2C N N -CH2CH(OH)C10H21 C10H21(HO)H CH2C- N N N

CH2CH(OH)C10H21 H NN ,CH2CH(OH)C10H21 C10H21(HO)HCH2C"N~"---'NNJ
CH2CH(OH)C10H21 3 tails C10H21(HO)HCH2C I NNH2 C10H21(HO)HCH2C"NNN J
CH2CH(OH)C10H21 H
C10H21(HO)HCH2C NN,CH2CH(OH)C10H21 C10H21(HO)HCH2C-N-----N N

CH2CH(OH)C10H21 N N "-~N,CH2C H(OH)C10H21 C1OH21(HO)HCH2C,Ni-, N J H
H

CH2CH(OH)C10H21 H N N'CH2CH(OH)C10H21 ClOH21(HO)HCH2C-NNv H
CH2CH(OH)C10H21 N i~ N -CH2CH(OH)C10H21 H2N~~NN

CH2CH(OH)C10H21 2 tails C10H21(HO)HCH2C NNH2 C10H21(HO)HCH2C-N '-"~Hi-,N
rNNH2 H
C10H21(HO)HCH2C'N ,_,--,, N--, N
CH2CH(OH)C10H21 H
~NN'CH2CH(OH)C10H21 C10H21(HO)HCH2C" N N N

H
N---~N-CH2CH(OH)C10H21 H2NN I'Ij CH2CH(OH)C10H21 CH2CH(OH)C10H21 N N -CH2CH(OH)C10H21 H2N~~NN
H

I tail /~
1 N-,~ NH2 ClOH21(HO)HCH2C" N ~~N--, N

CH2CH(OH)C10H21 N/-~ N "-~NH2 H2N~~N ;and I-Ij H

N--___N-CH2CH(OH)C10H21 H

C1oH21 C1oH21 JI ~ i~
[00226] In certain embodiments, each HO/ is independently HO / or ~oHz1 HO
[00227] In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00228] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 205 H2N--"\-NH

N NH
amine 205 with an epoxide-terminated compound C12. In certain embodiments, the amine 205-derived aminoalcohol lipidoid compounds (i.e., C12-205) and its various possible isomers are of the formulae below:

tails C1oH21 C1oH21~ON ~OH
OH '/-'NNN-^'y ClOH21 HO\ J HO\ J OH
ClOH21 TC1OH21 4 tails C10H21(HO)HCH2C (NH
%
C1oH21(HO)HCH2C,N--~ N"----N--~ N
C10H21(HO)HCH2C CH2CH(OH)C10H21 .
C10H21(HO)HCH2C ^NI .CH2CH(OH)ClOH21 C1oH21(HO)HCH2C,NNN( H
C10H21(HO)HCH2C

^ N.CH2CH(OH)CbOH21 C H HO)H r I
21( CH2C.NNNN
C10H21(HO)HCH2C CH2CH(OH)C10H21 C10H21(HO)HCH2C ^N-CH2CH(OH)C10H21 C,oH21(HO)HCH2C,N~-N-~NN( H CH2CH(OH)C10H21 3 tails C10H21(HO)HCH2C (NH
C1oH21(HO)HCH2C,NNN
C10H21(HO)HCH2C H

H ~NH
C10H21(HO)HCH2C.N--~,,NNN I

C1OH21(HO)HCH2C CH2CH(OH)C10H21 .

^N CH2CH(OH)C1OH21 H
C1oH21(HO)HCH2C.N---,_,N"---NNJ
C10H21(HO)HCH2C H
C10H21(HO)HCH2C NH

1o 21( ) CH2C.NN"/-N--~ N
H CH2CH(OH)C10H21 .
C10H21(HO)HCH2C rN-CH2CH(OH)C10H21 %
C1oH21(HO)HCH2C.N---~NNN
H H
rN.CH2CH(OH)C10H21 H
C1oH21(HO)HCH2C.NNNN
H CH2CH(OH)C10H21 CH2CH(OH)C1oH21 C1oH21(HO)HCH2C N"
HNN--~N
C10H21(HO)HCH2C H

2 tails C10H21(HO)HCH2C (NH
C1oH21(HO)HCH2C.NN"'---N~~N
H H

(NH
C10H27(HO)HCH2C.N-~~ NNN

H CH2CH(OH)C10H21 ^N.CH2CH(OH)C1OH21 C H HO
21( )HCHZC.N-~N"-N~~N
H H
C10H21(HO)HCH2C (NH
H2NNN~~N
CH2CH(OH)C1OH21 ;
C10H21(HO)HCH2C ( N-CH2CH(OH)C1OH21 H

NCH2CH(OH)C1OH21 i NNNN

CH2CH(OH)C10H21 1 tail (NH
C1oH21(HO)HCH2C.N---~N`---NN J
H H
C10H21(HO)HCH2C (NH
H2N~~N'/'-NN
H
N (NH
H2N~~~-NN
CH2CH(OH)C10H21 ; and N.CH2CH(OH)C10H21 H2N"-- NNN
H
ClOH21 C10H21 [00229] In certain embodiments, each HO is independently HO'/ or CaoH2i [00230] In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00231] In certain embodiments, the aminoalcohol lipidoid is of the ClOH21 HO-~
N--._,N'-/-N--,TClOH21 C1oH21 ^N ,, (N J HO` J OH

OH 1-T- OH ClOH21 formula C10H21 In certain embodiments, the aminoalcohol lipidoid compound is of the ClOH21 ClOH21 -T--' -N OH
OH ON '/"N~,,N'-/"N~yCIOH21 HO\ J HO\ J OH

formula C10H21 C10H21 In certain embodiments, the HO-~
NN'/-N--,,rCIOH21 ClOH21\ ^N^, IN J HO) OH
OH /OH ClOH21 aminoalcohol lipidoid compound is a mixure of C1OH21 C1oH21 C1oH21 -r"~N HOH
OH N~~ N-"- C70H21 HO J HO J CtOH21 T TT
and C10H21 C10H21 . In certain embodiments, each HO / is CtoH21 C1oHzt independently HO^/ or HOX

[00232] In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00233] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 96 H
Me N,_,,,_,NH2 amine 96 with an epoxide-terminated compound C16. In certain embodiments, the amine 96-derived aminoalcohol lipidoid compounds (i.e., C16-96) and its various possible isomers are of the formulae below:

3 tails Me CH2CH(OH)C14H29 C14H29(HO)HCH2C-N N' CH2CH(OH)C14H29 2 tails Me CH2CH(OH)C14H29 HN CH2CH(OH)C14H29 Me CH2CH(OH)C14H29 C14H29(HO)HCH2C'N - NH

1 tail Me CH2CH(OH)C14H29 HN,,,,NH

Me C14H29(HO)HCH2C- N,,, NH2 [00234] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 210 H2N--/_N \--j N---\-NH2 amine 210 with the epoxide-terminated compound C 12. In a similar manner as illustrated above, one skilled in the art will readily be able to determine the various possible 210-derived aminoalcohol lipidoid compounds (i.e., C12-210) isomeric structures that are possible from this reaction.
[00235] In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00236] In certain embodiments the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine (NH

H
220 amine 220 with the epoxide-terminated compound C12. In a similar manner as illustrated above, one skilled in the art will readily be able to determine the various possible 220-derived aminoalcohol lipidoid compounds (i.e., C12-220) isomeric structures that are possible from this reaction.
[00237] In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.
[00238] In certain embodiments, the aminoalcohol lipidoid compound or composition containing a mixture of aminoalcohol lipidoid compounds is prepared by reacting amine 111 H
H2NNN'-"-'NNH2 H H
amine 111 with the epoxide-terminated compound C12. In a similar manner as illustrated above, one skilled in the art will readily be able to determine the various possible 111-derived aminoalcohol lipidoid compounds (i.e., C12-111) isomeric structures that are possible from this reaction.
[00239] In certain embodiments the aminoalcohol lipidoid composition, is a composition containing one or more of the above aminoalcohol lipidoid compounds.

2. Synthesis of Aminoalcohol Lipidoid Compounds [00240] The inventive aminoalcohol lipidoid compounds may be prepared by any method known in the art. Preferably the aminoalcohol lipidoid compounds are prepared from commercially available starting materials, such as terminal-epoxide compounds, interior epoxide compounds, and amines. In another embodiment, the aminoalcohol lipidoid compounds are prepared from easily and/or inexpensively prepared starting materials. As would be appreciated by one of skill in the art, the inventive aminoalcohol lipidoid compounds can be prepared by total synthesis starting from commercially available starting materials. A
particular aminoalcohol lipidoid compound may be the desired final product of the synthesis, or a mixture of aminoalcohol lipidoid compounds may be the desired final product.
[00241] In certain embodiments, the inventive aminoalcohol lipidoid compound is prepared by reacting an amine with an epoxide-terminated compound. An exemplary reaction scheme is shown in Figure 1.
[00242] Any amine containing between one, two, and five amine functionalities is useful in preparing inventive aminoalcohol lipidoid compounds. Primary amines useful in this invention include, but are not limited to, methylamine, ethylamine, isopropylamine, aniline, substituted anilines, ethanolamine, decylamine, undecylamine, dodecylamine, tetradecylamine, hexadecylamine, and octadecylamine. The amine may be a bis(primary amine) including, but not limited to, ethylenediamine, 1,3 diaminopropane, 1,4 diamino butane, 1,5 diaminopentane, 1,6 diaminohexane, 2,2'(ethylenedioxy)bis(ethylamine). The amine may be a bis(secondary amine). Secondary amines useful in this invention include, but are not limited to dipropylamine and methylpentylamine. The amine may include both primary and secondary amines including, but not limited to, (2-aminoethyl) ethanolamine, diethylenetriamine and triethylenetetramine.
Preferably, the amine is commercially available. In certain embodiments, the amine is stereochemically pure (e.g., enantiomerically pure).
[00243] In certain embodiments, the amine used in the synthesis of the aminoalcohol lipidoid compound is of the formula:

62 H3C'N"-~ N.CH3 H2N'/"NNH2 114 H H H
96 H3C,N--------NH2 H2N NH2 H
98 H2N,NHNH2 H
103 HO~~N'-"--'H~~OH H2N NH2 H
109 H2NN--'OH

110 H2N'-"~ N -N H2 H2N NH2 N~- N ~\

N H2 H2N' /~ N i-~ NH2 113 H CH

R
Me n ~/~iNH2 kC2 H Y I N
H~--NHp I N~~NHZ n =0-14 R I Y R R=H,OMe.N02 R = OMe, H, NO2 Y = CH, N
N,-,'-,-,NH2 Cl _,~~NHp N N H

H
N,_,,-,,~,NH2 I H R R Me, Br, Cl, F3C, H
N N~~NH2 H R
N,_,-,,',NH2 Col H N R=Me,Et H ~N~ - NH2 N1 I N - NH2 ~I( O
H 'NH
N--'-N--'-NH2 ~~iNH2 Me-N
OJ kC2-~C~NH H
HOBN^~~NH aN~,NH2 H3C s ` H2 8 HO,~N-,~iNH2 H~/NH2 V N _,NH2 H v H N~,NH2 NNN H
MeH Me H

OH H H I X X= CH, N
N
= CH, N HOi~~NNH2 I N~~NH2 H X
R R = H, F, CH3, OMe N NH
z NH

X I Y H Y= H , N Me0'~`H'~ 2 ~o~N"~NH2 N NH2 I N-~~NH2 N
[00244] Epoxide-terminated compounds that are useful in the present invention include any epoxide-terminated compounds that are racemic or stereoisomers thereof, all of varying chain lengths and feature unique functional groups having varying degrees of saturation. In certain embodiments, the epoxide is stereochemically pure (e.g., enantiomerically pure). In certain embodiments, the epoxide contains one or more chiral centers. In certain embodiments, the epoxide-terminated compounds are of the formula:

~O O C12 C8b O'*"-vO O C16 C1o F F F F F F F F F
Clod F Cx, F O
F F F F F F F F F F

C11f F
F OCH CH3CHzJ
L-~
F F F F F F F F n n=0-16 n n=0-16 In certain embodiments, the epoxide-terminated compounds are of the formula:

C8 O p C14 C8b O"'~-Vp 0 C16 C1o p C18 ClOd F
F
F F F
F F F F F F
F F F

C11, F 0 - L~ ~ F O CH CH3CHz~
F F F F F F F F 2 In n=0-16 n n=0-16 In certain embodiments, the epoxide-terminated compounds are of the formula:

C8b F
F F F F F F F
FeW
4- .110 F F F F F
C11f F
F 0 CH CH CH2~
F`7\~~~FF F F F O O
L-ii F 2 n n n=0-16 n n0-16 [00245] In certain embodiments, the epoxide contains one or more chiral centers, such as those shown below:

C8b O
[00246] In certain embodiments, the enantiomeric epoxide R1 is resolved from the racemic mixture of epoxides using hydrolytic kinetic resolution (HKR) catalyzed with the (R,R)-HKR catalyst of the formula:

H; 'H
-N-, ZN
Co t-Bu O' 'O - t-Bu t-Bu t-Bu Ova In further embodiments, the enantiomeric epoxide R1 is resolved from the racemic mixture of epoxides using hydrolytic kinetic resolution (HKR) catalyzed with the (S,S)-HKR
catalyst of the formula:

H' . H
-N\ /N
Co t-Bu O" \O - t-Bu t-Bu t-Bu In certain embodiments, the aminoalcohol lipidois of the invention are prepared from a process comprising steps of.

VY OH
(a) converting the epoxide primary alcohol of the formula: 0 ; into the corresponding protected primary alcohol derivative of the formula: 0 -OPG1 (b) reacting the protected primary alcohol derivative of the formula: 0 ; with a R, -T--**, OPG, carbon-based nucleophile to produce the secondary alcohol of the formula: OH

R1-OPGj (c) converting the secondary alcohol of the formula: OH into the corresponding R, Y"_ OPG, protected secondary alcohol derivative of the formula OPG2 (d) deprotecting the protected secondary alcohol derivative of the formula R1Y-*" OPGi R1'1_rOH
OPG2 into the corresponding primary alcohol of the formula OPG2 R, Y,-- OH
(e) oxidizing the primary alcohol of the formula OPG2 into the corresponding aldehyde R,\^O

of the formula OPG2 Rj\^O
(f) condensing the aldehyde of the formula: OPG2 with an amine of the formula:
R, H Rc RC
N.~,~,,,,,,A.,~,,,,,,,N PG20 N.,,,,,,,,,,A~N/
/ \ /
RB RD ; to produce an imine of the formula: RB RD
and R, PG2O N A N/Rc (g) reducing an imine of the formula: RB RD ; to produce the R, PG2O Rc N" A N/
corresponding amine of the formula: RB RD ; wherein R, is hydrogen, a substituted, unsubstituted, branched or unbranched CI-20-aliphatic or a substituted, unsubstituted, branched or unbranched C1_20 heteroaliphatic, wherein at least one occurrence of R, is hydrogen; RB, Rc, and RD are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1.20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1.2o,-heteroaliphatic or -CH2CH(OH)RE; RB and RD together may optionally form a cyclic structure; Rc and RD together may optionally form a cyclic structure; RE is a substituted, unsubstituted, branched or unbranched C1.20 aliphatic or a substituted, unsubstituted, branched or unbranched C1.20 heteroaliphatic; and PG1 and PG2 are 0-protecting groups as described herein.

OH
In certain embodiments, the epoxide primary alcohol of step (a) is 0 ; and the amine of R, PG2O/-----\ /Rc /N A- N\
step (f) is RB RD . In certain embodiments, the epoxide primary alcohol R, ~-A
77-"0'-OH PGZO N^^^^^A-N/RC
p i and the amine of step (f) is RB RD.
of step (a) is 0 \
[00247) The chiral epoxides useful in the invention can be obtained from a variety of sources which are familiar to those skilled in the art of organic synthesis.
In some embodiments, the chiral epoxides useful in the invention can be obtained commercially. In some embodiments, the chiral epoxides useful in the invention can be synthesized according to methods known to those of skill in the art, such as, but not limited to the Sharpless epoxidation of primary and secondary allylic alcohols into 2,3-epoxyalcohols (Katsuki, et al., J. Am. Chem.
Soc. 1980, 102, 5974; Hill, et al., Org. S.yn., Coll. Vol. 7, p.461 (1990);
Vol. 63, p.66 (1985) and Katsuki, et al., Org. React. 1996, 48, 1-300; incorporated herein by reference.) In some embodiments, the chiral epoxides useful in the invention are obtained from the resolution of racemic epoxides. In some embodiments, the chiral epoxides useful in the invention are obtained by the separation of enantiomers or diastereoisomers on chiral columns.
[00248] In certain embodiments, the reaction is performed neat without the use of a solvent.
In other embodiments, a solvent is used for the reaction. Both or one of the starting amine or epoxide-terminated compound is dissolved in an organic solvent (e.g., THF, CH-,Ch, MeOH, EtOH, CHC13, hexanes, toluene, benzene, CC14, glyme, diethyl ether, etc.). The resulting solutions are combined, and the reaction mixture is heated to yield the desired aminoalcohol lipidoid compound. In certain embodiments, the reaction mixture is heated to a temperature ranging from 25 C to 100 C, preferably at approximately 90 C. The reaction may also be catalyzed. For example, the reaction may be catalyzed by the addition of an acid, base, or metal.
The reagents may be allowed to react for hours, days, or weeks. Preferably, the reaction is allowed to proceed from overnight (e.g., 8-12 hours) to 7 days.

[00249] The synthesized aminoalcohol lipidoid compounds may be purified by any technique known in the art including, but not limited to, precipitation, crystallization, chromatography, distillation, etc. In certain embodiments, the aminoalcohol lipidoid compound is purified through repeated precipitations in organic solvent (e.g., diethyl ether, hexane, etc.). In certain embodiments, the aminoalcohol lipidoid compound is isolated as a salt.
The aminoalcohol lipidoid compound is reacted with an acid (e.g., an organic acid or inorganic acid) to form the corresponding salt. In certain embodiments, the tertiary amine is alkylated to form a quaternary ammonium salt of the aminoalcohol lipidoid compound. The tertiary amines may be alkylated with any alkylating agent, for example, alkyl halides such as methyl iodide may be used to from the quaternary amino groups. The anion associated with the quaternary amine may be any organic or inorganic anion. Preferably, the anion is a pharmaceutically acceptable anion.
[00250] In certain embodiments, the reaction mixture results in a mixture of isomers with varying numbers and positions of epoxide-derived compound tails. Such mixtures of products or compounds may be used as is, or a single isomer, or compound, may be purified from the reaction mixture. When an amine is not exhaustively alkylated, the resulting primary, secondary, or tertiary amines may be further reacted with another aminoalcohol lipidoid compound, epoxide-terminated compound, or other electrophile. The resulting aminoalcohol lipidoid compound may then be optionally purified.
[00251] In certain embodiments, a desired aminoalcohol lipidoid compound is prepared by traditional total synthesis. In certain embodiments, a commercially available amine is the starting material. One or more amino groups of the amine are optionally protected. The unprotected amino groups are reacted with an epoxide-terminated compound. The product is optionally purified. Protecting groups are removed, and the free amino groups are optionally reacted with another aminoalcohol lipidoid compound, epoxide-terminated compound, or other electrophile. Such a sequence may be repeated depending on the desired complexity of the inventive product being prepared. The final product may then be optionally purified.
[00252] In one embodiment, a library of different aminoalcohol lipidoid compounds is prepared in parallel. A different amine and/or epoxide-terminated compound is added to each vial in a set of vials or to each well of a multi-well plate used to prepare the library. The array of reaction mixtures is incubated at a temperature and length of time sufficient to allow formation of the aminoalcohol lipidoid compounds to occur. In one embodiment, the vials are incubated at approximately 90 C overnight. In certain embodiments, the vials are incubated from 1 to 7 days at approximately 90 C. In certain embodiments, the vials are incubated from 3 to 4 days at approximately 90 C. In certain embodiments, the vials are incubated from I to 2 days at approximately 90 C. The aminoalcohol lipidoid compounds may then be isolated and purified using techniques known in the art. The aminoalcohol lipidoid compounds may then be screened using high-throughput techniques to identify aminoalcohol lipidoid compounds with a desired characteristic (e.g., solubility in water, solubility at different pH, ability to bind polynucleotides, ability to bind heparin, ability to bind small molecules, ability to bind protein, ability to form microparticles, ability to increase tranfection efficiency, etc.). In certain embodiments the aminoalcohol lipidoid compounds may be screened for properties or characteristics useful in gene therapy (e.g., ability to bind polynucleotides, increase in transfection efficiency).

3. Polynucleotide Complexes [00253] The ability of cationic compounds to interact with negatively charged polynucleotides through electrostatic interactions is well known. Cationic lipids such as Lipofectamine have been prepared and studied for their ability to complex and transfect polynucleotides. The interaction of the lipid with the polynucleotide is thought to at least partially prevent the degradation of the polynucleotide. By neutralizing the charge on the backbone of the polynucleotide, the neutral or slightly-positively-charged complex is also able to more easily pass through the hydrophobic membranes (e.g., cytoplasmic, lysosomal, endosomal, nuclear) of the cell. In certain embodiments, the complex is slightly positively charged. In certain embodiments, the complex has a positive c-potential, more preferably the (-potential is between 0 and +30.
[00254] The aminoalcohol lipidoid compounds of the present invention possess tertiary amines. Although these amines are hindered, they are available to interact with a polynucleotide (e.g., DNA, RNA, synthetic analogs of DNA and/or RNA, DNA/RNA hydrids, etc.).
Polynucleotides or derivatives thereof are contacted with the inventive aminoalcohol lipidoid compounds under conditions suitable to form polynucleotide/lipidoid complexes.
The lipidoid is preferably at least partially protonated so as to form a complex with the negatively charged polynucleotide. In certain embodiments, the polynucleotide/lipidoid complexes form particles that are useful in the delivery of polynucleotides to cells. In certain embodiments, multiple aminoalcohol lipidoid molecules may be associated with a polynucleotide molecule. The complex may include 1-1.00 aminoalcohol lipidoid molecules, 1-1000 aminoalcohol lipidoid molecules, 10-1000 aminoalcohol lipidoid molecules, or 100-10,000 aminoalcohol lipidoid molecules.
[00255] In certain embodiments, the complex may form a particle. In certain embodiments, the diameter of the particles ranges from 10-500 micrometers. In certain embodiments, the diameter of the particles ranges from 10-1200 micrometers. In certain embodiments, the diameter of the particles ranges from 50-150 micrometers. In certain embodiments, the diameter of the particles ranges from 10-500 nm, more preferably the diameter of the particles ranges from 10-1200 nm, and most preferably from 50-150 nm. The particles may be associated with a targeting agent as described below. In certain embodiments, the diameter of the particles ranges from 10-500 pm, more preferably the diameter of the particles ranges from 10-1200 pm, and most preferably from 50-150 pm. The particles may be associated with a targeting agent as described below.

4. Polynucleotide [00256] The polynucleotide to be complexed, encapsulated by the inventive aminoalcohol lipidoid compounds, or included in a composition with the inventive aminoalcohol lipidoid compounds may be any nucleic acid including, but not limited to, RNA and DNA.
In certain embodiments, the polynucleotide is DNA. In certain embodiments, the polynucleotide is RNA.
[00257] In certain embodiments, the polynucleotide is an RNA that carries out RNA
interference (RNAi). The phenomenon of RNAi is discussed in greater detail, for example, in the following references, each of which is incorporated herein by reference:
Elbashir et al., 2001, Genes Den., 15:188; Fire et al., 1998, Nature, 391:806; Tabara et al., 1999, Cell, 99:123;
Hammond et al., Nature, 2000, 404:293; Zamore et at., 2000, Cell, 101:25;
Chakraborty, 2007, Curr. Drug Targets, 8:469; and Morris and Rossi, 2006, Gene Ther., 13:553.
[00258] In certain embodiments, the polynucleotide is a dsRNA (double-stranded RNA).
[00259] In certain embodiments, the polynucleotide is an siRNA (short interfering RNA).
[00260] In certain embodiments, the polynucleotide is an shRNA (short hairpin RNA).
[00261] In certain embodiments, the polynucleotide is an miRNA (micro RNA).
micro RNAs (miRNAs) are genomically encoded non-coding RNAs of about 21 - 23 nucleotides in length that help regulate gene expression, particularly during development (see, e.g., Bartel, 2004, Cell, 116:281; Novina and Sharp, 2004, Nature, 430:161; and U.S. Patent Publication 2005/0059005;
also reviewed in Wang and Li, 2007, Front. Biosci., 12:3975; and Zhao, 2007, Trends Biochern.
Sci., 32:189; each of which are incorporated herein by reference).
[00262] In certain embodiments, the polynucleotide is an antisense RNA.
[00263] In some embodiments, a dsRNA, siRNA, shRNA, miRNA and/or antisense RNA
can be designed and/or predicted using one or more of a large number of available algorithms. To give but a few examples, the following resources can be utilized to design and/or predict dsRNA, siRNA, shRNA, and/or miRNA: algorithms found at Alnylum Online, Dharmacon Online, OligoEngine Online, Molecula Online, Ambion Online, BioPredsi Online, RNAi Web Online, Chang Bioscience Online, Invitrogen Online, LentiWeb Online GenScript Online, Protocol Online; Reynolds et a!., 2004, Nat. Biotechnol., 22:326; Naito et at., 2006, Nucleic Acids Res., 34:W448; Li et a!., 2007, RNA, 13:1765; Yiu et al., 2005, Bioinformatics, 21:144; and Jia et at., 2006, BMC Bioinformatics, 7: 271; each of which is incorporated herein by reference).
[00264] The polynucleotides may be of any size or sequence, and they may be single- or double-stranded. In certain embodiments, the polynucleotide is greater than 100 base pairs long.
In certain embodiments, the polynucleotide is greater than 1000 base pairs long and may be greater than 10,000 base pairs long. The polynucleotide is optionally purified and substantially pure. Preferably, the polynucleotide is greater than 50% pure, more preferably greater than 75%
pure, and most preferably greater than 95% pure. The polynucleotide may be provided by any means known in the art. In certain embodiments, the polynucleotide has been engineered using recombinant techniques (for a more detailed description of these techniques, please see Ausubel et at. Current Protocols in Molecular Biology (John Wiley & Sons, Inc., New York, 1999);
Molecular Cloning: A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989); each of which is incorporated herein by reference). The polynucleotide may also be obtained from natural sources and purified from contaminating components found normally in nature. The polynucleotide may also be chemically synthesized in a laboratory. In certain embodiments, the polynucleotide is synthesized using standard solid phase chemistry.

[00265] The polynucleotide may be modified by chemical or biological means. In certain embodiments, these modifications lead to increased stability of the polynucleotide.
Modifications include methylation, phosphorylation, end-capping, etc.
[00266] Derivatives of polynucleotides may also be used in the present invention. These derivatives include modifications in the bases, sugars, and/or phosphate linkages of the polynucleotide. Modified bases include, but are not limited to, those found in the following nucleoside analogs: 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C5-bromouri dine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, and 2-thiocytidine.
Modified sugars include, but are not limited to, 2'-fluororibose, ribose, 2'-deoxyribose, 3'-azido-2',3'-dideoxyribose, 2',3'-dideoxyribose, arabinose (the 2'-epimer of ribose), acyclic sugars, and hexoses. The nucleosides may be strung together by linkages other than the phosphodiester linkage found in naturally occurring DNA and RNA. Modified linkages include, but are not limited to, phosphorothioate and 5'-N-phosphoramidite linkages. Combinations of the various modifications may be used in a single polynucleotide. These modified polynucleotides may be provided by any means known in the art; however, as will be appreciated by those of skill in this art, the modified polynucleotides are preferably prepared using synthetic chemistry in vitro.
[00267] The polynucleotides to be delivered may be in any form. For example, the polynucleotide may be a circular plasmid, a linearized plasmid, a cosmid, a viral genome, a modified viral genome, an artificial chromosome, etc.
[00268] The polynucleotide may be of any sequence. In certain embodiments, the polynucleotide encodes a protein or peptide. The encoded proteins may be enzymes, structural proteins, receptors, soluble receptors, ion channels, pharmaceutically active proteins, cytokines, interleukins, antibodies, antibody fragments, antigens, coagulation factors, albumin, growth factors, hormones, insulin, etc. The polynucleotide may also comprise regulatory regions to control the expression of a gene. These regulatory regions may include, but are not limited to, promoters, enhancer elements, repressor elements, TATA box, ribosomal binding sites, stop site for transcription, etc. In certain embodiments, the polynucleotide is not intended to encode a protein. For example, the polynucleotide may be used to fix an error in the genome of the cell being transfected.

[00269] The polynucleotide may also be provided as an antisense agent or RNA
interference (RNAi) (Fire et al. Nature 391:806-811, 1998; incorporated herein by reference).
Antisense therapy is meant to include, e.g., administration or in situ provision of single- or double-stranded oligonucleotides or their derivatives which specifically hybridize, e.g., bind, under cellular conditions, with cellular mRNA and/or genomic DNA, or mutants thereof, so as to inhibit expression of the encoded protein, e.g., by inhibiting transcription and/or translation (Crooke "Molecular mechanisms of action of antisense drugs" Biochim. Biophys.
Acta 1489(l):31-44, 1999; Crooke "Evaluating the mechanism of action of anti proliferative antisense drugs" Antisense Nucleic Acid Drug Dev. 10(2):123-126, discussion 127, 2000;
Methods in Enzymology volumes 313-314, 1999; each of which is incorporated herein by reference). The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix (i.e., triple helix formation) (Chan et al. J. Mol. Med. 75(4):267-282, 1.997;
incorporated herein by reference).
[00270] In certain embodiments, the polynucleotide to be delivered comprises a sequence encoding an antigenic peptide or protein. Nanoparticles containing these polynucleotides can be delivered to an individual to induce an immunologic response sufficient to decrease the chance of a subsequent infection and/or lessen the symptoms associated with such an infection. The polynucleotide of these vaccines may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant, etc. A large number of adjuvant compounds are known; a useful compendium of many such compounds is prepared by the National Institutes of Health and can be found on the internet (www.niaid.nih.gov/daids/vaccine/pdf/compendium.pdf, incorporated herein by reference; see also Allison Dev. Biol. Stand. 92:3-11, 1998; Unkeless et al. Annu. Rev.
hnrnunol. 6:251-281, 1998; and Phillips et al. Vaccine 10:151-158, 1992; each of which is incorporated herein by reference).
[00271] The antigenic protein or peptides encoded by the polynucleotide may be derived from such bacterial organisms as Streptococccus pneumoniae, Haentophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacteriunt diphtheriae, Listeria inonocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinuin, Clostridium petfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus inutans, Pseudoinonas aeruginosa, Salmonella typhi, Haemophilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio cholerae, Legionella pneurnophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Leptospirosis interrogans, Borrelia burgdorferi, Camphylobacter jejuni, and the like; from such viruses as smallpox, influenza A
and B, respiratory syncytial virus, parainfluenza, measles, HIV, varicella-zoster, herpes simplex I and 2, cytomegalovirus, Epstein-Barr virus, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps, rabies, rubella, coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever, Rift Valley fever, hepatitis A, B, C, D, and E virus, and the like; and from such fungal, protozoan, and parasitic organisms such as Cryptococcus neofonnans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamvdial trachoinatis, Plasmodium falciparum, Trypanosoma brucei, Entanzoeba histotytica, Toxoplasma gondii, Trichomonas vaginalis, Schistosonia mansoni, and the like.

5. Particles [002721 The aminoalcohol lipidoid compounds of the present invention may also be used to form drug delivery devices. The inventive aminoalcohol lipidoid compounds may be used to encapsulate agents including polynucleotides, small molecules, proteins, peptides, metals, organometallic compounds, etc. The inventive aminoalcohol lipidoid compounds have several properties that make them particularly suitable in the preparation of drug delivery devices.
These include: 1) the ability of the lipid to complex and "protect" labile agents; 2) the ability to buffer the pH in the endosome; 3) the ability to act as a "proton sponge" and cause endosomolysis; and 4) the ability to neutralize the charge on negatively charged agents. In certain embodiments, the aminoalcohol lipidoid compounds are used to form particles containing the agent to be delivered. These particles may include other materials such as proteins, carbohydrates, synthetic polymers (e.g., PEG, PLGA), and natural polymers.
[00273] In certain embodiments, the diameter of the particles range from between I
micrometer to 1,000 micrometers. In certain embodiments, the diameter of the particles range from between from 1 micrometer to 100 micrometers. In certain embodiments, the diameter of the particles range from between from 1 micrometer to 10 micrometers. In certain embodiments, the diameter of the particles range from between from 10 micrometer to 100 micrometers. In certain embodiments, the diameter of the particles range from between from 100 micrometer to 1,000 micrometers. In certain embodiments, the particles range from 1-5 micrometers. In certain embodiments, the diameter of the particles range from between I nm to 1,000 nm. In certain embodiments, the diameter of the particles range from between from I
nm to 100 nm. In certain embodiments, the diameter of the particles range from between from I
nm to 10 nm. In certain embodiments, the diameter of the particles range from between from 10 nm to 100 nm.
In certain embodiments, the diameter of the particles range from between from 100 nm to 1,000 nm. In certain embodiments, the particles range from 1-5 nm. In certain embodiments, the diameter of the particles range from between 1 pm to 1,000 pm. In certain embodiments, the diameter of the particles range from between from 1 pm to 100 pm. In certain embodiments, the diameter of the particles range from between from 1 pm to 10 pm. In certain embodiments, the diameter of the particles range from between from 10 pm to 100 pm. In certain embodiments, the diameter of the particles range from between from 100 pm to 1,000 pm. In certain embodiments, the particles range from 1-5 pm.

6. Methods of Preparing Particles [00274] The inventive particles may be prepared using any method known in this art.
These include, but are not limited to, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, simple and complex coacervation, and other methods well known to those of ordinary skill in the art. In certain embodiments, methods of preparing the particles are the double emulsion process and spray drying. The conditions used in preparing the particles may be altered to yield particles of a desired size or property (e.g., hydrophobicity, hydrophilicity, external morphology, "stickiness", shape, etc.). The method of preparing the particle and the conditions (e.g., solvent, temperature, concentration, air flow rate, etc.) used may also depend on the agent being encapsulated and/or the composition of the matrix.
[00275] Methods developed for making particles for delivery of encapsulated agents are described in the literature (for example, please see Doubrow, M., Ed., "Microcapsules and Nanoparticles in Medicine and Pharmacy," CRC Press, Boca Raton, 1992;
Mathiowitz and Langer, J. Controlled Release 5:13-22, 1987; Mathiowitz et al. Reactive Polymers 6:275-283, 1987; Mathiowitz et al. J. Appl. Polymer Sci. 35:755-774, 1988; each of which is incorporated herein by reference).

[00276] If the particles prepared by any of the above methods have a size range outside of the desired range, the particles can be sized, for example, using a sieve. The particle may also be coated. In certain embodiments, the particles are coated with a targeting agent. In other embodiments, the particles are coated to achieve desirable surface properties (e.g., a particular charge).

7. Micelles and Liposomes [002771 The aminoalcohol lipidoid compounds of the invention may be used to prepare micelles or liposomes. Many techniques for preparing micelles and liposomes are known in the art, and any method may be used with the inventive aminoalcohol lipidoid compounds to make micelles and liposomes. In addition, any agent including polynucleotides, small molecules, proteins, peptides, metals, organometallic compounds, etc. may be included in a micelle or liposome. Micelles and liposomes are particularly useful in delivering hydrophobic agents such as hydrophobic small molecules.
[00278] In certain embodiments, liposomes (lipid or aminoalcohol lipidoid compound vesicles) are formed through spontaneous assembly. In other embodiments, liposomes are formed when thin lipid films or lipid cakes are hydrated and stacks of lipid crystalline bilayers become fluid and swell. The hydrated lipid sheets detach during agitation and self-close to form large, multilamellar vesicles (LMV). This prevents interaction of water with the hydrocarbon core of the bilayers at the edges. Once these particles have formed, reducing the size of the particle can be modified through input of sonic energy (sonication) or mechanical energy (extrusion). See Walde, P. "Preparation of Vesicles (Liposomes)" In Encylopedia of Nanoscience and Nanotechnology; Nalwa, H. S. Ed. American Scientific Publishers: Los Angeles, 2004; Vol. 9, pp. 43-79; Szoka et al. "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)" Ann. Rev. Biophys. Bioeng. 9:467-508, 1980; each of which is incorporated herein. The preparation of lipsomes involves preparing the aminoalcohol lipidoid compounds for hydration, hydrating the aminoalcohol lipidoid compounds with agitation, and sizing the vesicles to achieve a homogenous distribution of liposomes.
Aminoalcohol lipidoid compounds are first dissolved in an organic solvent to assure a homogeneous mixture of aminoalcohol lipidoid compounds. The solvent is then removed to form a lipidoid film. This film is thoroughly dried to remove residual organic solvent by placing the vial or flask on a vaccuum pump overnight. Hydration of the lipidoid film/cake is accomplished by adding an aqueous medium to the container of dry lipidoid and agitating the mixture. Disruption of LMV suspensions using sonic energy typically produces small unilamellar vesicles (SUV) with diameters in the range of 15-50 nm. Lipid extrusion is a technique in which a lipid suspension is forced through a polycarbonate filter with a defined pore size to yield particles having a diameter near the pore size of the filter used. Extrusion through filters with 100 nm pores typically yields large, unilamellar vesicles (LUV) with a mean diameter of 120-140 nm.
[00279] In certain embodiments, the polynucleotide is an RNA molecule (e.g., an RNAi molecule). In other embodiments, the polynucleotide is a DNA molecule. In certain embodiments, the aminoalcohol lipidoid is C14-120. In certain embodiments, the aminoalcohol lipidoid is C16-120. In certain embodiments, the aminoalcohol lipidoid is C14-98. In certain embodiments, the aminoalcohol lipidoid is C14-113. In certain embodiments, the aminoalcohol lipidoid is C18-96. In certain embodiments, the aminoalcohol lipidoid is C14-96. In certain embodiments, the aminoalcohol lipidoid is C14-110. In certain embodiments, the amount of aminoalcohol lipidoid compound in the liposome ranges from 30-80 mol%, preferably 40-70 mol%, more preferably 60-70 mol%. These liposomes may be prepared using any method known in the art. In certain embodiments (e.g., liposomes containing RNAi molecules), the liposomes are prepared by lipid extrusion.
[00280] Certain aminoalcohol lipidoid compounds can spontaneously self assemble around certain molecules, such as DNA and RNA, to form liposomes. In some embodiments, the application is the delivery of polynucleotides. Use of these aminoalcohol lipidoid compounds allows for simple assembly of liposomes without the need for additional steps or devices such as an extruder.
[00281] The following scientific papers described other methods for preparing liposomes and micelles: Narang et at. "Cationic Lipids with Increased DNA Binding Affinity for Nonviral Gene Transfer in Dividing and Nondividing Cells" Bioconjugate Chem. 16:156-68, 2005;
Holland et al. "Formation of stable cationic lipid/DNA complexes for gene transfer" Proc. Natl.
Acad. Sci. USA 93:7305-7309, July 1996; Byk et al. "Synthesis, Activity, and Structure-Activity Relationship Studies of Novel Cationic Lipids for DNA Transfer" J.
Med. Chem.
41(2):224-235, 1998; Wu et al. "Cationic Lipid Polymerization as a Novel Approach for Constructing New DNA Delivery Agents" Bioconjugate Chem. 12:251-57, 2001;
Lukyanov et al. "Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs" Advanced Drug Delivery Reviews 56:1273-1289, 2004; Tranchant et al.
"Physicochemical optimisation of plasmid delivery by cationic lipids" J. Gene Med. 6:S24-S35, 2004; van Balen et at. "Liposome/Water Lipophilicity: Methods, Information Content, and Pharmaceutical Applications" Medicinal Research Rev. 24(3):299-324, 2004; each of which is incorporated herein by reference.

8. Agent [00282] The agents to be delivered by the system of the present invention may be therapeutic, diagnostic, or prophylactic agents. Any chemical compound to be administered to an individual may be delivered using the inventive complexes, picoparticles, nanoparticles, microparticles, micelles, or liposomes. The agent may be a small molecule, organometallic compound, nucleic acid, protein, peptide, polynucleotide, metal, an isotopically labeled chemical compound, drug, vaccine, immunological agent, etc.
[00283] In certain embodiments, the agents are organic compounds with pharmaceutical activity. In another embodiment of the invention, the agent is a clinically used drug. In certain embodiments, the drug is an antibiotic, anti-viral agent, anesthetic, steroidal agent, anti-inflammatory agent, anti-neoplastic agent, antigen, vaccine, antibody, decongestant, antihypertensive, sedative, birth control agent, progestational agent, anti-cholinergic, analgesic, anti-depressant, anti-psychotic, 0-adrenergic blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non-steroidal anti-inflammatory agent, nutritional agent, etc.
[00284] In certain embodiments of the present invention, the agent to be delivered may be a mixture of agents.
[00285] Diagnostic agents include gases; metals; commercially available imaging agents used in positron emissions tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, and magnetic resonance imaging (MRI); and contrast agents. Examples of suitable materials for use as contrast agents in MRI
include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium.
Examples of materials useful for CAT and x-ray imaging include iodine-based materials.

[00286] Prophylactic agents include, but are not limited to, antibiotics, nutritional supplements, and vaccines. Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, dead organisms and viruses, genetically altered organisms or viruses, and cell extracts. Prophylactic agents may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant, etc. Prophylactic agents include antigens of such bacterial organisms as Streptococccus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans, Pseudoinonas aeruginosa, Salmonella typhi, Haenzophilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio cholerae, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema palliduin, Leptospirosis interrogans, Borrelia burgdorferi, Camphylobacterjejuni, and the like; antigens of such viruses as smallpox, influenza A and B, respiratory syncytial virus, parainfluenza, measles, HIV, varicella-zoster, herpes simplex I and 2, cytomegalovirus, Epstein-Barr virus, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps, rabies, rubella, coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever, Rift Valley fever, hepatitis A, B, C, D, and E virus, and the like; antigens of fungal, protozoan, and parasitic organisms such as Cryptococcus neofonnans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasina pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodium falciparum, Tr-panosoma brucei, Entamoeba histolytica, Tocoplasma gondii, Trichomonas vaginalis, Schistosoma mansoni, and the like. These antigens may be in the form of whole killed organisms, peptides, proteins, glycoproteins, carbohydrates, or combinations thereof.

9. Targeting Agents [00287] The inventive complexes, liposomes, micelles, microparticles, picoparticles and nanoparticles may be modified to include targeting agents since it is often desirable to target a particular cell, collection of cells, or tissue. A variety of targeting agents that direct pharmaceutical compositions to particular cells are known in the art (see, for example, Cotten et al. Methods Enz ym. 217:618, 1993; incorporated herein by reference). The targeting agents may be included throughout the particle or may be only on the surface. The targeting agent may be a protein, peptide, carbohydrate, glycoprotein, lipid, small molecule, nucleic acids, etc. The targeting agent may be used to target specific cells or tissues or may be used to promote endocytosis or phagocytosis of the particle. Examples of targeting agents include, but are not limited to, antibodies, fragments of antibodies, low-density lipoproteins (LDLs), transferrin, asialycoproteins, gp120 envelope protein of the human immunodeficiency virus (HIV), carbohydrates, receptor ligands, sialic acid, aptamers etc. If the targeting agent is included throughout the particle, the targeting agent may be included in the mixture that is used to form the particles. If the targeting agent is only on the surface, the targeting agent may be associated with (i.e., by covalent, hydrophobic, hydrogen bonding, van der Waals, or other interactions) the formed particles using standard chemical techniques.

10. Pharmaceutical Compositions [00288] Once the complexes, micelles, liposomes, or particles have been prepared, they may be combined with one or more pharmaceutical excipients to form a pharmaceutical composition that is suitable to administer to animals including humans. As would be appreciated by one of skill in this art, the excipients may be chosen based on the route of administration as described below, the agent being delivered, time course of delivery of the agent, etc.
[00289] Pharmaceutical compositions of the present invention and for use in accordance with the present invention may include a pharmaceutically acceptable excipient or carrier. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil;
olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar;
detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. The pharmaceutical compositions of this invention can be administered to humans and/or to animals, orally, rectally, parenterally, intracisternally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, or drops), bucally, or as an oral or nasal spray.
[00290] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredients (i.e., microparticles, nanoparticles, liposomes, micelles, polynucleotide/lipid complexes), the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[00291] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. In certain embodiments, the particles are suspended in a carrier fluid comprising 1%
(w/v) sodium carboxymethyl cellulose and 0.1% (v/v) Tween 80.
[00292] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00293] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the particles with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
[00294] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the particles are mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalciwn phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl. alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.
[00295] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[00296] The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

[00297] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[00298] Dosage forms for topical or transdermal administration of an inventive pharmaceutical composition include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The particles are admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention.
[00299] The ointments, pastes, creams, and gels may contain, in addition to the particles of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.
[00300] Powders and sprays can contain, in addition to the particles of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
[00301] Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the microparticles or nanoparticles in a proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the particles in a polymer matrix or gel.
[00302] These and other aspects of the present invention will be further appreciated upon consideration of the following Examples, which are intended to illustrate certain particular embodiments of the invention but are not intended to limit its scope, as defined by the claims.

EXAMPLES

Synthesis and Characterization of 1,2-aminoalcohols [003031 These lipidoids were synthesized by combining amines and epoxides in a glass vial equipped with a stirbar and heated to 90 C, as shown in Figure 1. The amines chosen contain between two and five amine functionalities, while the epoxides are racemic, of varying chain lengths and feature unique functional groups and varying degrees of saturation (Figure 2). The reaction times varied from 24 -72 hours at this temperature. Mixtures generally remained clear throughout the reaction and became noticeably viscous as the reaction progressed. Upon cooling, many became waxy solids. The extent of the reaction could be controlled by the number of equivalents of epoxide added to the reaction mixture. For example, in the examples shown, amine 114 has a maximum of five points for substitution. Addition of five equivalents of epoxide would yield an amine core with five alkane chains linked by a 1,2-aminoalcohol.
Addition of four equivalents of epoxide would yield only four chains linked by the same structure. This was verified by thin layer chromatography (TLC), which showed primarily one product existing in the crude reaction mixtures set up as described.
[003041 To verify the identity of the molecules, a few test reactions were set up and purified by silica gel chromatography. The components of the crude reaction mixture were separated and tested by NMR and mass spectrometry. Again, in the case of amine 114, three products were identified: three, four and five tailed products. The molecular weight was confirmed by mass spectrometry, and the structure was verified by NMR (Figure 3, which shows characterization data of epoxide lipidoids derived from amine 114). These isolated compounds were then used as standards versus selected members of the library for TLC analysis. Reactions set up to fully substitute the amine had similar Rf and staining profiles to the fully substituted standard.
Reactions set up to occupy n-I positions of the amine had similar Rf and staining profiles to n-I
standard (Figure 4).

In vitro screening for RNA delivery [00305] Epoxide lipidoids were tested for their ability to deliver siRNA to a HeLa cell line that stably expresses both firefly and Renilla luciferase. Efficacy was determined by complexing the lipidoid with siRNA specific for firefly luciferase, adding this mixture to cells and measuring the subsequent ratio of firefly to Renilla expression. This procedure was performed in 96-well microtiter plates to enable high throughput testing of the materials. In this assay, reduction of both firefly and Renilla expression indicates toxicity, while reduction of only firefly expression is an indication of specific knockdown due to siRNA. Initial screening results of selected members of the library are shown in Figure 5. Many members of this sampling showed some ability to transfect cells and give rise to some knockdown of firefly luciferase. Of these the best performers were generally lipidoids derived from epoxides of 14 carbons or longer coupled with monomers of three or more amine functional groups. A few show nearly complete ablation of firefly expression, even at the lowest dose of lipidoid tested.

RNA Encapsulation Efficiency [00306] Formulation for in vitro experiments is a simple mixing of RNA with lipidoid at a set ratio in buffer prior to addition to cells. In vivo formulation requires the addition of extra ingredients to facilitate circulation throughout the body. To test the ability of these lipidoids to form particles suitable for in vivo work, we followed a standard formulation procedure utilized in the lab. These particles consisted of 42% lipidoid, 48% cholesterol and 10%
PEG. After formation of the particle, RNA was added and allowed to integrate with the complex. The encapsulation efficiency was determined using a standard Ribogreen assay. As shown in the table below, these particles were on the order of 100 non after extrusion, with some achieving encapsulation efficiency of over 90%.

Particle size and entrapment efficiency of selected epoxide lipidoids Compound Size (nm) Entrapment (%) C 14-120-B 95.2 92.75 C 16-120-B 128.4 67.22 C 14-98-B 126.9 44.84 C 14-113-B 92.7 96.42 [00307] HepG2 cells were seeded at a density of 15,000 cells per well into opaque white 96-well plates (Corning-Costar, Kennebunk, ME) 24 hours prior to transfection to allow for growth and confluence. Working dilutions of lipidoids were made in 25 mM
sodium acetate (pH
5) at a concentration of 0.5 mg/ml. For gene delivery experiments pCMV-Luc firefly luciferase DNA (ElimBiopharmaceuticals, South San Francisco, CA) was used. Lipidoid:DNA
complexes were formed by electrostatic interaction between positively charged lipidoid molecules and negatively charged nucleic acids. By varying the volume of lipidoid solution added to a constant amount of DNA, varying weight:weight ratios of lipidoid to DNA were tested.
Lipidoid solution (75 l) was added to DNA solution (75 l) and mixed well. Mixtures were then incubated at room temperature for 20 minutes to allow for complexation. These complexes (30 pl) were then added to serum containing medium (200 p 1) and mixed well. Growth medium was then removed from the cells and Iipidoid:DNA complex containing medium was immediately added. Total DNA loading was 300ug DNA per well. Lipofectamine 2000 transfection was performed as described by the vendor. Complexes were allowed to incubate with cells for 48 hours.
Luciferase expression was then quantified by Bright-Glo assay (Promega, Madison, WI). Briefly, 48 hours post-transfection, the lipidoid:DNA complex containing growth medium was removed from cells using a 12-channel aspirating wand. 200u1 of a 1:1 mixture of Bright-Glo reagent and non-phenol red containing DMEM was added to each well of the 96-well plate with cells. After minute incubation at room temperature, luminescence was measured using a luminometer.
(n=3). Exemplary results are depicted in Figure 6.

[00308] Lipidoid-based siRNA formulations comprised lipidoid, cholesterol, polyethylene glycol-lipid (PEG-lipid) and siRNA. Stock solutions of Lipidoid, mPEG2000-DMG

(synthesized by Alnylam), and cholesterol MW 387 (Sigma-Aldrich) were prepared in ethanol and mixed to yield a molar ratio of 42:10:48. Mixed lipids were added to 200 mM sodium acetate buffer pH 5.2 to yield a solution containing 35% ethanol, resulting in spontaneous formation of empty lipidoid nanoparticles. Resulting nanoparticles were extruded through an 80 nm membrane (three passes). siRNA in 35% ethanol and 50 mM sodium acetate pH
5.2 was added to the nanoparticles at 10:1 (wt/wt) total lipids : siRNA and incubated at 37 C for 30 min.
Ethanol removal and buffer exchange of siRNA-containing lipidoid nanoparticles was achieved by dialysis against PBS using a 3,500 MWCO membrane. Particle size was determined using a Malvern Zetasizer NanoZS (Malvern). siRNA content and entrapment efficiency was determined by Ribogreen assay.
[00309] C57BL/6 mice (Charles River Labs) received either saline or siRNA in lipidoid formulations via tail vein injection at a volume of 0.01. ml/g. Mice were dosed at either 1.75 or 4 mg/kg entrapped siRNA. At 48 hours after administration, animals were anesthetized by isofluorane inhalation and blood was collected into serum separator tubes by retroorbital bleed.
Serum levels of Factor VII protein were determined in samples using a chromogenic assay (Biophen FVII, Aniara Corporation) according to the manufacturer's protocols.
A standard curve was generated using serum collected from saline-treated animals. Exemplary results are depicted' in Figure 7.

In Vitro Screening of Epoxide Library [00310] Compounds of the epoxide-based lipidoid library were synthesized according to the procedures described herein. The compounds were then screened for siRNA
delivery efficacy to a cancer cell line, using a Hela-derived cell line genetically engineered to express luciferase reporter proteins. In these experiments, the ability of each material to facilitate sequence-specific gene silencing was evaluated by comparison of protein levels in treated groups to untreated controls. For each compound, delivery experiments were performed using varying weight ratios of lipidoid : siRNA. In the original disclosure, knockdown results for the entire library were shown. An abbreviated data set is shown in Figure I 1 demonstrating the results for the top 25 performing compounds in the in vitro screen, including C16-96-B, C14-200 and/or C 14-205, and CI 2-200 and/or C 12-205.

In Vivo Screening of Top Performing Epoxide Lipidoids [00311] To test siRNA delivery efficacy in vivo, a mouse model for liver delivery was used.
Factor VII, a hepatocyte-specific blood clotting factor, served as a model protein for knockdown studies. Once produced by hepatocytes, Factor VII is released into the bloodstream, and a baseline level of expression can be determined by simple blood draw and quantification of protein levels by colorimetric assay. By delivering anti-Factor VII siRNA to hepatocytes, knockdown of this model protein can be achieved and a percentage of silencing can be determined by comparison to an untreated control.
[00312] Following the in vitro screen, compounds were purified as detailed in Part I (see Example 14). For in vivo testing, the compounds were formulated with cholesterol and a PEG-lipid for serum stability and siRNA packaging. In these experiments, lipidoids were formulated at a 42 : 48 : 10 molar ratio of lipidoid : cholesterol : PEG. The weight ratio of total lipids (lipidoid+cholesterol+PEG) to siRNA was 10 : 1. After each formulation, the particles were characterized for size and siRNA entrapment efficiency using dynamic light scattering and Ribogreen assay, respectively. The total dose of siRNA administered in the initial screen varies from group to group due to the differences in entrapment efficiency of the lipidoid particles. In all experiments, the dose of siRNA administered to each mouse is consistent according to body weight. The knockdown results from the in vivo screen are shown in Figure 12.
B I and B2 nomenclature signify different compounds visualized by TLC and isolated during purification.
As shown, C14-1 I-B and C 16-96-B were the lead compounds from the initial screen. It should be noted that while some compounds did not show efficacy in this screen, a simple adjustment of formulation composition may greatly improve the results.

Following the initial in vivo screening experiments, two compounds were used to conduct a dose response. In these experiments and all subsequent experiments, the siRNA dose is based on total siRNA content in the formulation, not entrapped siRNA. The dose response results are shown in Figure 13a and Figure 14a. In addition to Factor VII measurement, the change in mouse body weight is recorded and a loss in weight is generally considered formulation induced toxicity (See Figure l3b and Figure 14b). Tables I and 2 tabulate the formulation parameters and characterization data from these experiments.

Table 1-Formulation parameters and characterization data for C 16-96-B dose response formulation Formulation Characterization Lipidoid Lipid:Chol:PEG Total Lipid:siRNA Entrapment Size C 16-96-B 65:29:6 10:1 81% 107.8nm Table 2-Formulation parameters and characterization data for C14-110-B dose response formulation Formulation Characterization Total Lipidoid Li id:Chol:PEG Lipid:siRNA Entrapment Size B 42:48:10 10:1 44% 115nm [00313) After completing the dose response, C16-96-B was chosen for further investigation and optimization. In the next experiments, the percent composition of the formulations was varied to observe the effect of composition on particle size, entrapment, and efficacy. The compositions investigated are shown in Table 3. Figure 15 shows the knockdown results from the formulations tested. Where the formulation in red was the previous best, it is shown that efficacy can be improved by formulating particles at different compositions.

Table 3-Formulation parameters and characterization data for C16-96-B
formulation optimization experiment Formulation Parameters Total Formulation Lipidoid Chol PE id:siRNA Entrapment 1 63 31 6 8.5:1 80%
2 65 29 6 8.5:1 80%
3 67 27 6 8.5:1 80%

4 69 25 6 8.5:1 84%
71 23 6 8.5:1 85%
6 63 33 4 8.5:1 85%
7 65 31 4 8.5:1 85%
8 67 29 4 8.5:1 84%
9 69 27 4 8.5:1 83%
71 25 4 8.5:1 85%

[00314] A second dose response was conducted with the new percent composition parameters. The knockdown results and particle formulation/characteristics are shown in Figure 16 and Table 4, respectively. By formulating at this composition, approximately 40%
knockdown was achieved at a dose of 0.25 mg/kg. Using this result as the new benchmark, the library was revisited and previously untested materials were screened at 0.25 mg/kg in attempt to find other compounds which could give similar or better results.

Table 4 Formulation Characterization Total Lipidoid Lipid:Chol:PEG Lipid:siRNA Entrapment Size C16-96-B 71:23:6 20:1 83% 205nm [00315] In the revisited in vivo screen, compound C12-200 and/or C12-205 was identified as giving nearly complete silencing at a dose of 0.25 mg/kg. As depicted in Figure 12, the slightly longer tailed version of this compound, C12-200 and/or C12-205was previously identified as a highly efficient delivery agent, showing complete silencing at a much higher dose of 7.5 mg/kg total siRNA. It is quite possible that this compound could facilitate complete silencing at much lower doses, but this has not yet been fully explored as the focus has been on C12-200 and/or C12-205. Following the discovery of the efficacy of this compound, the characterization experiments detailed in Part 1 (see Example 14) were initiated.

[00316] The knockdown and body weight change results of this screen are depicted in Figure 17b, and Table 5 tabulates the formulation parameters and characteristics. Figure 17a depicts knockdown results for a second batch of C16-96-B. In previous experiments, this compound had resulted in approximately 40% knockdown at a dose of 0.25 mg/kg.
From mass spec analysis, it was shown that this batch is two-tailed as opposed to the more efficacious three-tailed version that had been used in the previous studies.

Table 5- Formulation parameters and characterization data for revisited in vivo screening Formulation Parameters Total Entrapment Size Formulation Lipid Chol PEG Lipid:siRNA (%) (nm) C14-96-13 73.1 21.3 5.6 8.5 87 81.7 C16-96-B 71.0 23.0 6.0 8.5 55 170.2 C 12-200 and/or C 12-205 45.0 45.5 9.5 8.5 36 167 C 18-62-B 52.7 39.1 8.2 8.5 86 227.4 [00317] A low-dose response was performed on C12-200 and/or C12-205. The knockdown and body weight loss results are shown in Figure 18a and Figure 18b.
The results show that efficient knockdown is achieved and extremely low doses of siRNA. In comparison to ND98, our previous best compound from the original lipidoid library, comparable knockdown can be achieved with 100-fold lower doses of siRNA. The formulation parameters and characterization data are shown in Table 6.
Table 6-Formulation parameters and characterization data for C 12-200 and/or C
12-205 and ND
98 formulations Formulation Parameters Total Size Formulation Lipid Chol PEG Lipid:siRNA Entra ment(% (nm) C 12-200 and/or C12-205 48.2 42.8 8.9 8.5 45 154.1 ND98 42.0 48.0 10.0 8.5 99 83.9 [00318] To further improve delivery efficacy, the percent composition of the and/or C12-205 formulation was modified incrementally. These formulations were screened at a dose of 0.01 mg/kg to identify formulations which may perform better than the previous compositions. The results of these experiments are shown in Figure 19 along with the formulation parameters and characteristics in Table 7. As expected, more efficacious delivery can be achieved by tuning the composition of the formulation. This optimization work is currently ongoing, along with synthesis of longer and shorter tailed versions of the C12-200 and/or C12-205 structure.

Table 7- Formulation parameters and characterization data for C 12-200 and/or 205formulations Formulation Parameters Total Size Formulation Lipid Choi PEG Lipid:siRNA Entrapment(%) (nm) 1 65.0 25.0 10.0 8.5 0 129 2 60.0 30.0 10.0 8.5 1 128 3 55.0 35.0 10.0 8.5 16 156 4 50.0 40.0 10.0 8.5 30 136 45.0 45.0 10.0 8.5 46 140 6 40.0 50.0 10.0 8.5 44 168 7 35.0 55.0 10.0 8.5 40 154 8 50.0 45.0 5.0 8.5 29 157 9 45.0 50.0 5.0 8.5 34 154 40.0 55.0 5.0 8.5 27 159 11 35.0 60.0 5.0 8.5 34 155 Part 1: Lipidoids based on amine 111 [00319] Amine 111 (tetraethylenepentamine, or TEPA) is represented as the linear polyamine of the following structure:
H
H2N'-"-'NNNNH2 H H
amine 111 [00320] The expected products of the reaction between amine 111 and the 12 carbon terminal epoxide C12 are illustrated as follows.

H2NN_,NNe,,~_,NH2 + 0 _ I
H H neat 111 C12-epoxide (6 equivalents) R R R R R H
R=N-'~N_~N-~N~iN.R
R R m/z = 1478 R R m/z = 1294 R R (and isomers) R.N,_~ NN'-'_~'NiN,~,NH2 R OH

R R m/z = 1110 C1OH21 (and isomers) [00321] This reaction was performed, and the crude reaction mixture was separated based on the assumption that the order of product elution from polar silica gel would be: a) 7 tail (max substitution on 111 amine); b) 6 tail isomers (the isomers corresponding to 6 epoxides having reacted with the 111 amine); c) 5 tail isomers, and so on. It was expected that the MALDI-MS.
spectra of the crude reaction mixture would reveal peaks corresponding to the m/z ratios of these compounds (calculated [M+H+] for the expected 7 tail, 6 tail, and 5 tail products: 1481, 1295, and 1111, respectively). Material was isolated from the crude reaction mixture that, based on TLC analysis, was assumed to be the mixture of 6 tail isomers. This "purified"
material performed quite well in the in vivo anti-Factor VII transfection assay.
[00322] MALDI-MS spectra (see Figure 20a) of the crude reaction mixture and of the purified "6 tail" material suggested compounds (see Figure 20b). Technical grade tetraethlenepentamine (TEPA) is a mixture of compounds with similar boiling points; some of these compounds are of the following formulae:

H H
H2N---_,-N"/~N---,~1V"/--N----,,NH2 H2N'-"-'N ,~NH2 PEHA H
TAEA

H H r NH
H2NN~/~HN-/~NH2 H2N~-'NN J PEEDA
111 linear TEPA H 220 H2N'/~NN 200 205 HN- ~-1 H N NH
n H2N---N \--/ N --\-NH2 [00323] Reaction of the C12 epoxide with these compounds accounts for most of the intense peaks in the MALDI mass spectra of the crude reaction mixture (Figure 20a). The m/z ratios observed for the "purified" material (Figure 20b) are consistent with amine 200 or 205 reacting with 5 equivalents of epoxide (calculated m/z for [M+H+] 1137, found 1137) and with amine 210 or 220 reacting with 4 equivalents of epoxide (calculated m/z for [M+H+] 910, found 910). The structures of these compounds are illustrated as follows:

Me'N - NH2 +
R
introduce variation here O O

H2,}-CHn=0-16 H2 1n n=0-16 [00324] To determine if this result was reproducible, an epoxide ring opening reaction was performed using the C12 epoxide and two different batches of amine 111. MALDI-MS was performed on each crude reaction mixture. In the reaction between the C12 epoxide and an older batch of 111 amine, an array of compounds were observed that were also observed in the original crude reaction mixture (see Figure 20a). The MALDI spectrum of the crude reaction mixture using the C12 epoxide and a newer batch of amine 111 (see Figure 21a) contains predominant peaks with rn/z ratios of 1481 (linear amine 111 and 7 epoxide tails) and 1137 (consistent with amine 200 or 205 with 5 epoxide tails). The peak at m/z 910 in this spectrum was small. This might be a result of batch to batch differences in the 111 amine. Purification of the second reaction allowed isolation of a highly pure sample of the m/z 1137 material;
we have designated this material "C12-200 and/or C12-205". The 1H NMR spectrum of C12-200 and/or C12-205 is consistent with the proposed structure (see Figure 22).
[00325] We are developing a library of materials based on the reaction of amines 200, 205, 210, and 220 and related amine structures with epoxides of varying length as depicted below:

H2NN'I--- Ni~N
H
200 ( NNH2 H2N'-/~'NNJ
H + n n=0-16 H2N-/--N \-/ N--\--NH2 H2N~"-'NN
H

RI'N- R1, R2 =
N R2 alkyl, alkenyl, alkynyl, polyamines, hydrogen [00326] These amines are being prepared in pure form using techniques familiar to one skilled in the art. We also propose a library of materials derived from free-based commercially available 111 amine pentahydrochloride according to the following scheme:

H2N_~N-/~N-~N-/~NH2 base H2N~\H~-/~NH2 = 0 - 16 H
commercially available in pure form the actual linear pentamine having the following structure:
H
H2N,_/,, NN'-/-'N-,,iNH2 H H
amine 111 Part 2: Lipidoids based on amine 96 [00327] This Example describes the synthesis of a library of structures that are variations of the amino alcohols lipidoid derived from the reaction of amine 96 with a C16 epoxide as follows:

R R HN--~N,T, R
Me HO\ J OH R = C14H29 OH Me H OH ~( R
based upon the core 96 amine. First, variations at the position of the methyl group are achieved according to the following scheme:

H ~~NH2 + 0 Me'N
R
introduce variation here O -~}'- O

HZnCHn=O-16 H2Jn n=0-16 by reacting the terminal epoxides with an assortment of commercially available amines as depicted below.

Me~C 4n N~~NH2 N~,NH2 I ~i 2 n=O-14 H RY R R=H,OMe.NO2 H R = OMe, H, NO2 Y = CH, N
N,-,--~NH2 CI

N,_,~~NH2 N U N,_,~NH2 R = Me, Br, CI, F3C, N - N H R
N,~ NH2 H
N
R
N - NH2 0 H N H R=Me,Et H N,/~NH2 N NNH2 >r N~~NH2 N~~NH2 Me,N
J H H
0") H2 ~C -~-NH
HO~~Ni~~NH2 9N~~NH2 H3C s ` H2 8 Based on this strategy, the resulting library would contain approximately 800 possible amino alcohols of varying structure.
[00328] Similar amine starting materials are available wherein the length of the carbon chain between the two amines is longer or shorter than amine 96 as depicted below.
HZ
Me~C4NNH2 O NNH2 O yNNH2 H n=0-14 H

O N~-NH2 A NNH2 H LN~/-'NNH2 NNN
MeO OH H Me H
NNH2 N~~NNH2 NNH2 OH H H C)~
X X= CH, N

H X = CH, N HO"~N NH2 Q01 N
R R = H, F, CH3, OMe N NH

NH
X Y H Y= H CIV McO~~H~~ 2 O(Oal-I NH2 H~/~~NH2 N--,,_~NH2 HO,,,,-, NNH2 H

A library of compounds resulting from the reaction of these amines with the various terminal epoxides would provide an additional - 700 amino alcohol lipidoids.
[00329] A protection / deprotection synthetic strategy could provide multiple variations, where the two core amines are functionalized with different alkyl epoxides according to the following scheme:

R? ^ N'-~N.Pi 1. Remove P1 R1 R2 H ~-rN N
OH Y 2. Reaction with different epoxide OH Me H OH
P is protecting group Y are aforementioned variations This strategy could allows for substitution at one amine position with a functional group other than an epoxide (e.g., alkyl halide, isothiocyanate, chloroformate, acid halide) generating two different functional groups on the same amine core as follows:

1. Reaction with first component' 2. Removal of protecting group P1 HN'---'N'P1 3. Reaction with epoxide Z' NN--yR1 Y H Y H OH
wherein the first component can be any of the following or similar derivatives:
Alkyl bromides isocyanates isothiocyanates / \ Br O O S S
11 1 11 It Br C R.N'C.N C : R.N.C,N
Br N.R H N.R H
Br acid chlorides chloroformates Br Br O O 11 O O

ClAR=* R.C.N,s CIO'R : R.O.C.N
Br The following is an exemplary scheme illustrates general synthetic procedures to generate various compounds having two different functional groups on the same amine core as follows:
Remove P1H0\ /R~\ 2 equiv. HO` R, HO
Jr \ /RR1 or R2) ~` epoxide HN~~N"P1 epoxide HO RI
H H N NHZ ~ R
Y
isothiocyanate Y Y Y / OH
isocyanate / 1 equiv. epoxide alkyl halide Z,NN"P1 Y Y
H 1. Remove P1 `N~/~NJ (R1 or R2) Y 2.2 equiv. epoxide H
1. Remove P1 Y
2. 1 equiv. epoxide isothiocyanate /
HO\ / R1 isocyanate z /
J alkyl halide Z,N~~N_R1 N~~N

JY
R1 N^~N" (R1 or R2) LY z wherein, Y is an aryl, heteroaryl, alkyl group (unreactive with epoxides, isocyanates, isothiocyanates and/or alkyl halides); and Z represents fragment from isocyanate, isothiocyante, alkyl halide, having the following exemplary structures:
S O

NAN-R3 ~NAN'R3 N
H H

[00330] Various multi-step sequences could be used to introduce additional hydroxyl groups near the amine core at positions different from those generated through epoxide ring opening as follows:

1 10 1 0. 3 methathesis R2 R3 dihydroxylation N N R
RZ R3~
R~ NNR' N~~N, R1 ~i a OH
Similar routes could provide the means to generate both hydroxyl groups and additional unsaturation as follows:

RZ R3 ring opening Rl NIV O
Rj~ NN OH J
!I

methathesis R2 R3 R, =~R4 OH
Reductive amination as a first step after differential protection of the amine core provides access to a multitude of commercially available aldehydes and perhaps a way to introduce multiple hydroxyl groups through reductive amination using simple carbohydrates (a known procedure) as follows:
R2 0 NaBH3(CN) R2 R~ N~,,NH2 + HAR3 R1 N,NvR3 for example:

R2 + NaBH3(CN) ~iJ N
R12 HO'~ 'OH R1 OH
OH OH
OH

Synthesis of 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (C12-200 and/or C12-205) ^Ni~NHz HzNHsiN 5 quiv O NN - N(C1oH21 90 C, 2 days C,oH21\ ^N, IN ) HO` J OH
H rNH OH/OH C1OH21 N--- N T

may contain inseparable isomer C1oH21\T^ON ~OH
OH '/-'N^,_iN1/~N~CloH21 HO HO ) OH

may contain inseparable isomer [00331] A 250 mL glass pressure vessel was charged with 2-decyloxirane (20.0 grams, 109 mmoles), tetraethylenepentamine (Sigma-Aldrich technical grade, 2.93 grams, 15.5 mmoles) and a magnetic stir bar. The vessel was sealed and immersed in a silicone oil bath at 90 C. The reaction mixture was stirred vigorously for -72 hours at 90 C. The pressure vessel was then removed from the oil bath, allowed to cool to room temperature, then opened with caution. - 9 grams of the resulting viscous, slightly yellow oil were purified via chromatography on silica gel (gradient elution from dichloromethane to 83.5:16.3:1.5 dichloromethane /
methanol / aqueous ammonium hydroxide). Fractions containing the desired compound were pooled and concentrated by rotary evaporation. The resulting yellow oil was dissolved in -15 mL of ethyl acetate; decolorizing charcoal was added to this mixture. The solution was warmed to 68 C and then filtered through Celite; the filtrate was concentrated by rotary evaporation; residual solvent was removed under reduced pressure overnight affording - 1.3 grams of a pale yellow viscous oil. The starting material may contain inseparable isomer NI-(2-aminoethyl)-N2-(2-(piperazin-I-yl)ethyl)ethane-1,2-diamine; and the product may contain an inseparable isomer l,l'-(2-((2-hydroxydodecyl)(2-((2-hydroxydodecyl)(2-(4-(2-hydroxydodecyl)piperazin- l-yl)ethyl)amino)ethyl)-amino)-ethylazanediyl)-didodecan-2-ol.

Amino alcohol lipidoids prepared from chiral epoxides Antimicrobial lipidoids (e.g., C12-200, C16-96) can be prepared by reacting lipophilic, racemic terminal epoxides with low molecular weight polyamines. This approach is illustrated directly below with amine 200 and a generic terminal epoxide. There are two problems with this approach that complicate the isolation of pure products: the use of racemic epoxides, and addition of amines to the second carbon atom (C2) in the epoxide chain. In the following Examples, we report: a) the issues that may arise from the use of racemic epoxides can be avoided through the use of stereochemically pure terminal epoxides; and b) side products that may arise from additions at C2 of the epoxide can be avoided through an alternate synthetic route involving reductive amination.
R
Ogeneric ~>-R epoxide OH

+ I N~~NH2 90 C R I NON H2N'~N~~NG OH L.OH N^ /R
H T ~"' R HO`*J OH
= chiral center R
Reactions of racemic epoxides The epoxides used in the initial library synthesis were purchased from commercial sources as racemic mixtures: each epoxide contained an equal proportion of the R and S
enantiomer. Achiral amines are equally likely to react with either stereoisomer. The effect of using racemic epoxides can be illustrated by considering the simple case of the reaction between an amine with one reactive site (e.g., piperidine) and a racemic epoxide (illustrated directly below). In this case, two aminoalcohol lipidoid products are generated: the R
and S enantiomers.
In theory, these products are separable through chromatography on a chiral stationary phase; in practice, developing and scaling up a method to perform this separation is difficult and expensive.
0 (R) GNH R
+ OH OH
O (S) R 11%~ NG + R L N
piperidine ~> R (R) (S) racemic mixture -of epoxides The situation becomes more complex when the starting amine has multiple reactive sites.
For N reactive sites of an amine starting material, 2N stereoisomers are generated. For example, amine 200 (five reactive sites) reacts with a racemic epoxide generating 32 stereoisomers. In our experience, these products are inseparable. This issue can be resolved by performing the reaction with epoxides that are stereochemically pure (e.g., a single enantiomer of an epoxide). This is illustrated directly below.

GNH + O (R) N (R) R CJOH
piperidine epoxide single product (single enantiomer) A few terminal epoxides are commercially available as single enantiomers, but the cost of these compounds is prohibitive. Racemic epoxides can be resolved (separated into constituent enantiomers) by several means, including chromatography on a chiral stationary phase. We resolved the epoxides using a chemical method known as hydrolytic kinetic resolution (HKR).
Efficient HKR of racemic epoxides can be achieved using a procedure described by Jacobsen (Schaus, et al., J. Am. Chem. Soc. 2002, 124, 1307-1315; which is incorporated herein by reference). The process is illustrated directly below. A chiral catalyst and water are added to a solution containing the racemic epoxide. In the presence of the chiral catalyst, the rate of hydrolysis of one epoxide enantiomer is much greater than the rate of hydrolysis for the other enantiomer. This allows selective hydrolysis of the unwanted epoxide enantiomer (to a 1,2-diol).
The 1,2-diol can be separated from the epoxide by removing the epoxide through distillation under reduced pressure.

Ovs) R H2O (0.5 equivalents), O ( H2O (0.5 equivalents), HO R
(SS)-catalyst R (RR) -catalyst (R) O (S) O (R) HO~~R v.--'\ V-~
R
OH
racemic mixture of epoxides Step 1. The resolution of epoxydodecane by HKR

M = Co(OAc) -H ; "H
-N,~ /N
M
t-Bu O `1O - 3-t-Bu O t-Bu t-Bu 0 (R) + (S) ~=. HO~~C9H19 (R,R)-HKR catalyst (above) 1 mole % catalyst loading Isopropanol (1:1 v/v with epoxide) H2O (0.55 equiv) 0 C to rt, about 24 h [00332] (R)-(+)-1,2-epoxydodecane. An oven-dried round bottom flask containing a magnetic stir bar was charged with the (R,R)-HKR catalyst (Schaus, et al., J.
Ain. Chem. Soc.
2002, 124, 1307-1315); CAS Number 176763-62-5, 1.31 g, 2.17 mmol.
Dichloromethane (34 mL) and then glacial acetic acid (1.30 mL) were added to the flask. The resulting solution was stirred vigorously for 1.5 h; during this time the color of the mixture changed from dark red to brown. The solvent was removed by rotary evaporation until the material appeared dry. 1,2-epoxydodecane (40.0 g, 217 mmol) then isopropyl alcohol (reagent grade, 47 mL) were added to the flask containing the oxidized catalyst and a magnetic stir bar. The flask was immersed in an ice bath. H2O (2.15 mL, 119 mmol, 0.55 equiv relative to epoxide) was added dropwise to the stirred mixture. The flask was sealed with a rubber septum and the solution was allowed to warm to room temperature. After stirring for 2 days, the reaction mixture was diluted with - 200 mL of hexanes. The resulting solution was filtered through paper to remove the white precipitate (1,2-diol). The filtrate was concentrated by rotary evaporation. The resulting dark red oily liquid was dissolved in -- 150 mL of hexanes and filtered in order to remove a substantial amount of white crystalline precipitate (diol). The filtrate was transferred into a 250 mL
round bottom flask and concentrated by rotary evaporation. The desired product was isolated by distillation under vacuum (literature: 124 C / 15 mm Hg). The desired product (14.3 grams, 71.5%
of theoretical yield) was collected as a clear oil. The product was determined to be 100% ee by chiral chromatography of the 2-napthylenethiol derivative.

Step 2. The synthesis of (R)-C12-200 O (R) HZN"-'N^ 80 C C9H19-: (R) HO C9H19 l C9H19 --~ ,/
~'N'-/-'N_,NH2 + HO (R) (R) -."/ N N-N0 H
``//N__/- (R) =C9H19 (R)-OH

\C9H19 [00333] (R)-C12-200. Amine 200 (640 mg, 2.97 mmol) and (R)-1,2-epoxydodecane (2.27 g, 12.1 mmol) were added to a vial containing a magnetic stir bar. The vial was sealed and warmed on a 80 C reaction block for 5 days. The reaction mixture was allowed to cool to room temperature, and the desired product was isolated by chromatography on silica gel (gradient elution from CH2C12 to 175:22:3 CH2CI2/MeOH/NH4OH (aq.)). Fractions were pooled and concentrated affording (R)-C12-200 (665 mg) as a pale yellow oil. 'H NMR (600 MHz, CDC13):
S 4.37 (br s, -OH, 4H), 3.63 (app. br s, 3H), 3.56 (app. br s, 2H), 2.84-2.21 (m, 30H), 1.43-1.26 (m, 90H), 0.88 (t, J = 7.0 Hz, 15 H); MALDI-TOF-MS in/z: calcd for C70H146N505 [M + H+]
1137.1, found 1137.6.

In vivo transfection with chiral amino alcohol lipidoids [00334] Preliminary in vivo transfections using anti-Factor VII siRNA
formulated with were performed using (R)-C12-200 and (S)-C12-200 in mice. At 0.01 mg/kg siRNA
dosing, approximately 50% reduction of systemic Factor VII was achieved using either the R or S forms of C12-200; there difference between these results and those obtained using C12-200 (the lipidoid prepared using amine 200 and racemic C12 epoxide) were insignificant.

Synthesis of amino alcohol lipidoids by the reductive amination approach The first carbon atom in a terminal epoxide is the preferred site of attack during nucleophilic addition. 2D-NMR analysis of amino alcohol lipidoids shows that the majority of addition occurs at Cl of the epoxide, as illustrated directly below.
Nevertheless, a trace amount of addition at C2 does occur. 2D-NMR analysis of compounds (S)-C12-205 and (R)-suggest that roughly 10% of the lipid "tails" are the result of amine attack at C2 of the epoxide.
These regioisomeric tails are likely distributed randomly throughout the entire population of lipid tails in the material. Efforts to limit this side reaction with the epoxides have not been successful.
To avoid this side reaction, we proposed and executed an alternate synthetic strategy.

R NH2 + L~61 ) R vNI OH R1 + R2^N OH
R' -' H
~C1 product from addition product from addition at C1 of the epoxide at C2 of the epoxide A retrosynthetic analysis of this strategy is presented directly below. The desired product is C (as illustrated directly below), from addition of amine A to C l of epoxide B. D is the undesired constitutional isomer formed when amine A attacks C2 of epoxide B.
Reductive amination of aldehyde fragment E with amine A and a reducing agent (giving F), followed by removal of the protecting group on the secondary alcohol, should generate product C. This route does not generate undesired structure D. This approach has two advantages: it does not generate the side product from reaction at C2 of the epoxide (e.g., D, directly below), and avoids the generation of a mixture of stereoisomers. To demonstrate that this strategy is feasible, we prepared a substrate analogous to E and reacted this component with an amine, ultimately generating the desired product (analogous to Q.

C I, R2 NH + /~ R, NRl + R2^NLOH
R' A B i= chiral center I I R3J D

) OP OP
R NR1 R JNH + H R1 F A O E

Synthesis of (S)-C12-205 by reductive amination approach Trityl chloride, a. Nonyl bromide, OH DMAP, Et3N, 77"**'_OCPh3 Mg, 12 THF, C10H21~OCPh3 b. Cul, THF, 401 1. BnCI, NaH, THF, 0 C10H21 1 OCPh3 0 C to reflux C10H21~OH Swern Ct0H21 H
OH - OBn 404 OBn 402 2. p-TsOH-H20 403 Step 1. Synthesis of fragment 404 for the reductive amination approach 7/100'-OCPh3 [00335] (S)-2-((trityloxy)methyl)oxirane (401). Trityl protected glycidol derivative 401 was prepared as described previously (Schweizer, et al., Synthesis 2007, 3807-3814; which is incorporated herein by reference.) A solution of (R)-glycidol (5.0 g, 61 mmol) in CH2CI2 (30 mL) was added by syringe to a stirred solution of trityl chloride (18.6 g, 66.8 mmol) and triethylamine (16.9 mL, 122 mmol) in CH2Cl2 (67 mL) in an ice bath under argon. DMAP (742 mg, 6.08 mmol) was added to the reaction mixture following addition of the glycidol. The reaction was allowed to warm to room temperature. After 14 hours, the reaction mixture was diluted with 300 mL saturated aqueous NH4CI. The mixture was further diluted to - 1 L with water to dissolve precipitated salts. The product was extracted from the quenching solution with Et2O (3 x); combined ethereal layers were washed with brine, dried over MgSO4, filtered through paper, and concentrated by rotary evaporation to a white solid. The crude product was purified by recrystallization from boiling MeOH (200 rnL) affording the desired product 401 (14.1 g, 73%) as white crystals. NMR analysis of this material was consistent with that reported in the literature. (Schweizer, et al., Synthesis 2007, 3807-3814.) C1OH21\^OCPh3 OH
[00336] (S)-2-(benzyloxy)dodeean-1-ol (403). A 60 wt. % suspension of NaH in mineral oil (2.01 g, 50.3 mmol) was added to an oven-dried round bottom flask containing a magnetic stir bar. THF (120 mL) was added to the flask by syringe under Ar, and the flask was submerged in an ice bath. Crude 402 (14.9 g, 33.5 mmol) was dissolved in anhydrous THF
(50 mL) and was added slowly to the stirred suspension of NaH. The reaction mixture was allowed to warm to room temperature. Benzyl chloride (5.8 mL, 50 mmol) was added to the reaction mixture. The flask was fitted with a reflux condenser, and the mixture was warmed to reflux under Ar overnight. After the reaction mixture had cooled, NH4Cl (sat. aq., - 300 mL) was added slowly to quench residual NaH. The suspension was transferred into a separatory funnel using H2O (300 mL) and Et2O (200 mL). The organic layer was extracted with additional Et20;
ethereal layers were dried over MgSO4, filtered through paper, and concentrated to a yellow oil. This material was purified by chromatography on silica (gradient elution from hexanes to EtOAc); desired fractions were pooled and concentrated affording 15 g of a slightly yellow oil. This oil was dissolved in 1:1. MeOH/THF (100 mL). p-TsOH.H20 (572 mg) was added to the mixture; the solution was stirred for 6 hours. The reaction mixture was concentrated onto Celite by rotary evaporation and purified by chromatography on silica gel (gradient elution from hexanes to ethyl acetate). Fractions containing the desired product were pooled and concentrated affording 403 (5.44 g, 66%) as a clear oil. 'H NMR (400 MHz, CDC13): 6 7.39-7.29 (m, 5H), 4.64 (d, J = 11.6 Hz, IH), 4.55 (d, J = 11.6 Hz, 1H), 3.74-3.67 (m, 1H), 3.60-3.49 (m, 2H), 1.93-1.90 (m, 1H), 1.68-1.60 (m, 1H), 1.53-1.45 (m, 1H), 1.40-1.40 (m, 16H), 0.89 (t, J= 6.9 Hz, 3H).
O
ClOH21 H
OBn [00337] (S)-2-(benzyloxy)dodecanal (404). CH2CI2 (10 mL) and oxalyl chloride (1.72 mL, 20.3 mmol) were added to an oven-dried 2-neck round bottom flask containing a magnetic stir bar under Ar. The flask was immersed in a dry ice / acetone bath. A solution of DMSO (2.88 mL, 40.6 mmol) in CH2C12 (10 mL) was added to the stirred solution of oxalyl chloride slowly.
403 (5.4 g, 18.5 mmol) was dissolved in CH2Cl2 and added dropwise, over a period of 15 minutes, to the cold, stirred reaction mixture. After stirring for 2 hours, Et3N (12.9 mL, 18.46 mmol) was added to the reaction mixture, which was then allowed to warm to room temperature.
The mixture was diluted with Et20 (- 300 mL) and water. The ether layer was washed with sat.
aq. NaHCO3, IM aq. HCI, and brine. The Et2O layer was then dried over MgSO4, filtered through paper, and concentrated by rotary evaporation. The crude product was purified by chromatography on silica (gradient elution from hexanes to 1:1 EtOAc/hexanes);
fractions containing the desired product were pooled and concentrated affording 404 (3.58 g, 67%) as a clear, slightly viscous oil. 'H NMR (400 MHz, CDC13): 8 9.66 (d, J = 1.9 Hz, I
H), 7.37-7.31 (m, 5H), 4.69 (d, J = 11.7 Hz, 1H), 4.55 (d, J = 11.7 Hz, 1H), 3.78-3.75 (m, I
H), 1.68 (dd, J =
14.3, 7.2 Hz, 2H), 1.49-1.35 (m, 2H), 1.25 (br s, 14H), 0.89 (t, J = 6.7, 3H) Step 2. Reductive amination pure form of (S)-C12-205 ClOH21 H 0 1.NaCNBHs, HO OH
O,/-, NH2 C1oH21.AH CH30H, AcOH OH (S)N 1 (S)C1oH21 205 404 OBn 2.Pd/C, H , C10H21 (S N
McOH/H'20/AcOH (S)-C12-205 [00338] 1-(2-aminoethyl)piperazine (205, 39 L, 0.3 mmol) was added to a vial containing a magnetic stir bar. MeOH (10 mL) and the aldehyde 404 (971 mg, 3.34 mmol) were added to the vial. NaCNBH3 (188 mg, 3 mmol) was then added to the mixture. Glacial AcOH
was added dropwise to the stirred solution until the pH (as measured using indicator strips) was:
approximately 5.5. The mixture bubbled during the addition of the AcOH. The mixture was stirred for 4 days, whereupon it was diluted with IM NaOH (aq.) and CH2CI2.
The aqueous layer was extracted an additional time with CH2C1,. The combined organic layers were washed with brine, dried over MgSO4, filtered through paper and concentrated. The desired intermediate was purified by chromatography on silica (CH2CI2 to 10% MeOH/CH2C12) affording a yellow oil (83 mg). This oil was dissolved in 25 mL 7:2:1 MeOH/H20/AcOH. A portion of 10 wt.
% Pd/C was added to the solution. The reaction mixture was stirred under H2 (slightly above atmospheric pressure) for 8 hours. The reaction mixture was filtered through Celite to remove the Pd/C and then concentrated to a film. Mass spectral analysis of this material indicated that it was the pure, desired product (S)-C12-205. MALDI-TOF-MS in/z: calcd for C42H88N303 [M + H+], 682.7;
found 682.9.

[00339] Having now described some illustrative embodiments of the invention, it should be apparent to those skilled in the art that the foregoing is merely illustrative and not limiting, having been presented by way of example only. Numerous modifications and other illustrative embodiments are within the scope of one of ordinary skill in the art and are contemplated as falling within the scope of the invention. In particular, although many of the examples presented herein involve specific combinations of method acts or system elements, it should be understood that those acts and those elements may be combined in other ways to accomplish the same objectives. Acts, elements, and features discussed only in connection with one embodiment are not intended to be excluded from a similar role in other embodiments. Further, for the one or more means-plus-function limitations recited in the following claims, the means are not intended to be limited to the means disclosed herein for performing the recited function, but are intended to cover in scope any means, known now or later developed, for performing the recited function.
Use of ordinal terms such as "first", "second", "third", etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.
Similarly, use of a), b), etc., or i), ii), etc. does not by itself connote any priority, precedence, or order of steps in the claims. Similarly, the use of these terms in the specification does not by itself connote any required priority, precedence, or order.
[003401 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention.
Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

Claims (347)

What is claimed is:
1. A compound of formula:

wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic alkylene, optionally interrupted by 1 or more heteroatoms independently selected from O, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
R1 is hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen;
R B, R C, and R D are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1-20-heteroaliphatic or -CH2CH(OH)R E;
R B and R D together may optionally form a cyclic structure;
R C and R D together may optionally form a cyclic structure; and R E is a substituted, unsubstituted, branched or unbranched C1-20 aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein R B, R C, and R D are all the same.
3. The compound of claim 2, wherein R B, R C, and R D are all hydrogen or all C1-C6 alkyl.
4. The compound of claim 3, wherein R B, R C, and R D are all hydrogen.
5. The compound of claim 3, wherein R B, R C, and R D are all C1-C6 alkyl.
6. The compound of claim 2, wherein R B, R C, and R D are all hydroxyalkyl.
7. The compound of claim 2, wherein R B, R C, and R D are all aminoalkyl.
8. The compound of claim 1, wherein each of R B, R C, and R D are hydrogen or methyl.
9. The compound of claim 1 wherein at least two of R B, R C, and R D are the same.
10. The compound of claim 1 wherein R B, R C, and R D are all different.
11. The compound of claim 1 wherein R1 are is selected from the group consisting of:
12. The compound of claim 1, wherein R1 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 aliphatic.
13. The compound of claim 1, wherein R1 is unsubstituted, acyclic, branched or unbranched C1-C20 aliphatic.
14. The compound of claim 1, wherein R1 is substituted, acyclic, branched or unbranched C1-C20 aliphatic.
15. The compound of claim 1, wherein R1 is branched C1-C20 aliphatic.
16. The compound of claim 1, wherein R1 is unbranched C1-C20 aliphatic.
17. The compound of claim 1, wherein R1 is fluorinated C1-C30 aliphatic.
18. The compound of claim 1, wherein R1 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkyl.
19. The compound of claim 1, wherein R1 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C15 alkyl.
20. The compound of claim 1, wherein R1 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C10 alkyl.
21. The compound of claim 1, wherein R1 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C5 alkyl.
22. The compound of claim 1, wherein R1 is selected from the group consisting of:
23. The compound of claim 1, wherein R1 is substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkenyl.
24. The compound of claim 1, wherein R1 is selected from the group consisting of:

25. The compound of claim 1, wherein R1 is selected from the roup consisting of:
ID
26. The compound of claim 1, wherein R1 is selected from the group consisting of:

27. The compound of claim 1, wherein R1 is unsubstituted, acyclic, branched or unbranched C1-C20 heteroaliphatic.
28. The compound of claim 1, wherein is is substituted or unsubstituted, branched or unbranched aliphatic.
29. The compound of claim 1, wherein is substituted or unsubstituted, branched or unbranched alkyl.
30. The compound of claim 1, wherein is substituted or unsubstituted, branched or unbranched heteroaliphatic.
31. The compound of claim 1, wherein is selected from the group consisting of:
32. The compound of claim 1, wherein wherein each is
33. The compound of claim 1, wherein wherein each is
34. A compound of formula:

wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic alkylene, optionally interrupted by 1 or more heteroatoms independently selected from O, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
R1 and R2 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen and at least one occurrence of R2 is hydrogen;
R C and R D are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1-20-heteroaliphatic or -CH2CH(OH)R E;
R C and R D together may optionally form a cyclic structure; and R E is a substituted, unsubstituted, branched or unbranched C1-20 aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic;
or a pharmaceutically acceptable salt thereof.
35. The compound of claim 34, wherein wherein each is
36. The compound of claim 34, wherein wherein each is
37. The compound of claim 34, wherein wherein each is
38. The compound of claim 34, wherein wherein each is
39. The compound of claim 34, wherein R C and R D are both the same.
40. The compound of claim 34, wherein each of R C and R D are independently hydrogen, or C1-C6 alkyl.
41. The compound of claim 34, wherein R C and R D are both hydrogen.
42. The compound of claim 34, wherein R C and R D are both C1-C6 alkyl.
43. The compound of claim 34, wherein R C and R D are both hydroxyalkyl.
44. The compound of claim 34, wherein R C and R D are both aminoalkyl.
45. The compound of claim 34, wherein R C and R D are different.
46. The compound of claim 34, wherein each of R1 and R2 are, independently, selected from the group consisting of:

47. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 aliphatic.
48. The compound of claim 34, wherein each of R1 and R2 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 aliphatic.
49. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted, acyclic, branched or unbranched C1-C20 aliphatic.
50. The compound of claim 34, wherein R1 and R2 are branched C1-C20 aliphatic.
51. The compound of claim 34, wherein R1 and R2 are unbranched C1-C20 aliphatic.
52. The compound of claim 34, wherein R1 and R2 are fluorinated C1-C20 aliphatic.
53. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkyl.
54. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C15 alkyl.
55. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C10 alkyl.
56. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C5 alkyl.
57. The compound of claim 34, wherein each of R1 and R2 are, independently, selected from the group consisting of:

58. The compound of claim 34, wherein each of R1 and R2 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkenyl.
59. The compound of claim 34, wherein each of R1 and R2 are, independently, selected from the group consisting of:

60. The compound of claim 34, wherein each of R1 and R2 are, independently, selected from the group consisting of:

61. The compound of claim 34, wherein each of R1 and R2 are, independently, selected from the group consisting of:

62. The compound of claim 34, wherein each of R1 and R2 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 heteroaliphatic.
63. The compound of claim 34 wherein R1 and R2 are both the same.
64. The compound of claim 62, wherein each of R1 and R2 are indpendently hydrogen, or C1-C6 alkyl.
65. The compound of claim 63, wherein R1 and R2 are both hydrogen.
66. The compound of claim 63, wherein R1 and R2 are both C1-C6 alkyl.
67. The compound of claim 63, wherein R1 and R2 are both hydroxyalkyl.
68. The compound of claim 63, wherein R1 and R2 are both aminoalkyl.
69. The compound of claim 34, wherein R1 and R2 are different.
70. The compound of claim 34, wherein is substituted or unsubstituted, branched or unbranched aliphatic.
71. The compound of claim 34, wherein is substituted or unsubstituted, branched or unbranched alkyl.
72. The compound of claim 34, wherein is substituted or unsubstituted, branched or unbranched heteroaliphatic.
73. The compound of claim 34, wherein is selected from the group consisting of:

74. A compound of formula:

wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic alkylene, optionally interrupted by 1 or more heteroatoms independently selected from O, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
R1 and R3 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen and at least one occurrence of R3 is hydrogen;

R B and R D are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1-20-heteroaliphatic or -CH2CH(OH)R E;
R B and R D together may optionally form a cyclic structure; and R E is a substituted, unsubstituted, branched or unbranched C1-20 aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic;
or a pharmaceutically acceptable salt thereof.
75. The compound of claim 74, wherein wherein each is
76. The compound of claim 74, wherein wherein each is
77. The compound of claim 74, wherein wherein each is
78. The compound of claim 74, wherein wherein each is
79. The compound of claim 74, wherein R B and R D are both the same.
80. The compound of claim 74, wherein each of R B and R D are independently hydrogen, or C1-C6 alkyl.
81. The compound of claim 79, wherein R B and R D are both hydrogen.
82. The compound of claim 79, wherein R B and R D are both C1-C6 alkyl.
83. The compound of claim 79, wherein R B and R D are both hydroxyalkyl.
84. The compound of claim 79, wherein R B and R D are both aminoalkyl.
85. The compound of claim 74, wherein R B and R D are different.
86. The compound of claim 74, wherein each of R1 and R3 are, independently, selected from the group consisting of:

87. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 aliphatic.
88. The compound of claim 74, wherein each of R1 and R3 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 aliphatic.
89. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted, acyclic, branched or unbranched C1-C20 aliphatic.
90. The compound of claim 74, wherein R1 and R3 are branched C1-C20 aliphatic.
91. The compound of claim 74, wherein R1 and R3 are unbranched C1-C20 aliphatic.
92. The compound of claim 74, wherein R1 and R3 are fluorinated C1-C20 aliphatic.
93. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkyl.
94. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C15 alkyl.
95. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C10 alkyl.
96. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C5 alkyl.
97. The compound of claim 74, wherein each of R1 and R3 are, independently, selected from the group consisting of:

98. The compound of claim 74, wherein each of R1 and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkenyl.
99. The compound of claim 74, wherein each of R1 and R3 are, independently, selected from the group consisting of:

100. The compound of claim 74, wherein each of R1 and R3 are, independently, selected from the group consisting of:

101. The compound of claim 74, wherein each of R1 and R3 are, independently, selected from the group consisting of:

102. The compound of claim 74, wherein each of R1 and R3 are, independently, unsubstituted, acyclic, branched or unbranched C1-20 heteroaliphatic.
103. The compound of claim 74, wherein R1 and R3 are both the same.
104. The compound of claim 102, wherein each of R1 and R3 are independently hydrogen, or C1-C6 alkyl.
105. The compound of claim 103, wherein R1 and R3 are both hydrogen.
106. The compound of claim 103, wherein R1 and R3 are both C1-C6 alkyl.
107. The compound of claim 103, wherein R1 and R3 are both hydroxyalkyl.
108. The compound of claim 103, wherein R1 and R3 are both aminoalkyl.
109. The compound of claim 74, wherein R1 and R3 are different.
110. The compound of claim 74, wherein is substituted or unsubstituted, branched or unbranched aliphatic.
111. The compound of claim 74, wherein is substituted or unsubstituted, branched or unbranched alkyl.
112. The compound of claim 74, wherein is substituted or unsubstituted, branched or unbranched heteroaliphatic.
113. The compound of claim 74, wherein is selected from the group consisting of:

114. A compound of formula:

wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic alkylene, optionally interrupted by 1 or more heteroatoms independently selected from O, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring;
R1, R2, and R3 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen, at least one occurrence of R2 is hydrogen and at least one occurrence of R3 is hydrogen;

R D is hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1-20-heteroaliphatic or -CH2CH(OH)R E; and R E is a substituted, unsubstituted, branched or unbranched C1-20 aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic;
or a pharmaceutically acceptable salt thereof.
115. The compound of claim 114, wherein wherein each is
116. The compound of claim 114, wherein wherein each is
117. The compound of claim 114, wherein wherein each is
118. The compound of claim 114, wherein wherein each is
119. The compound of claim 114, wherein wherein each is
120. The compound of claim 114, wherein wherein each is
121. The compound of claim 114, wherein R D is hydrogen or C1-C6 alkyl.
122. The compound of claim 114, wherein R D is hydrogen.
123. The compound of claim 114, wherein R D is C1-C6 alkyl.
124. The compound of claim 113, wherein R D is hydrogen or methyl.
125. The compound of claim 113, wherein R D is hydroxyalkyl.
126. The compound of claim 113, wherein R D is aminoalkyl.
127. The compound of claim 113, wherein R1, R2, and R3 are all the same.
128 The compound of claim 113, wherein at least two of R1, R2, and R3 are the same.
129. The compound of claim 1, 13, wherein R1, R2, and R3 are all different.
130. The compound of claim 113, wherein each of R1, R2, and R3 are, independently, selected from the group consisting of:

131. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 aliphatic.
132. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 aliphatic.
133. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted, acyclic, branched or unbranched C1-C20 aliphatic.
134. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, branched C1-C20 aliphatic.
135. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, unbranched C1-C20 aliphatic.
136. The compound of claim 114, wherein each of R1, R2, and R3 are, independently;
fluorinated C1-C20 aliphatic.
137. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkyl.
138. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C15 alkyl.
139. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C10 alkyl.
140. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C5 alkyl.
141. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, selected from the group consisting of:

142. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkenyl.
143. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, selected from the group consisting of:

144. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, selected from the group consisting of:

145. The compound of claim 114, wherein R1, R2, and R3 are, independently, selected from the group consisting of:

146. The compound of claim 114, wherein each of R1, R2, and R3 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 heteroaliphatic.
147. The compound of claim 114, wherein is substituted or unsubstituted, branched or unbranched aliphatic.
148. The compound of claim 114, wherein is substituted or unsubstituted, branched or unbranched alkyl.
149. The compound of claim 114, wherein is substituted or unsubstituted, branched or unbranched heteroaliphatic.
150. The compound of claim 114, wherein is selected from the group consisting of:
151. A compound of formula:

wherein:
A is a substituted or unsubstituted, branched or unbranched, cyclic or acyclic alkylene, optionally interrupted by 1 or more heteroatoms independently selected from O, S and N, or A is a substituted or unsubstituted, saturated or unsaturated 4-6-membered ring; and R1, R2, R3, and R4 are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen, at least one occurrence of R2 is hydrogen, at least one occurrence of R3 is hydrogen and at least one occurrence of R4 is hydrogen;
or a pharmaceutically acceptable salt thereof.
152. The compound of claim 151, wherein wherein each is .
153. The compound of claim 151, wherein wherein each is .
154. The compound of claim 151, wherein wherein each is .
155. The compound of claim 151, wherein wherein each is .
156. The compound of claim 151, wherein wherein each is .
157. The compound of claim 151, wherein wherein each is .
158. The compound of claim 151, wherein wherein each is .
159. The compound of claim 151, wherein wherein each is .
160. The compound of claim 151, wherein R1, R2, R3, and R4 are all the same.
161. The compound of claim 151, wherein at least two of R1, R2, R3, and R4 are the same.
162. The compound of claim 151, wherein at least three of R1, R2, R3, and R4 are the same.
163. The compound of claim 151, wherein R1, R2, R3, and R4 are all different.
164. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, selected from the group consisting of:

165. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 aliphatic.
166. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 aliphatic.
167. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted, acyclic, branched or unbranched C1-C20 aliphatic.
168. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, branched C1-C20 aliphatic.
169. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, unbranched C1-C20 aliphatic.
170. The compound of claim 151, wherein R1, R2, R3, and R4 are, independently, fluorinated C1-C20 aliphatic.
171. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkyl.
172. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C15 alkyl.
173. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C10 alkyl.
174. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C5 alkyl.
175. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, selected from the group consisting of:

176. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-C20 alkenyl.
177. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, selected from the group consisting of:

178. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, selected from the group consisting of:

179. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, selected from the group consisting of:

180. The compound of claim 151, wherein each of R1, R2, R3, and R4 are, independently, unsubstituted, acyclic, branched or unbranched C1-C20 heteroaliphatic.
181. The compound of claim 151, wherein is substituted or unsubstituted, branched or unbranched aliphatic.
182. The compound of claim 151, wherein is substituted or unsubstituted, branched or unbranched alkyl.
183. The compound of claim 151, wherein is substituted or unsubstituted, branched or unbranched heteroaliphatic.
184. The compound of claim 151, wherein is selected from the group consisting of:
185. A compound selected from the group consisting of:

186. The compound of claim 185, wherein each is
187. The compound of claim 185, wherein each is
188. A compound selected from the group consisting of:

189. The compound of claim 188, wherein each is
190. The compound of claim 188, wherein each is
191. A compound selected from the group consisting of:

192. The compound of claim 191, wherein each is
193. The compound of claim 191, wherein each is
194. A compound selected from the group consisting of:

195. The compound of claim 194, wherein each is
196. The compound of claim 194, wherein each is
197. A compound of formula:

wherein:
p is an integer between 1 and 3, inclusive;
m is an integer between 1 and 3, inclusive;
R A is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;

R F is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; each occurrence of R5 is independently hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;

wherein, at least one of R A, R F, R Y, and R Z is or each occurrence of x is an integer between 1 and 10, inclusive;
each occurrence of y is an integer between 1 and 10, inclusive;
each occurrence of R Y is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or each occurrence of R Z is hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or ;
or a pharmaceutically acceptable salt thereof.
198. The compound of claim 197, wherein each is
199. The compound of claim 197, wherein each is
200. The compound of claim 197, wherein p is 1.
201. The compound of claim 197, wherein p is 2.
202. The compound of claim 197, wherein m is 1.
203. The compound of claim 197, wherein m is 2.
204. The compound of claim 197, wherein both p and m are 1.
205. The compound of claim 197, wherein R A is hydrogen.
206. The compound of claim 197, wherein R A is C1-C6 alkyl.
207. The compound of claim 197, wherein R A is
208. The compound of claim 207, wherein each
209. The compound of claim 207, wherein each
210. The compound of claim 197, wherein R A is
211. The compound of claim 207 or 210, wherein R5 is C8-C16 aliphatic.
212. The compound of claim 207 or 210, wherein R5 is C8-C16 alkyl.
213. The compound of claim 197, wherein R A is
214. The compound of claim 197, wherein R A is
215. The compound of claim 197, wherein R A is
216. The compound of claim 215, wherein each
217. The compound of claim 215, wherein each
218. The compound of claim 197, wherein R A is
219. The compound of claim 197, wherein R A is
220. The compound of claim 197, wherein R A is hydrogen.
221. The compound of claim 197, wherein R F is C1-C6 alkyl.
222. The compound of claim 197, wherein R F is
223. The compound of claim 222, wherein each
224. The compound of claim 222, wherein each
225. The compound of claim 197, wherein R F is
226. The compound of claim 222 or 225, wherein R6 is C8-C16 aliphatic.
227. The compound of claim 222 or 225, wherein R6 is C8-C16 alkyl.
228. The compound of claim 197, wherein R F is
229. The compound of claim 197, wherein R F is
230. The compound of claim 197, wherein R F is
231. The compound of claim 197, wherein R F

is
232. The compound of claim 197, wherein R F is
233. The compound of claim 197, wherein x=1.
234. The compound of claim 197, wherein x=2.
235. The compound of claim 197, wherein x=3.
236. The compound of claim 197, wherein y=1.
237. The compound of claim 197, wherein y=2.
238. The compound of claim 197, wherein y=3.
239. The compound of claim 197, wherein x=1 and y=2.
240. The compound of claim 197, wherein x=1 and y=3.
241. The compound of claim 197, wherein R F is
242. The compound of claim 241, wherein each
243. The compound of claim 241, wherein each
244. The compound of claim 197, wherein R A is and R F is
245. The compound of claim 197, wherein R A is and R F is
246. The compound of claim 245, wherein each
247. The compound of claim 245, wherein each
248. The compound of claim 197, wherein R A is and R F
is
249. The compound of claim 248, wherein each
250. The compound of claim 248, wherein each
251. The compound of claim 197 of the formula:

252. The compound of claim 251, wherein each
253. The compound of claim 251, wherein each
254. The compound of claim 197 of the formula:

255. The compound of claim 254, wherein each
256. The compound of claim 254, wherein each
257. A mixture comprising compound and compound
258. The compound of claim 257, wherein each
259. The compound of claim 257, wherein each
260. A compound of formula:

wherein:
each occurrence of R A is independently hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; wherein at least one R A
is each occurrence of R5 is independently hydrogen; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 aliphatic; substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;
each occurrence of x is an integer between 1 and 10, inclusive;
each occurrence of y is an integer between 1 and 10, inclusive;
or a pharmaceutically acceptable salt thereof.
261. The compound of claim 260, wherein each
262. The compound of claim 260, wherein each
263. The compound of claim 260, wherein each occurrence of R A is independently hydrogen;
264. The compound of claim 263, wherein each
265. The compound of claim 263, wherein each
266. The compound of claim 263, wherein at least one R A is hydrogen.
267. The compound of claim 263, wherein no R A is hydrogen.
268. The compound of claim 260, wherein at least one R A is
269. The compound of claim 268, wherein each
270. The compound of claim 268, wherein each
271. The compound of claim 260, wherein at least one R A is
272. The compound of claim 260, wherein R5 is C1-C20 aliphatic.
273. The compound of claim 260, wherein R5 is C8-C16 aliphatic.
274. The compound of claim 260, wherein R5 is C8-C16 alkyl.
275. The compound of claim 260, wherein x is 1.
276. The compound of claim 260, wherein x is 2.
277. The compound of claim 260, wherein x is 3.
278. The compound of claim 260, wherein y is 1.
279. The compound of claim 260, wherein y is 2.
280. The compound of claim 260, wherein y is 3.
281. The compound of claim 260, wherein y is 4.
282. The compound of claim 260, wherein y is 5.
283. The compound of claim 260, wherein at least one R A is selected from the group consisting alkenyl group, an alkynyl group, or a substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic.
284. The compound of claim 260, wherein at least one R A is an alkenyl group.
285. The compound of claim 284, wherein the alkenyl group is selected from the group consisting of:

286. The compound of claim 260, wherein at least one R A is an alkynyl group.
287. The compound of claim 286, wherein the alkynyl group is
288. The compound of claim 260, wherein at least one R A is a substituted or unsubstituted, cyclic or acyclic, branched or unbranched C1-20 heteroaliphatic group.
289. The compound of claim 288, wherein the heteroaliphatic group is
290. The compound of claim 288, wherein the heteroaliphatic group is
291. The compound of claim 288, wherein the heteroaliphatic group is
292. The compound of claim 288, wherein heteroaliphatic group is
293. The compound of claim 288, wherein two R A variables are the same.
294. The compound of claim 283, wherein three R A variables are the same.
295. The compound of claim 283, wherein each R A variable is different from the other.
296. A compound prepared by reacting an amine of one of the formulae:

with an epoxide-containing compound of one of the formulae:

297. A compound of the formulae:

298. A pharmaceutical composition comprising a compound of any one of claims 1, 34, 74, 114, 151, 197, or 260; and a pharmaceutical agent.
299. The pharmaceutical composition of claim 298, wherein the pharmaceutical agent is selected from the groups consisting of polynucleotides, proteins, peptides, and small molecule drugs.
300. The pharmaceutical composition of claim 299, wherein the pharmaceutical agent is a polynucleotide.
301. A method of preparing a compound of any one of claims 1, 34, 74, 114, 151, 197, or 260 the method comprising the step of reacting one or more equivalents of an amine of one of the formulae:

with an epoxide-containing compound of one of the formulae:

to form a compound of one of formulae:

wherein A, R1, R2, R3, R4, R B, R C, R D, R A, R F, p, m, R A, x and y are as defined herein.
302. The compound of claim 301, wherein wherein each
303. The compound of claim 301, wherein wherein each
304. The compound of claim 301, wherein wherein each
305. The compound of claim 301, wherein wherein each
306. The compound of claim 301, wherein wherein each
307. The compound of claim 301, wherein wherein each
308. The compound of claim 301, wherein wherein each
309. The compound of claim 301, wherein wherein each
310. The compound of claim 301, wherein the epoxide-containing compound of one of the formulae:

311. The compound of claim 301, wherein the epoxide-containing compound of one of the formulae:

312. The compound of claim 301, wherein the epoxide-containing compound of one of the formulae:

313. A method of preparing a compound of claim 197, the method comprising the step of reacting one or more equivalents of an amine of the formula: and/or with an epoxide-containing compound of the formula to form a compound of formula: wherein R A, R F, p and m are as defined herein.
314. A method of preparing a compound of any one of claims 1, 34, 74, 114, 151, 197, or 260, comprising steps of:
(a) resolving a racemic mixture of epoxides the formula:
into an enantiomeric epoxide of the formula:

(b) reacting an equivalent of one of the enantiomeric epoxides of the formula with one or more equivalents of an amine of the formula:
wherein R1 is hydrogen, a substituted, unsubstituted, branched or unbranched aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen;
R B, R C, and R D are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1-20-heteroaliphatic or -CH2-CH(OH)R E;
R B and R D together may optionally form a cyclic structure;
R C and R D together may optionally form a cyclic structure; and R E is a substituted, unsubstituted, branched or unbranched C1-20 aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic.
315. The method according to claim 314, wherein the racemic mixture of epoxides is one of the formulae:

316. The method according to claim 314,wherein the enantiomeric epoxide is one of the formulae:

317. The method according to claim 314,wherein the enantiomeric epoxide is one of the formulae:

318. The method according to claim 314,wherein the enantiomeric epoxide is one of the formulae:

319. The method according to claim 314, wherein the amine is one of the formulae:
320. The method according to claim 314, wherein the enantiomeric epoxide is resolved from the racemic mixture of epoxides using hydrolytic kinetic resolution (HKR) catalyzed with the (R,R)-HKR catalyst of the formula:

321. The method according to claim 314, wherein the enantiomeric epoxide is resolved from the racemic mixture of epoxides using hydrolytic kinetic resolution (HKR) catalyzed with the (S,S)-HKR catalyst of the formula:

322. A method of preparing a compound of any one of claims 1, 34, 74, 114, 151, 197, or 260, comprising steps of:
(a) converting the epoxide primary alcohol of the formula:
into the corresponding protected primary alcohol derivative of the formula:

(b) reacting the protected primary alcohol derivative of the formula:

with a carbon-based nucleophile to produce the secondary alcohol of the formula:
(c) converting the secondary alcohol of the formula:
into the corresponding protected secondary alcohol derivative of the formula (d) deprotecting the protected secondary alcohol derivative of the formula into the corresponding primary alcohol of the formula (e) oxidizing the primary alcohol of the formula into the corresponding aldehyde of the formula (f) condensing the aldehyde of the formula:
with an amine of the formula:

to produce an imine of the formula:

(f) reducing an imine of the formula:

to produce the corresponding amine of the formula:
wherein R1 is hydrogen, a substituted, unsubstituted, branched or unbranched aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic, wherein at least one occurrence of R1 is hydrogen;
R B, R C, and R D are, independently, hydrogen, a substituted, unsubstituted, branched or unbranched C1-20-aliphatic, or a substituted, unsubstituted, branched or unbranched C1-20-heteroaliphatic or -CH2CH(OH)R E;
R B and R D together may optionally form a cyclic structure;
R C and R D together may optionally form a cyclic structure;
R E is a substituted, unsubstituted, branched or unbranched C1-20 aliphatic or a substituted, unsubstituted, branched or unbranched C1-20 heteroaliphatic; and PG1 and PG2 are O-protecting groups as described herein.
323. The method of claim 322, wherein the epoxide primary alcohol of step (a) is and the amine of step (f) is
324. The method of claim 322, wherein the epoxide primary alcohol of step (a) is and the amine of step (f) is
325. The method of claim 301, wherein the step of reacting is performed with no solvent present.
326. The method of claim 301, wherein the step of reacting is performed in the presence of an aprotic solvent.
327. The method of claim 301, wherein the solvent is tetrahydrofuran, diethyl ether, ethyl acetate, DMSO, DMF, methanol, ethanol or water.
328. The method of claim 301, wherein the step of reacting is performed at a temperature ranging from 25 °C to 100 °C.
329. The method of claim 328, wherein the step of reacting is performed at approximately 90 °C.
330. The method of claim 301 further comprising the step of purifying the product.
331. The method of claim 301 further comprising alkylating at least one amine in the product with an alkyl halide.
332. The method of claim 301, wherein the alkyl halide is methyl iodide.
333. A microparticle comprising a compound of any one of claims 1, 34, 74, 114, 151, 197 or 260; and an agent to be delivered.
334. A liposome comprising of any one of claims 1, 34, 74, 114, 151, 197 or 260; and an agent to be delivered.
335. The liposome of claim 334, wherein the agent is a polynucleotide.
336. The liposome of claim 334, hwerein the agent is RNA.
337. The liposome of claim 334, wherein the agent is a drug.
338. The liposome of claim 334, wherein the agent is a protein or peptide.
339. The liposome of claim 334, wherein the agent is a small molecule.
340. The liposome of claim 334, wherein the agent is a gas.
341. The liposome of claim 334, wherein the liposome ranges in size from 10 nanometers to 2000 nanometers.
342. The liposome of claim 334 further comprising cholesterol.
343. The liposome of claim 334 further comprising PEG.
344. The liposome of claim 334 comprising a compound of claim 1;
an agent, wherein the agent is an RNA;

cholesterol; and PEG.
345. A micelle comprising a compound of any one of claims 1, 34, 74, 114, 151, 197 or 260;
and an agent to be delivered.
346. A complex comprising a compound of any one of claims 1, 34, 74, 114, 151, 197 or 260;
and a polynucleotide.
347. A method of administering an agent, the method comprising step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of claim 1, 34, 74, 114, 151, 197 or 260; and an agent to be delivered.
CA2742954A 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof Active CA2742954C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3006395A CA3006395C (en) 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11241408P 2008-11-07 2008-11-07
US61/112,414 2008-11-07
US16651809P 2009-04-03 2009-04-03
US61/166,518 2009-04-03
PCT/US2009/006018 WO2010053572A2 (en) 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3006395A Division CA3006395C (en) 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof

Publications (2)

Publication Number Publication Date
CA2742954A1 true CA2742954A1 (en) 2010-05-14
CA2742954C CA2742954C (en) 2018-07-10

Family

ID=42153459

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2742954A Active CA2742954C (en) 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof
CA3006395A Active CA3006395C (en) 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3006395A Active CA3006395C (en) 2008-11-07 2009-11-06 Aminoalcohol lipidoids and uses thereof

Country Status (10)

Country Link
US (6) US8969353B2 (en)
EP (2) EP2365962B1 (en)
JP (4) JP6087504B2 (en)
KR (1) KR101734955B1 (en)
CN (2) CN104910025B (en)
AU (1) AU2009311667B2 (en)
CA (2) CA2742954C (en)
ES (1) ES2646630T3 (en)
MX (3) MX2011004859A (en)
WO (1) WO2010053572A2 (en)

Families Citing this family (446)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
IL302142B1 (en) 2008-10-20 2024-03-01 Alnylam Pharmaceuticals Inc Compositions and Methods for Inhabiting Expression of TRANSTHYRETIN
WO2010053572A2 (en) * 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
AU2010245933B2 (en) * 2009-05-05 2016-06-16 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
NZ596186A (en) * 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
WO2011056883A1 (en) * 2009-11-03 2011-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
HUE029284T2 (en) 2010-07-06 2017-02-28 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
PT3243526T (en) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Delivery of rna to trigger multiple immune pathways
MX2013000164A (en) 2010-07-06 2013-03-05 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery.
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino alcohols), their preparation, and uses thereof
JP6124078B2 (en) * 2010-08-26 2017-05-10 ツイ，クンユァン Macrocyclic aliphatic compounds and their applications
MX2013002336A (en) 2010-08-31 2013-03-18 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna.
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
EP4108671A1 (en) 2010-10-01 2022-12-28 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
BR112013008700B8 (en) 2010-10-11 2022-10-04 Novartis Ag SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE
US20120136073A1 (en) 2010-11-15 2012-05-31 Life Technologies Corporation Amine-Containing Transfection Reagents and methods for making and using same
DK2691443T3 (en) * 2011-03-28 2021-05-03 Massachusetts Inst Technology CONJUGIATED LIPOMERS AND USES OF THESE
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
ES2663360T3 (en) 2011-06-08 2018-04-12 Translate Bio, Inc. Cleavable lipids
KR102128248B1 (en) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
KR20130024079A (en) 2011-08-30 2013-03-08 현대자동차주식회사 Solid scr system and heating method of solid reductant using the same
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (en) 2011-10-03 2019-08-30 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
KR101329702B1 (en) 2011-10-06 2013-11-14 연세대학교 산학협력단 Polyamine-based vector for delivery of small interfering RNA
UA119028C2 (en) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі N-terminal functionalized amino acid derivatives capable of forming microspheres encapsulating the drug
HUE048622T2 (en) 2011-11-18 2020-08-28 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
US9872911B2 (en) 2011-12-16 2018-01-23 Massachusetts Institute Of Technology Alpha-aminoamidine polymers and uses thereof
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2858679B1 (en) 2012-06-08 2021-02-24 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CN103087012B (en) * 2012-12-28 2014-10-22 四川大学 Epoxy compound and cationic polymer as well as preparation methods thereof
ES2859923T3 (en) 2013-02-28 2021-10-04 Univ Tufts Disulfide compounds for the supply of pharmaceutical agents
BR112015022868B1 (en) 2013-03-14 2023-05-16 Ethris Gmbh CFTR MRNA COMPOSITIONS AND RELATED USES AND METHODS
SG11201507474QA (en) 2013-03-14 2015-10-29 Shire Human Genetic Therapies RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
DK2970456T3 (en) 2013-03-14 2021-07-05 Translate Bio Inc METHODS AND COMPOSITIONS FOR DELIVERING MRNA-CODED ANTIBODIES
KR20150128687A (en) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. Methods for purification of messenger rna
ES2795249T3 (en) 2013-03-15 2020-11-23 Translate Bio Inc Synergistic enhancement of nucleic acid delivery through mixed formulations
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014186366A1 (en) * 2013-05-13 2014-11-20 Tufts University Nanocomplexes for delivery of saporin
US10888622B2 (en) 2013-05-14 2021-01-12 Trustees Of Tufts College Nanocomplexes of modified peptides or proteins
DK3011029T3 (en) 2013-06-17 2020-03-16 Broad Inst Inc ADMINISTRATION, MODIFICATION AND OPTIMIZATION OF TANDEM GUIDE SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION
WO2014204727A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
EP3597755A1 (en) 2013-06-17 2020-01-22 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
MX2015017312A (en) 2013-06-17 2017-04-10 Broad Inst Inc Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy.
KR20160019553A (en) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
WO2014210356A1 (en) * 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
EP3013964B1 (en) * 2013-06-28 2020-05-06 ethris GmbH Compositions for introducing rna into cells
LT3019619T (en) 2013-07-11 2021-12-10 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
MX2016005236A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Cns delivery of mrna and uses thereof.
EP3501605B1 (en) 2013-10-22 2023-06-28 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
PE20161242A1 (en) 2013-10-22 2016-12-11 Massachusetts Inst Technology LIPID FORMULATIONS FOR THE ADMINISTRATION OF MESSENGER RNA
EP3060258A1 (en) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
WO2015089419A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
MX2016007328A (en) 2013-12-12 2017-07-19 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing.
RU2016128077A (en) 2013-12-12 2018-12-06 Те Брод Инститьют Инк. DELIVERY, APPLICATION AND APPLICATIONS IN THE THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TREATMENT OF CONDITIONED HBV AND VIRAL DISEASES AND DISORDERS
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CA2932436A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3110954A1 (en) 2014-02-26 2017-01-04 Ethris GmbH Compositions for gastrointestinal administration of rna
AU2015229750A1 (en) 2014-03-09 2016-09-15 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
US9215876B2 (en) 2014-03-24 2015-12-22 International Business Machines Corporation 1,3,6-dioxazocan-2-ones and antimicrobial cationic polycarbonates therefrom
US9624191B2 (en) 2014-03-24 2017-04-18 International Business Machines Corporation Cyclic carbonate monomers and ring opened polycarbonates therefrom
LT3122878T (en) 2014-03-24 2019-02-11 Translate Bio, Inc. Mrna therapy for the treatment of ocular diseases
CA3177878A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
AU2015249312B2 (en) 2014-04-25 2021-07-29 Translate Bio, Inc. Methods for purification of messenger RNA
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
AU2015266764B2 (en) 2014-05-30 2019-11-07 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
WO2015200465A1 (en) 2014-06-24 2015-12-30 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
BR112016030852A2 (en) 2014-07-02 2018-01-16 Shire Human Genetic Therapies rna messenger encapsulation
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US10736966B2 (en) 2014-08-12 2020-08-11 Massachusetts Institute Of Technology Brush-poly (glycoamidoamine)-lipids and uses thereof
GB201414464D0 (en) 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening
ES2780904T3 (en) 2014-08-17 2020-08-27 Broad Inst Inc Genomic editing using Cas9 nickases
ES2928500T3 (en) 2014-08-29 2022-11-18 Alnylam Pharmaceuticals Inc Patisiran for use in the treatment of transthyretin-mediated amyloidosis
WO2016036966A1 (en) 2014-09-04 2016-03-10 Preceres Inc. Hydrazinyl lipidoids and uses thereof
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
US9943595B2 (en) 2014-12-05 2018-04-17 Translate Bio, Inc. Messenger RNA therapy for treatment of articular disease
WO2016094342A1 (en) 2014-12-08 2016-06-16 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
EP3230451B1 (en) 2014-12-12 2021-04-07 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
US20180000953A1 (en) * 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3256487A4 (en) 2015-02-09 2018-07-18 Duke University Compositions and methods for epigenome editing
EP3900702A1 (en) 2015-03-19 2021-10-27 Translate Bio, Inc. Mrna therapy for pompe disease
WO2016168469A1 (en) * 2015-04-17 2016-10-20 The Regents Of The University Of California Fatty acid analogs and methods of use thereof
WO2016165831A1 (en) 2015-04-17 2016-10-20 Curevac Ag Lyophilization of rna
WO2016176191A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
CN107530448A (en) 2015-05-20 2018-01-02 库瑞瓦格股份公司 Include long-chain RNA dry powder composite
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
CA3012631A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
SG10201912329YA (en) 2015-06-18 2020-02-27 Broad Inst Inc Crispr Enzyme Mutations Reducing Off-Target Effects
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA2990172A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
GB2560250A (en) 2015-06-30 2018-09-05 Ethris Gmbh ATP-Binding cassette family coding polyribonucleotides and formulations thereof
WO2017015637A1 (en) 2015-07-22 2017-01-26 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
ES2842300T3 (en) 2015-07-31 2021-07-13 Alnylam Pharmaceuticals Inc Transthyretin (TTR) RNAi Compositions and Methods for Their Use for the Treatment or Prevention of TTR-Associated Diseases
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11427817B2 (en) 2015-08-25 2022-08-30 Duke University Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases
US10881682B2 (en) * 2015-08-26 2021-01-05 International Business Machines Corporation Therapeutic compositions comprising n-alkyl-hydroxy polymers
US11247968B2 (en) 2015-09-14 2022-02-15 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
LT3350157T (en) 2015-09-17 2022-02-25 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US20180334688A1 (en) 2015-10-13 2018-11-22 Duke University Genome engineering with type i crispr systems in eukaryotic cells
CA3024543A1 (en) 2015-10-22 2017-04-27 The Broad Institute, Inc. Type vi-b crispr enzymes and systems
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
ES2924407T3 (en) 2015-12-10 2022-10-06 Modernatx Inc Compositions and methods for the delivery of therapeutic agents
WO2017100744A1 (en) * 2015-12-11 2017-06-15 Preceres Inc. Aminolipidoids and uses thereof
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
JP7114465B2 (en) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of drugs
WO2017112852A1 (en) * 2015-12-23 2017-06-29 Preceres Inc. Modified polyethyleneimines and uses thereof
HRP20220525T1 (en) 2015-12-23 2022-05-27 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
MA43587A (en) 2016-01-10 2018-11-14 Modernatx Inc THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES
EP3440206B1 (en) 2016-04-08 2020-10-28 Translate Bio, Inc. Multimeric coding nucleic acid and uses thereof
US20200263190A1 (en) 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3026112A1 (en) 2016-04-19 2017-10-26 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
WO2017184768A1 (en) 2016-04-19 2017-10-26 The Broad Institute Inc. Novel crispr enzymes and systems
BR112018073699A2 (en) 2016-05-16 2019-05-07 The Board Of Regents Of The University Of Texas System amino cationic sulfonamide lipids and amphiphilic zwitterionic amino lipids
CN115919769A (en) 2016-05-16 2023-04-07 德克萨斯大学系统董事会 Compositions for delivering tRNA as nanoparticles and methods of use thereof
IL263079B1 (en) 2016-05-18 2024-01-01 Modernatx Inc Polynucleotides encoding relaxin
MA45050A (en) * 2016-05-18 2019-03-27 Modernatx Inc LIPOPROTEIN LIPASE CODING POLYNUCLEOTIDES FOR THE TREATMENT OF HYPERLIPIDEMIA
AU2017271665B2 (en) 2016-05-27 2023-11-23 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger RNA
BR112018075479A2 (en) * 2016-06-09 2019-03-19 Curevac Ag hybrid carriers for nucleic acid loading
US20190336608A1 (en) 2016-06-09 2019-11-07 Curevac Ag Cationic carriers for nucleic acid delivery
AU2017283479B2 (en) 2016-06-13 2023-08-17 Translate Bio, Inc. Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
CN109642231A (en) 2016-06-17 2019-04-16 博德研究所 VI type CRISPR ortholog and system
IL246378A0 (en) 2016-06-21 2016-11-30 Technion Res & Dev Foundation Hybrid muco-adhesive polymer/lipid drug delivery systems for treating oral cancers
US20210222164A1 (en) 2016-06-29 2021-07-22 The Broad Institute, Inc. Crispr-cas systems having destabilization domain
KR101816795B1 (en) 2016-06-30 2018-01-10 한국화학연구원 Novel tertiary amine-based polyol and preparation method of polyurethane using the same autocatalysts
CN110114461A (en) 2016-08-17 2019-08-09 博德研究所 Novel C RISPR enzyme and system
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3500270A1 (en) 2016-08-19 2019-06-26 Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal Mir-127 agents for use in the treatment of renal fibrosis
JP6778380B2 (en) * 2016-08-23 2020-11-04 昭和電工マテリアルズ株式会社 Adsorbent
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3538073A1 (en) 2016-11-10 2019-09-18 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US11400109B2 (en) 2016-11-10 2022-08-02 Translate Bio, Inc. Subcutaneous delivery of messenger RNA
US11464836B2 (en) 2016-12-08 2022-10-11 Curevac Ag RNA for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
US11464847B2 (en) 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine
DK3565891T3 (en) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res METHODS OF ALTERING GENE EXPRESSION BY DISRUPTING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS
ES2899323T3 (en) 2017-02-27 2022-03-10 Translate Bio Inc Messenger RNA purification methods
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
US10975369B2 (en) 2017-02-27 2021-04-13 Translate Bio, Inc. Methods for purification of messenger RNA
JOP20190200A1 (en) 2017-02-28 2019-08-27 Univ Pennsylvania Compositions useful in treatment of spinal muscular atrophy
MA47687A (en) 2017-02-28 2021-03-31 Univ Pennsylvania ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND ITS USES
CN110582572A (en) 2017-03-01 2019-12-17 宾夕法尼亚州立大学托管会 Gene therapy for ocular disorders
US10961184B2 (en) 2017-03-07 2021-03-30 Translate Bio, Inc. Polyanionic delivery of nucleic acids
US11739308B2 (en) 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
JP7220154B2 (en) 2017-03-15 2023-02-09 モデルナティエックス インコーポレイテッド Crystalline forms of amino lipids
RS63953B1 (en) 2017-03-15 2023-02-28 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
WO2018167320A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
SG11201906297QA (en) 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
AU2018251801A1 (en) 2017-04-12 2019-11-07 Massachusetts Institute Of Technology Novel type VI crispr orthologs and systems
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
US11879133B2 (en) 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
AU2018265531A1 (en) 2017-05-11 2019-11-14 The Trustees Of The University Of Pennsylvania Gene therapy for neuronal ceroid lipofuscinoses
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
US11793887B2 (en) 2017-05-31 2023-10-24 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
US20200268666A1 (en) 2017-06-14 2020-08-27 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3641834B1 (en) 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
EP3648791A1 (en) 2017-07-04 2020-05-13 CureVac AG Novel nucleic acid molecules
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
KR20200089656A (en) 2017-09-19 2020-07-27 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
EP3684397A4 (en) 2017-09-21 2021-08-18 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
JP2021501572A (en) 2017-10-19 2021-01-21 キュアバック アーゲー New artificial nucleic acid molecule
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
JP7423520B2 (en) 2017-11-16 2024-01-29 アストラゼネカ・アクチエボラーグ Compositions and methods for improving the efficacy of Cas9-based knock-in policies
EP3714048A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
MA50802A (en) 2017-11-22 2020-09-30 Modernatx Inc POLYNUCLEOTIDES CODING FOR ALPHA AND BETA SUB-UNITS OF PROPIONYL-COA CARBOXYLASE FOR THE TREATMENT OF PROPIONIC ACIDEMIA
MX2020005663A (en) 2017-11-30 2020-08-20 Univ Pennsylvania Gene therapy for mucopolysaccharidosis iiia.
JP7384797B2 (en) 2017-11-30 2023-11-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Gene therapy for mucopolysaccharidosis type IIIB
WO2019110067A1 (en) * 2017-12-07 2019-06-13 Aarhus Universitet Hybrid nanoparticle
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
CA3084061A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
MA51523A (en) 2018-01-05 2020-11-11 Modernatx Inc POLYNUCLEOTIDES CODING ANTI-BODY ANTI-CHIKUNGUNYA VIRUS
EP3746496A1 (en) 2018-02-02 2020-12-09 Translate Bio, Inc. Cationic polymers
CA3091543A1 (en) 2018-02-19 2019-08-22 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
CN110506035B (en) 2018-03-16 2022-08-12 株式会社东芝 Biodegradable compound, lipid particle, composition containing lipid particle, and kit
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
CN112292395A (en) 2018-04-17 2021-01-29 库瑞瓦格股份公司 Novel RSV RNA molecules and compositions for vaccination
JP2021522228A (en) 2018-04-25 2021-08-30 エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ Lipid-based formulations for RNA delivery
CA3097912A1 (en) 2018-05-15 2019-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger rna
AU2019271215A1 (en) 2018-05-16 2020-12-03 Translate Bio, Inc. Ribose cationic lipids
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
CN112437767B (en) 2018-05-24 2023-10-27 川斯勒佰尔公司 thioester cationic lipids
US20210213140A1 (en) 2018-05-30 2021-07-15 Translate Bio, Inc. Phosphoester Cationic Lipids
US20200016274A1 (en) 2018-05-30 2020-01-16 Translate Bio, Inc. Messenger rna vaccines and uses thereof
EP3802507A1 (en) 2018-05-30 2021-04-14 Translate Bio, Inc. Vitamin cationic lipids
CA3100214A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
CA3107055A1 (en) 2018-07-23 2020-01-30 Translate Bio, Inc. Dry powder formulations for messenger rna
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3830301A1 (en) 2018-08-01 2021-06-09 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
CA3106035A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Cas12b enzymes and systems
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
JP7171895B2 (en) 2018-08-29 2022-11-15 エコラボ ユーエスエー インコーポレイティド Multiply-charged ionic compounds derived from polyamines and compositions thereof, and methods for their preparation
AU2019333042A1 (en) 2018-08-29 2021-03-04 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
CN113164556A (en) 2018-08-30 2021-07-23 特纳亚治疗股份有限公司 Cardiac cell reprogramming with cardiac myoprotein and ASCL1
MA53545A (en) 2018-09-02 2021-07-14 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR VERY LONG CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
GB2606038B (en) 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
JP2021535226A (en) 2018-09-04 2021-12-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Compositions and Methods for Organ-Specific Delivery of Nucleic Acids
JP2021536250A (en) 2018-09-07 2021-12-27 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Compositions and Methods for Improved nucleases
MA53608A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR THE E1-ALPHA, E1-BETA AND E2 SUBUNITS OF THE BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX FOR THE TREATMENT OF LEUCINOSIS
MA53609A (en) 2018-09-13 2021-07-21 Modernatx Inc POLYNUCLEOTIDES ENCODED GLUCOSE-6-PHOSPHATASE FOR THE TREATMENT OF GLYCOGENOSIS
EP3849617A1 (en) 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
JP2022500444A (en) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. A polynucleotide encoding polypeptide A1, a family of uridine diphosphate glycosyltransferases for the treatment of Crigler-Najer syndrome
CN113164623A (en) 2018-09-18 2021-07-23 维恩维纽克公司 ARC-based capsids and uses thereof
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
US20210378962A1 (en) 2018-10-19 2021-12-09 Translate Bio, Inc. Pumpless encapsulation of messenger rna
WO2020097409A2 (en) 2018-11-08 2020-05-14 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
CA3115119A1 (en) 2018-11-08 2020-05-14 Translate Bio, Inc. Methods and compositions for messenger rna purification
CA3117882A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
EP3876914A2 (en) 2018-11-09 2021-09-15 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
US20220071905A1 (en) 2018-11-09 2022-03-10 Translate Bio, Inc. Peg lipidoid compounds
CA3117866A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
EP3880174A2 (en) 2018-11-12 2021-09-22 Translate Bio, Inc. Methods for inducing immune tolerance
CA3119976A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Cationic lipid compounds
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
TW202039534A (en) 2018-12-14 2020-11-01 美商美國禮來大藥廠 Kras variant mrna molecules
CN113453707A (en) 2018-12-21 2021-09-28 库瑞瓦格股份公司 RNA for malaria vaccine
WO2020142754A2 (en) 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
CN113412273A (en) 2019-01-07 2021-09-17 川斯勒佰尔公司 Compositions and methods for treating primary ciliary dyskinesia
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
MX2021010559A (en) 2019-03-07 2021-12-15 Univ California Crispr-cas effector polypeptides and methods of use thereof.
WO2020186213A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Novel nucleic acid modifiers
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
US11359291B2 (en) 2019-04-16 2022-06-14 Ecolab Usa Inc. Use of multiple charged cationic compounds derived from polyamines and compositions thereof for corrosion inhibition in a water system
US20220177423A1 (en) 2019-04-18 2022-06-09 Translate Bio, Inc. Cystine cationic lipids
US20220233444A1 (en) 2019-04-22 2022-07-28 Translate Bio, Inc. Thioester cationic lipids
US20220257724A1 (en) 2019-05-03 2022-08-18 Translate Bio, Inc. Di-thioester cationic lipids
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
MX2021013959A (en) 2019-05-14 2022-04-01 Translate Bio Inc Improved process of preparing mrna-loaded lipid nanoparticles.
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
IL288284B1 (en) 2019-05-22 2024-02-01 Massachusetts Inst Technology Circular rna compositions and methods
EP3976593A1 (en) 2019-05-31 2022-04-06 Translate Bio, Inc. Macrocyclic lipids
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
EP3986858A1 (en) 2019-06-21 2022-04-27 Translate Bio, Inc. Tricine and citric acid lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
MA56539A (en) 2019-06-24 2022-04-27 Modernatx Inc ENDONUCLEASE RESISTANT MESSENGER RNA AND USES THEREOF
EP3986480A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Messenger rna comprising functional rna elements and uses thereof
JP2022541740A (en) 2019-07-08 2022-09-27 トランスレイト バイオ， インコーポレイテッド Improved mRNA-loaded lipid nanoparticles and processes for making them
EP3997226A1 (en) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
JP2022542562A (en) 2019-07-23 2022-10-05 トランスレイト バイオ， インコーポレイテッド Stable composition and process of making mRNA-loaded lipid nanoparticles
US20220323542A1 (en) 2019-07-30 2022-10-13 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
AU2020328855A1 (en) 2019-08-14 2022-03-03 CureVac SE RNA combinations and compositions with decreased immunostimulatory properties
CN115023499A (en) 2019-08-16 2022-09-06 麻省理工学院 Targeted trans-splicing using CRISPR/Cas13
BR112022004759A2 (en) 2019-09-19 2022-06-21 Modernatx Inc Branched tail lipid compositions and compounds for intracellular delivery of therapeutic agents
EP4031561A1 (en) 2019-09-20 2022-07-27 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
CN114728176A (en) 2019-10-09 2022-07-08 川斯勒佰尔公司 Compositions, methods and uses of messenger RNA
CA3155074A1 (en) * 2019-10-18 2021-04-22 The Trustees Of The University Of Pennsylvania Lipid and lipid nanoparticle formulation for drug delivery
WO2021081058A1 (en) 2019-10-21 2021-04-29 Translate Bio, Inc. Compositions, methods and uses of messenger rna
ES2961245T3 (en) 2019-12-04 2024-03-11 Orna Therapeutics Inc Circular RNA compositions and methods
CA3162368A1 (en) 2019-12-20 2021-06-24 Shrirang KARVE Rectal delivery of messenger rna
JP2023508881A (en) 2019-12-20 2023-03-06 トランスレイト バイオ， インコーポレイテッド An improved process for preparing mRNA-loaded lipid nanoparticles
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
KR102198736B1 (en) 2020-01-15 2021-01-05 이화여자대학교 산학협력단 Lipid nanoparticles for in vivo drug delivery and uses thereof
US20230285297A1 (en) * 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
WO2021173840A1 (en) 2020-02-25 2021-09-02 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
CN115552022A (en) 2020-03-02 2022-12-30 特纳亚治疗股份有限公司 MicroRNA-controlled gene vector expressed by cardiac muscle cells
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
JP2023522848A (en) 2020-04-08 2023-06-01 アストラゼネカ・アクチエボラーグ Compositions and methods for improved site-specific modification
WO2021226463A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
EP4146342A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
CA3177940A1 (en) 2020-05-07 2021-11-11 Anusha DIAS Optimized nucleotide sequences encoding sars-cov-2 antigens
MX2022014258A (en) 2020-05-12 2023-02-22 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression.
EP4149556A1 (en) 2020-05-14 2023-03-22 Translate Bio, Inc. Peg lipidoid compounds
AU2021273502A1 (en) 2020-05-15 2023-02-02 Translate Bio, Inc. Lipid nanoparticle formulations for mRNA delivery
BR112022023554A2 (en) 2020-05-19 2023-04-11 Orna Therapeutics Inc CIRCULAR RNA COMPOSITIONS AND METHODS
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
US20230193311A1 (en) 2020-05-20 2023-06-22 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
EP3993828A1 (en) 2020-05-29 2022-05-11 CureVac AG Nucleic acid based combination vaccines
AU2021278984A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
CA3182026A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
WO2021247507A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
MX2022016528A (en) 2020-06-17 2023-06-02 The Trustees Of The Univ Of Pennsylvania Compositions and methods for treatment of gene therapy patients.
WO2022006527A1 (en) 2020-07-02 2022-01-06 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
KR20230038503A (en) 2020-07-13 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compositions useful for the treatment of Charcot-Marie-Tooth disease
US20230272052A1 (en) 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2022076562A1 (en) 2020-10-06 2022-04-14 Translate Bio, Inc. Improved process and formulation of lipid nanoparticles
IL301643A (en) 2020-10-07 2023-05-01 Regenxbio Inc Gene therapy for ocular manifestations of cln2 disease
WO2022076803A1 (en) 2020-10-09 2022-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2022081544A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US20220133631A1 (en) 2020-10-12 2022-05-05 Translate Bio, Inc. Process of preparing ice-based lipid nanoparticles
US20220160633A1 (en) 2020-11-09 2022-05-26 Translate Bio, Inc. Compositions for delivery of codon-optimized mrna
IL302625A (en) 2020-11-13 2023-07-01 Modernatx Inc Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
AU2021386737A1 (en) 2020-11-25 2023-07-13 Translate Bio, Inc. Stable liquid lipid nanoparticle formulations
CN116670152A (en) 2020-12-01 2023-08-29 宾夕法尼亚州大学信托人 Novel compositions having tissue-specific targeting motifs and compositions containing the same
CA3200192A1 (en) 2020-12-01 2022-06-09 Justin PERCIVAL Compositions and uses thereof for treatment of angelman syndrome
CN116829149A (en) * 2020-12-07 2023-09-29 塔夫茨大学信托人 Lipid compositions and methods of use thereof
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20220204889A1 (en) * 2020-12-23 2022-06-30 Ecolab Usa Inc. Non-cationic softeners and methods of use
CA3206285A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
EP4268851A1 (en) * 2020-12-24 2023-11-01 EnhancedBio Inc. Composition for preventing or treating cancer, containing lipid nanoparticles
JP2024504614A (en) 2021-01-14 2024-02-01 トランスレイト バイオ， インコーポレイテッド Methods and compositions for delivering mRNA-encoded antibodies
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
US20240091380A1 (en) 2021-02-01 2024-03-21 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022169508A1 (en) 2021-02-08 2022-08-11 The Board Of Regents Of The University Of Texas System Unsaturated dendrimers compositions,related formulations, and methods of use thereof
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4297728A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
EP4297722A1 (en) 2021-02-26 2024-01-03 Ethris GmbH Formulations for aerosol formation and aerosols for the delivery of nucleic acid
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204549A1 (en) 2021-03-25 2022-09-29 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
CN117377491A (en) 2021-03-26 2024-01-09 葛兰素史克生物有限公司 Immunogenic compositions
JP2024512669A (en) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Tanotransmission polypeptides and their use in the treatment of cancer
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
WO2022214522A2 (en) 2021-04-07 2022-10-13 Astrazeneca Ab Compositions and methods for site-specific modification
AU2022258312A1 (en) 2021-04-12 2023-10-26 The Trustees Of The University Of Pennsylvania Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
EP4326338A1 (en) 2021-04-19 2024-02-28 Translate Bio, Inc. Improved compositions for delivery of mrna
BR112023021971A2 (en) 2021-04-23 2024-02-20 The Trustees Of The Univ Of Pennsylvania COMPOSITIONS WITH BRAIN-SPECIFIC DIRECTION MOTIFS AND COMPOSITIONS CONTAINING THE SAME
EP4083227A1 (en) 2021-04-29 2022-11-02 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
WO2022248645A1 (en) 2021-05-27 2022-12-01 Astrazeneca Ab Cas9 effector proteins with enhanced stability
WO2022266096A1 (en) * 2021-06-14 2022-12-22 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
CN117881395A (en) 2021-07-01 2024-04-12 翻译生物公司 Compositions for delivery of mRNA
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
CA3171750A1 (en) 2021-07-30 2023-02-02 Tim SONNTAG Mrnas for treatment or prophylaxis of liver diseases
CN115724806A (en) * 2021-08-25 2023-03-03 广州谷森制药有限公司 Novel cationic lipid compound (II)
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
CA3230056A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023031855A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
WO2023044006A1 (en) 2021-09-17 2023-03-23 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
CA3233490A1 (en) * 2021-09-28 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell targeted delivery of therapeutic agents
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
WO2023056418A1 (en) * 2021-10-01 2023-04-06 The Trustees Of The University Of Pennsylvania Lipid nanoparticle (lnp) compositions and methods of use thereof
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023059806A1 (en) 2021-10-06 2023-04-13 Massachusetts Institute Of Technology Lipid nanoparticles for drug delivery to microglia in the brain
AR127312A1 (en) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CN115957187A (en) * 2021-10-09 2023-04-14 北京启辰生生物科技有限公司 Lipid nanoparticle composition and drug delivery system prepared from same
WO2023069397A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
TW202334080A (en) 2021-11-08 2023-09-01 美商歐納醫療公司 Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023086893A1 (en) 2021-11-10 2023-05-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
US11510975B1 (en) * 2021-11-29 2022-11-29 Replicate Bioscience, Inc. Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
WO2023102517A1 (en) 2021-12-02 2023-06-08 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023115013A1 (en) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
TW202340461A (en) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
TW202342064A (en) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023133574A1 (en) 2022-01-10 2023-07-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful for treatment of c9orf72-mediated disorders
CN114507195B (en) * 2022-01-14 2024-02-13 华南理工大学 Lipid compound, composition containing lipid compound and application of lipid compound
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN116554042A (en) * 2022-01-30 2023-08-08 康希诺生物股份公司 Novel ionizable lipids for nucleic acid delivery and LNP compositions and vaccines thereof
WO2023143601A1 (en) * 2022-01-30 2023-08-03 康希诺生物股份公司 Novel ionizable lipid used for nucleic acid delivery as well as lnp composition and vaccine thereof
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023183616A1 (en) 2022-03-25 2023-09-28 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
WO2023214405A1 (en) 2022-05-01 2023-11-09 Yeda Research And Development Co. Ltd. Reexpression of hnf4a to alleviate cancer-associated cachexia
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023242817A2 (en) 2022-06-18 2023-12-21 Glaxosmithkline Biologicals Sa Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
US20240042021A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN117164468B (en) * 2023-10-26 2024-01-30 南京澄实生物医药科技有限公司 Ionizable lipid compound and application thereof

Family Cites Families (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2580922A (en) 1942-09-19 1952-01-01 Nat Aluminate Corp Prevention of foaming in steam generation
US2759021A (en) 1951-01-19 1956-08-14 Armour & Co Substituted trimethylene diamines
US2647121A (en) 1951-02-02 1953-07-28 Ruth P Jacoby Diamine-bis-acetamides
US2819718A (en) 1953-07-16 1958-01-14 Isidore H Goldman Drainage tube
US2717909A (en) * 1953-09-24 1955-09-13 Monsanto Chemicals Hydroxyethyl-keryl-alkylene-ammonium compounds
US2844629A (en) 1956-04-25 1958-07-22 American Home Prod Fatty acid amides and derivatives thereof
GB866408A (en) 1957-10-21 1961-04-26 Arnold Hoffman & Co Inc Quaternary ammonium salts
US3096560A (en) 1958-11-21 1963-07-09 William J Liebig Process for synthetic vascular implants
US3170953A (en) 1960-09-06 1965-02-23 Dow Chemical Co N-hydroxymaleamic acid
NL269967A (en) 1960-10-05
DE1155118B (en) 1961-12-30 1963-10-03 Basf Ag Process for the preparation of sulfonamides substituted on the nitrogen atom
US3268576A (en) 1962-01-23 1966-08-23 American Cyanamid Co Di-alkanoic acid esters of 2, 2'-(ethylenedhino)-di-1-butanols
FR1378382A (en) 1962-12-01 1964-11-13 Sandoz Sa Amides of amino-propionic acid, usable in particular for the treatment of textile fibers
GB1072118A (en) 1962-12-01 1967-06-14 Sandoz Ag Amides of aminopropionic acid
BE642774A (en) 1963-04-02 1964-07-22
US3354209A (en) 1964-02-19 1967-11-21 Hercules Inc Poly(dihydroxyalkyl) tertiary amines
US3350325A (en) 1964-07-31 1967-10-31 Dow Chemical Co Water soluble polymer of diglycidyl ether and an alkanolamine
JPS5141663B1 (en) 1966-03-12 1976-11-11
US3682980A (en) 1966-10-31 1972-08-08 Mobil Oil Corp Aminobenzoquinones and aminonaphthoquinones as additives for imparting oxidative stability to organic compositions
JPS4822365B1 (en) * 1968-10-25 1973-07-05
US3542581A (en) 1968-11-05 1970-11-24 Eastman Kodak Co Method of de-aggregating oxonol dye-containing gelatin layers
NL143127B (en) 1969-02-04 1974-09-16 Rhone Poulenc Sa REINFORCEMENT DEVICE FOR A DEFECTIVE HEART VALVE.
JPS4822365Y1 (en) 1969-11-28 1973-06-29
JPS5210847B1 (en) * 1969-12-30 1977-03-26
US3614954A (en) 1970-02-09 1971-10-26 Medtronic Inc Electronic standby defibrillator
US3614955A (en) 1970-02-09 1971-10-26 Medtronic Inc Standby defibrillator and method of operation
GB1361627A (en) 1970-08-04 1974-07-30 Marumo H Detergent composition
US4258061A (en) 1970-08-07 1981-03-24 Pfizer Inc. Interferon induction in animals by amines
JPS5012146Y2 (en) 1971-07-27 1975-04-15
US3964861A (en) 1971-12-23 1976-06-22 Allied Chemical Corporation Alkoxylated aliphatic amines to inhibit ozone fading of dyed polyamides
JPS5122416B2 (en) 1972-11-11 1976-07-09
US3945052A (en) 1972-05-01 1976-03-23 Meadox Medicals, Inc. Synthetic vascular graft and method for manufacturing the same
US3805301A (en) 1972-07-28 1974-04-23 Meadox Medicals Inc Tubular grafts having indicia thereon
US4022833A (en) 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
GB1377449A (en) * 1973-04-02 1974-12-18 Sterling Drug Inc N,n-bridged-bis-2-alkyl-2-hydroxy ethylamine compounds
JPS49127908A (en) * 1973-04-20 1974-12-07
JPS5624664B2 (en) 1973-06-28 1981-06-08
US4013507A (en) 1973-09-18 1977-03-22 California Institute Of Technology Ionene polymers for selectively inhibiting the vitro growth of malignant cells
JPS5123537A (en) * 1974-04-26 1976-02-25 Adeka Argus Chemical Co Ltd KASOZAISOSEIBUTSU
GB1527592A (en) 1974-08-05 1978-10-04 Ici Ltd Wound dressing
US3956502A (en) * 1974-09-04 1976-05-11 Nalco Chemical Company Polyamine alcohols as microbiocides
US3995623A (en) 1974-12-23 1976-12-07 American Hospital Supply Corporation Multipurpose flow-directed catheter
JPS5813576B2 (en) 1974-12-27 1983-03-14 アデカ ア−ガスカガク カブシキガイシヤ Stabilized synthetic polymer composition
JPS5524302Y2 (en) 1975-03-31 1980-06-10
US4281669A (en) 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
DE2520814A1 (en) 1975-05-09 1976-11-18 Bayer Ag Light stabilisation of polyurethanes - using polymeric tert. amines from aliphatic diamines and (meth)acrylic esters or amides
DE2530243C2 (en) 1975-07-07 1985-03-07 Henkel KGaA, 4000 Düsseldorf Use of N-substituted aminoalkanols as antimicrobial agents
JPS5210847A (en) 1975-07-16 1977-01-27 Nippon Steel Corp Pinch roll
US4096860A (en) 1975-10-08 1978-06-27 Mclaughlin William F Dual flow encatheter
JPS5278924U (en) 1975-12-11 1977-06-13
JPS5278924A (en) 1975-12-26 1977-07-02 Hodogaya Chem Co Ltd Solubilization of dye in hydrocarbon solvent
CA1069652A (en) 1976-01-09 1980-01-15 Alain F. Carpentier Supported bioprosthetic heart valve with compliant orifice ring
US4134402A (en) 1976-02-11 1979-01-16 Mahurkar Sakharam D Double lumen hemodialysis catheter
US4072146A (en) 1976-09-08 1978-02-07 Howes Randolph M Venous catheter device
US4335723A (en) 1976-11-26 1982-06-22 The Kendall Company Catheter having inflatable retention means
US4099528A (en) 1977-02-17 1978-07-11 Sorenson Research Co., Inc. Double lumen cannula
US4140126A (en) 1977-02-18 1979-02-20 Choudhury M Hasan Method for performing aneurysm repair
US4265745A (en) 1977-05-25 1981-05-05 Teijin Limited Permselective membrane
US4182833A (en) 1977-12-07 1980-01-08 Celanese Polymer Specialties Company Cationic epoxide-amine reaction products
US4180068A (en) 1978-04-13 1979-12-25 Motion Control, Incorporated Bi-directional flow catheter with retractable trocar/valve structure
DE2960875D1 (en) 1978-04-19 1981-12-10 Ici Plc A method of preparing a tubular product by electrostatic spinning
US4284459A (en) 1978-07-03 1981-08-18 The Kendall Company Method for making a molded catheter
US4227533A (en) 1978-11-03 1980-10-14 Bristol-Myers Company Flushable urinary catheter
DE2903979A1 (en) 1979-02-02 1980-08-07 Henkel Kgaa Hydroxy-carboxylic acid amide derivs. - prepd. by acylating hydroxyalkyl alkylene di:amine and used as greying inhibitors in detergent compsns.
US4375817A (en) 1979-07-19 1983-03-08 Medtronic, Inc. Implantable cardioverter
JPS5682859A (en) 1979-12-11 1981-07-06 Sakura Color Prod Corp Ink composition
DE3010841A1 (en) 1980-03-21 1981-10-08 Ulrich Dr.med. 6936 Haag Uthmann CATHEDER
US4308085A (en) 1980-07-28 1981-12-29 Jenoptik Jena Gmbh Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts
US4339369A (en) 1981-04-23 1982-07-13 Celanese Corporation Cationic epoxide-amine reaction products
US4406656A (en) 1981-06-01 1983-09-27 Brack Gillium Hattler Venous catheter having collapsible multi-lumens
JPS588770A (en) 1981-07-09 1983-01-18 Sakura Color Prod Corp Ink composition for jet printing
US4475972A (en) 1981-10-01 1984-10-09 Ontario Research Foundation Implantable material
CS222448B1 (en) 1981-12-11 1983-06-24 Martin Capka Method of making the tetrakis /2-hydroxypropyl/ alkylendiamine
US4401472A (en) * 1982-02-26 1983-08-30 Martin Marietta Corporation Hydraulic cement mixes and processes for improving hydraulic cement mixes
US4568329A (en) 1982-03-08 1986-02-04 Mahurkar Sakharam D Double lumen catheter
US5201998A (en) 1982-05-28 1993-04-13 Ciba-Geigy Corporation Process for sizing paper with anionic hydrophobic sizing agents and cationic retention aids
US4546499A (en) 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
US4530113A (en) 1983-05-20 1985-07-23 Intervascular, Inc. Vascular grafts with cross-weave patterns
US4550447A (en) 1983-08-03 1985-11-05 Shiley Incorporated Vascular graft prosthesis
US4647416A (en) 1983-08-03 1987-03-03 Shiley Incorporated Method of preparing a vascular graft prosthesis
US5104399A (en) 1986-12-10 1992-04-14 Endovascular Technologies, Inc. Artificial graft and implantation method
US4571241A (en) 1983-12-16 1986-02-18 Christopher T Graham Urinary catheter with collapsible urethral tube
US4710169A (en) 1983-12-16 1987-12-01 Christopher T Graham Urinary catheter with collapsible urethral tube
US5197977A (en) 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US4737518A (en) 1984-04-03 1988-04-12 Takeda Chemical Industries, Ltd. Lipid derivatives, their production and use
US4562596A (en) 1984-04-25 1986-01-07 Elliot Kornberg Aortic graft, device and method for performing an intraluminal abdominal aortic aneurysm repair
US4782836A (en) 1984-05-24 1988-11-08 Intermedics, Inc. Rate adaptive cardiac pacemaker responsive to patient activity and temperature
GB8413911D0 (en) 1984-05-31 1984-07-04 British Petroleum Co Plc Encapsulating organic material
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4662382A (en) 1985-01-16 1987-05-05 Intermedics, Inc. Pacemaker lead with enhanced sensitivity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4860751A (en) 1985-02-04 1989-08-29 Cordis Corporation Activity sensor for pacemaker control
CA1320724C (en) 1985-07-19 1993-07-27 Koichi Kanehira Terpene amino alcohols and medicinal uses thereof
ATE77806T1 (en) 1985-08-05 1992-07-15 Miyoshi Yushi Kk PROCESSES FOR THE DEPOSITION OF METALS.
US4701162A (en) 1985-09-24 1987-10-20 The Kendall Company Foley catheter assembly
EP0233140B1 (en) 1986-01-10 1989-11-08 Ciba-Geigy Ag Lubricant additives containing sulphur and nitrogen
DE3616824A1 (en) 1986-05-17 1987-11-19 Schering Ag USE OF CURABLE RESIN MIXTURES FOR SURFACE COATINGS AND PRINTING INKS AND METHOD FOR THE PRODUCTION THEREOF
DE3780374D1 (en) 1986-07-31 1992-08-20 Irnich Werner FREQUENCY ADAPTING HEART PACEMAKER.
US4778825A (en) 1986-08-29 1988-10-18 The University Of Akron Macrophage stimulation by quadrol
US4960409A (en) 1986-09-11 1990-10-02 Catalano Marc L Method of using bilumen peripheral venous catheter with adapter
JPH0829776B2 (en) 1986-10-29 1996-03-27 東燃化学株式会社 Synthetic resin container and mold for manufacturing the same
US4720517A (en) 1986-11-24 1988-01-19 Ciba-Geigy Corporation Compositions stabilized with N-hydroxyiminodiacetic and dipropionic acids and esters thereof
US4873370A (en) * 1987-03-03 1989-10-10 Pennzoil Products Company Alkylene diamines for use in friction and wear reducing compositions
JPH0199679A (en) 1987-10-09 1989-04-18 Miyoshi Oil & Fat Co Ltd Method for fixing heavy metals in soil or solid waste
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
US5047540A (en) 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
US4892540A (en) 1988-04-21 1990-01-09 Sorin Biomedica S.P.A. Two-leaflet prosthetic heart valve
US5176661A (en) 1988-09-06 1993-01-05 Advanced Cardiovascular Systems, Inc. Composite vascular catheter
US5024671A (en) 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft
US5200395A (en) 1988-10-18 1993-04-06 Ajinomoto Company, Inc. Pharmaceutical composition of BUF-5 for treating anemia
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5141749A (en) * 1988-12-05 1992-08-25 Eastman Kodak Company Tetraamides and method for improving feed utilization
FR2645866B1 (en) 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US5122616A (en) * 1989-09-11 1992-06-16 Ethyl Petroleum Additives, Inc. Succinimides
US5101824A (en) 1990-04-16 1992-04-07 Siemens-Pacesetter, Inc. Rate-responsive pacemaker with circuitry for processing multiple sensor inputs
US5405379A (en) 1990-07-26 1995-04-11 Lane; Rodney J. Self expanding vascular endoprosthesis for aneurysms
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
JPH0765267B2 (en) 1990-08-22 1995-07-12 花王株式会社 Softening agent
DK0480667T3 (en) 1990-10-09 1996-06-10 Cook Inc Percutaneous stent construction
ATE120971T1 (en) 1990-12-19 1995-04-15 Osypka Peter PACEMAKER LEAD WITH AN INNER CHANNEL AND WITH AN ELECTRODE HEAD.
US5116360A (en) 1990-12-27 1992-05-26 Corvita Corporation Mesh composite graft
US5405363A (en) 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5545449A (en) * 1991-10-02 1996-08-13 Weyerhaeuser Company Polyether-reinforced fiber-based materials
US5151105A (en) 1991-10-07 1992-09-29 Kwan Gett Clifford Collapsible vessel sleeve implant
JP2684276B2 (en) 1991-11-27 1997-12-03 富士写真フイルム株式会社 Silver halide color photographic materials
US5284491A (en) 1992-02-27 1994-02-08 Medtronic, Inc. Cardiac pacemaker with hysteresis behavior
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
SE9200951D0 (en) 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
DE4218744C2 (en) 1992-06-04 1997-11-06 Schering Ag Process for the preparation of N-β-hydroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes
KR950702628A (en) 1992-08-01 1995-07-29 치세이 라 Antiallergic Agents
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5380778A (en) * 1992-09-30 1995-01-10 Minnesota Mining And Manufacturing Company Fluorochemical aminoalcohols
US5461223A (en) 1992-10-09 1995-10-24 Eastman Kodak Company Bar code detecting circuitry
JPH06211978A (en) * 1992-10-28 1994-08-02 Takeda Chem Ind Ltd New polyether polyol and production of polyurethane foam therefrom
US5300022A (en) 1992-11-12 1994-04-05 Martin Klapper Urinary catheter and bladder irrigation system
US5496362A (en) 1992-11-24 1996-03-05 Cardiac Pacemakers, Inc. Implantable conformal coil patch electrode with multiple conductive elements for cardioversion and defibrillation
US5716395A (en) 1992-12-11 1998-02-10 W.L. Gore & Associates, Inc. Prosthetic vascular graft
DE69424406T2 (en) 1993-02-19 2000-10-26 Nippon Shinyaku Co Ltd MEDICINAL COMPOSITION CONTAINING A NUCLEIC ACID COPOLYMER
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5697953A (en) 1993-03-13 1997-12-16 Angeion Corporation Implantable cardioverter defibrillator having a smaller displacement volume
FR2703055B1 (en) 1993-03-22 1995-07-07 Guerbet Sa New polyiodinated compounds, their preparation and their use as contrast agents for radiology.
US5624976A (en) 1994-03-25 1997-04-29 Dentsply Gmbh Dental filling composition and method
US5314430A (en) 1993-06-24 1994-05-24 Medtronic, Inc. Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use
FR2707289B1 (en) 1993-07-06 1995-08-11 Chemoxal Sa Process for the preparation of a hydroxylated compound of secondary or tertiary amine.
DE4325848A1 (en) 1993-07-31 1995-02-02 Basf Ag Process for the preparation of N- (2-hydroxyethyl) piperazine
EP0647462A1 (en) 1993-10-06 1995-04-12 The Kansai Electric Power Co., Inc. Method for removing carbon dioxide from combustion exhaust gas
US5609624A (en) 1993-10-08 1997-03-11 Impra, Inc. Reinforced vascular graft and method of making same
SE9303481L (en) 1993-10-22 1995-04-23 Berol Nobel Ab hygiene composition
WO1995013033A1 (en) 1993-11-08 1995-05-18 Lazarus Harrison M Intraluminal vascular graft and method
KR960705798A (en) 1993-11-24 1996-11-08 벤자민 에프 맥그로우 AMPHIPHILIC DERIVATIVES OF PIPERAZINE
US5464924A (en) 1994-01-07 1995-11-07 The Dow Chemical Company Flexible poly(amino ethers) for barrier packaging
FR2714830B1 (en) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
US5858747A (en) 1994-07-20 1999-01-12 Cytotherapeutics, Inc. Control of cell growth in a bioartificial organ with extracellular matrix coated microcarriers
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
JP2001523215A (en) * 1995-04-17 2001-11-20 イマークス ファーマシューティカル コーポレーション Hybrid magnetic resonance contrast agent
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5772694A (en) 1995-05-16 1998-06-30 Medical Carbon Research Institute L.L.C. Prosthetic heart valve with improved blood flow
US5679852A (en) 1995-06-02 1997-10-21 Schering Aktiengesellschaft Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5607385A (en) 1995-08-17 1997-03-04 Medtronic, Inc. Device and algorithm for a combined cardiomyostimulator and a cardiac pacer-carioverter-defibrillator
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
FR2740978B1 (en) 1995-11-10 1998-01-02 Ela Medical Sa IMPLANTABLE DEFIBRILLATOR / CARDIOVERVER ACTIVE MEDICAL DEVICE
DE19541788A1 (en) * 1995-11-09 1997-05-15 Max Planck Gesellschaft New fluoroalkyl-(poly)hydroxy hydrocarbon(s) with e.g. amino groups
FR2741066B1 (en) 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5913848A (en) 1996-06-06 1999-06-22 Luther Medical Products, Inc. Hard tip over-the-needle catheter and method of manufacturing the same
US5736573A (en) 1996-07-31 1998-04-07 Galat; Alexander Lipid and water soluble derivatives of drugs
JPH1099679A (en) 1996-09-30 1998-04-21 Kobe Steel Ltd Deodorant for basic gas
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6887665B2 (en) 1996-11-14 2005-05-03 Affymetrix, Inc. Methods of array synthesis
US6204297B1 (en) 1996-11-26 2001-03-20 Rhodia Inc. Nonionic gemini surfactants
JPH10197978A (en) 1997-01-09 1998-07-31 Mitsubishi Paper Mills Ltd Silver halide photographic sensitive material
FR2760193B1 (en) 1997-02-28 1999-05-28 Transgene Sa LIPIDS AND COMPLEXES OF CATIONIC LIPIDS AND ACTIVE SUBSTANCES, IN PARTICULAR FOR THE TRANSFECTION OF CELLS
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5945326A (en) 1997-03-20 1999-08-31 New England Biolabs, Inc. Method for cloning and producing the Spel restriction endonuclease
US5958894A (en) 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
JPH115786A (en) 1997-06-13 1999-01-12 Pola Chem Ind Inc Novel aminohydroxypropylpiperazine derivative
US6067471A (en) 1998-08-07 2000-05-23 Cardiac Pacemakers, Inc. Atrial and ventricular implantable cardioverter-defibrillator and lead system
JPH1180142A (en) 1997-09-05 1999-03-26 Pola Chem Ind Inc Production of diphenylalkyl compound
US6096075A (en) 1998-01-22 2000-08-01 Medical Carbon Research Institute, Llc Prosthetic heart valve
FR2774092B1 (en) 1998-01-26 2000-02-18 Air Liquide PROCESS FOR THE PREPARATION OF GRAFT POLYAZACYCLOALCANES ON SILICA GEL AND USE OF THE GRAFT COMPOUNDS
US6013429A (en) 1998-02-27 2000-01-11 Eastman Kodak Company Photographic element with new singlet oxygen quenchers
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6176877B1 (en) 1998-04-20 2001-01-23 St. Jude Medical, Inc. Two piece prosthetic heart valve
DE19822602A1 (en) 1998-05-20 1999-11-25 Goldschmidt Ag Th Process for the preparation of polyamino acid esters by esterification of acidic polyamino acids or transesterification of polyamino acid esters
NO313244B1 (en) 1998-07-08 2002-09-02 Crew Dev Corp Process for the isolation and production of magnesite or magnesium chloride
US6055454A (en) 1998-07-27 2000-04-25 Cardiac Pacemakers, Inc. Cardiac pacemaker with automatic response optimization of a physiologic sensor based on a second sensor
JP4898991B2 (en) 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー Sheathed medical device
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6169923B1 (en) 1999-04-23 2001-01-02 Pacesetter, Inc. Implantable cardioverter-defibrillator with automatic arrhythmia detection criteria adjustment
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
DK2280020T3 (en) 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
DE19937721A1 (en) 1999-08-10 2001-02-15 Max Planck Gesellschaft New diketopiperazines
AU780535B2 (en) 1999-08-27 2005-03-24 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US6358278B1 (en) 1999-09-24 2002-03-19 St. Jude Medical, Inc. Heart valve prosthesis with rotatable cuff
US6371983B1 (en) 1999-10-04 2002-04-16 Ernest Lane Bioprosthetic heart valve
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
US6370434B1 (en) 2000-02-28 2002-04-09 Cardiac Pacemakers, Inc. Cardiac lead and method for lead implantation
US6565960B2 (en) 2000-06-01 2003-05-20 Shriners Hospital Of Children Polymer composite compositions
IL138474A0 (en) 2000-09-14 2001-10-31 Epox Ltd Highly branched water-soluble polyamine oligomers, process for their preparation and applications thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020094528A1 (en) 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
JP2002167368A (en) 2000-12-01 2002-06-11 Nitto Denko Corp Alkyl group-substituted dendrimer and method for preparing the same
US20020192721A1 (en) 2001-03-28 2002-12-19 Engeneos, Inc. Modular molecular clasps and uses thereof
KR100823815B1 (en) 2001-04-23 2008-04-21 신에쓰 가가꾸 고교 가부시끼가이샤 Novel Tertiary Amine Compounds Having an Ester Structure and Processes for Preparing Same
FR2825370A1 (en) 2001-05-31 2002-12-06 Inst Nat Sante Rech Med KERATINOCYTES OBTAINED FROM MAMMALIAN EMBRYONIC STEM CELLS
US6656977B2 (en) 2001-07-20 2003-12-02 Air Products And Chemical, Inc. Alkyl glycidyl ether-capped polyamine foam control agents
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
EP2385122B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7132295B2 (en) 2001-11-09 2006-11-07 Bayer Aktiengesellschaft Isotopically coded affinity markers 3
DE10207178A1 (en) 2002-02-19 2003-09-04 Novosom Ag Components for the production of amphoteric liposomes
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7601367B2 (en) * 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
US20040028804A1 (en) 2002-08-07 2004-02-12 Anderson Daniel G. Production of polymeric microarrays
AU2003260724A1 (en) 2002-08-22 2004-03-11 Celltran Limited Cell culture surface
CA2504910A1 (en) 2002-11-04 2004-05-21 Ge Bayer Silicones Gmbh & Co. Kg Linear polyamino and/or polyammonium polysiloxane copolymers i
WO2004048345A2 (en) 2002-11-22 2004-06-10 Novo Nordisk A/S 2,5-diketopiperazines for the treatment of obesity
US6998508B2 (en) 2003-03-10 2006-02-14 Air Products And Chemicals, Inc. Tertiary alkanolamines containing surface active alkyl groups
US6737485B1 (en) 2003-04-22 2004-05-18 E. I. Du Pont De Nemours And Company Titanium chelate dispersions
US7619017B2 (en) 2003-05-19 2009-11-17 Wacker Chemical Corporation Polymer emulsions resistant to biodeterioration
EP1644479A4 (en) 2003-06-16 2008-04-23 Mark W Grinstaff Functional synthetic molecules and macromolecules for gene delivery
JP2005041845A (en) 2003-07-25 2005-02-17 Kawaken Fine Chem Co Ltd N-(2-hydroxyalkyl)-n-alkylaminocarboxylic acid composition, stimulus relieving agent for surfactant containing the same and method for producing the composition
WO2005028619A2 (en) 2003-09-15 2005-03-31 Massachusetts Institute Of Technology Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20050123596A1 (en) 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
US20050069590A1 (en) 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
AU2004287652A1 (en) 2003-11-10 2005-05-19 Nippon Kayaku Kabushiki Kaisha Diimonium salt compound and use thereof
US7022214B2 (en) 2004-01-21 2006-04-04 Bio-Rad Laboratories, Inc. Carrier ampholytes of high pH range
US7556684B2 (en) * 2004-02-26 2009-07-07 Construction Research & Technology Gmbh Amine containing strength improvement admixture
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
JP4510881B2 (en) 2004-04-20 2010-07-28 デンドリティック ナノテクノロジーズ，インコーポレイテッド Dendritic polymers with enhanced expandability and internal functionality
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
DE102004043342A1 (en) * 2004-09-08 2006-03-09 Bayer Materialscience Ag Blocked polyurethane prepolymers as adhesives
GB0502482D0 (en) 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
CA2599328C (en) 2005-02-23 2012-04-17 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
US7977452B2 (en) 2005-03-28 2011-07-12 Dendritic Nanotechnologies, Inc. Janus dendrimers and dendrons
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
ITMI20051155A1 (en) 2005-06-20 2006-12-21 Maflon S R L NEW FLUORURED COMPOUNDS, THEIR SYNTHESIS AND USE.
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
KR100716210B1 (en) 2005-09-20 2007-05-10 웅진코웨이주식회사 Preparation method of polyamide reverse osmosis composite membrane and polyamide reverse osmosis composite membrane prepared therefrom
WO2007073489A2 (en) 2005-12-22 2007-06-28 Trustees Of Boston University Molecules for gene delivery and gene therapy, and methods of use thereof
CN100569877C (en) 2005-12-30 2009-12-16 财团法人工业技术研究院 Contain the dendritic structural compounds of branch and the application thereof of many UV crosslinking reactive group
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
US20070275923A1 (en) 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
EP2032652A4 (en) 2006-06-05 2011-08-17 Massachusetts Inst Technology Crosslinked, degradable polymers and uses thereof
ES2293834B1 (en) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas COMPOSED WITH INHIBITING ACTIVITY OF UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS THERAPEUTIC APPLICATIONS.
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology End-modified poly(beta-amino esters) and uses thereof
EP2063887B1 (en) * 2006-08-30 2013-05-29 The Regents of the University of Michigan New small molecule inhibitors of mdm2 and the uses thereof
KR100905901B1 (en) 2006-09-07 2009-07-02 웅진코웨이주식회사 Amine aqueous solution for forming an active layer of polyamide reverse osmosis composite membrane, polyamide reverse osmosis composite membrane prepared thereby, and preparation method thereof
JP5076419B2 (en) 2006-09-19 2012-11-21 東ソー株式会社 Amine catalyst composition for producing polyurethane resin and method for producing polyurethane resin using the same
KR101129509B1 (en) 2006-10-03 2012-04-13 알닐람 파마슈티칼스 인코포레이티드 Lipid containing formulations
JP2008202015A (en) 2007-02-23 2008-09-04 Toyo Ink Mfg Co Ltd Pressure-sensitive adhesive composition
EP2139461A2 (en) * 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
JP2010522723A (en) * 2007-03-29 2010-07-08 ノバルティス アーゲー 3-Imidazolyl-indole for the treatment of proliferative diseases
JP5186126B2 (en) 2007-03-29 2013-04-17 公益財団法人地球環境産業技術研究機構 Novel triazine derivatives, their production and their use as gas separation membranes
WO2008137470A1 (en) 2007-05-01 2008-11-13 Pgr-Solutions Multi-chain lipophilic polyamines
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
NZ584048A (en) 2007-10-02 2012-08-31 Marina Biotech Inc Lipopeptides for delivery of nucleic acids
EP2225303A1 (en) 2007-12-27 2010-09-08 E. I. du Pont de Nemours and Company Hydroxy alkyl isocyanurates
WO2009086547A1 (en) 2008-01-03 2009-07-09 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
DE102008013500A1 (en) 2008-03-10 2009-09-17 Evonik Degussa Gmbh New chiral selectors and stationary phases for the separation of enantiomeric mixtures
JP5024216B2 (en) 2008-07-23 2012-09-12 トヨタ自動車株式会社 Ignition timing control device and ignition timing control method for internal combustion engine
EP2743265B1 (en) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
SG196818A1 (en) 2008-10-16 2014-02-13 Marina Biotech Inc Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
WO2010062322A2 (en) 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
WO2010053572A2 (en) * 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EP2377848B1 (en) 2008-12-26 2013-10-02 NOF Corporation Arginine derivative and cosmetic comprising same
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
ES2531009T3 (en) 2008-12-29 2015-03-09 Mannkind Corp Dicetopiperazine substituted analogs for use as agents for drug administration
US20100222489A1 (en) 2009-02-27 2010-09-02 Jiang Dayue D Copolymer composition, membrane article, and methods thereof
WO2010114789A1 (en) 2009-04-02 2010-10-07 The Siemon Company Telecommunications patch panel
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
US20120196923A1 (en) 2009-05-15 2012-08-02 Kaushal Rege Polymers for delivering a substance into a cell
ES2943333T3 (en) 2009-06-12 2023-06-12 Mannkind Corp Diketopiperazine microparticles with defined surface areas
JP5694320B2 (en) 2009-07-30 2015-04-01 ラボラトリオス・サルバト・ソシエダッド・アノニマＬａｂｏｒａｔｏｒｉｏｓ Ｓａｌｖａｔ， Ｓ．Ａ． APAF-1 inhibitor compounds
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
CA2782463A1 (en) 2009-12-11 2011-06-16 Chemseq International Ab Methods and compositions for complex binding of metal ions
GB0921871D0 (en) 2009-12-15 2010-01-27 Univ Leuven Kath Novel antifungal compounds
CN101863544B (en) 2010-06-29 2011-09-28 湖南科技大学 Cyanuric acid-based heavy metal chelating flocculant and preparation method thereof
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino alcohols), their preparation, and uses thereof
AP3391A (en) 2010-12-20 2015-08-31 Glenmark Pharmaceuticals Sa 2-Amino-4-arylthiazole compounds as TROA1 antagonists
JP5257528B2 (en) 2011-03-04 2013-08-07 東洋インキＳｃホールディングス株式会社 Crosslinkable composition
DK2691443T3 (en) 2011-03-28 2021-05-03 Massachusetts Inst Technology CONJUGIATED LIPOMERS AND USES OF THESE
WO2012133737A1 (en) 2011-03-31 2012-10-04 公益財団法人地球環境産業技術研究機構 Crosslinkable amine compound, polymer membrane using crosslinkable amine compound, and method for producing polymer membrane
EP2532649B1 (en) 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
ES2663360T3 (en) 2011-06-08 2018-04-12 Translate Bio, Inc. Cleavable lipids
KR102128248B1 (en) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
JO3115B1 (en) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
CL2014000988A1 (en) 2011-10-20 2014-11-03 Oryzon Genomics Sa Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency.
UA119028C2 (en) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі N-terminal functionalized amino acid derivatives capable of forming microspheres encapsulating the drug
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
JP5991937B2 (en) 2013-03-06 2016-09-14 Ｊｘエネルギー株式会社 Friction modifier and lubricating oil composition
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
KR101355583B1 (en) 2013-10-04 2014-01-24 한국지질자원연구원 Simplicity valuable mineral decollator and valuable mineral separating method using thereof
PE20161242A1 (en) 2013-10-22 2016-12-11 Massachusetts Inst Technology LIPID FORMULATIONS FOR THE ADMINISTRATION OF MESSENGER RNA
MX2016005236A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Cns delivery of mrna and uses thereof.
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CA2990172A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell

Also Published As

Publication number Publication date
US8450298B2 (en) 2013-05-28
US20190177289A1 (en) 2019-06-13
CN102245559A (en) 2011-11-16
EP2365962B1 (en) 2017-07-05
JP6637141B2 (en) 2020-01-29
US8969353B2 (en) 2015-03-03
CA2742954C (en) 2018-07-10
JP6087504B2 (en) 2017-03-01
MX2021001144A (en) 2021-04-13
ES2646630T3 (en) 2017-12-14
US20100331234A1 (en) 2010-12-30
MX353900B (en) 2018-02-01
WO2010053572A9 (en) 2010-07-22
CN104910025A (en) 2015-09-16
KR20110087311A (en) 2011-08-02
US10189802B2 (en) 2019-01-29
AU2009311667B2 (en) 2016-04-14
JP6902287B2 (en) 2021-07-14
MX2011004859A (en) 2011-08-03
WO2010053572A2 (en) 2010-05-14
US10844028B2 (en) 2020-11-24
EP3269395A1 (en) 2018-01-17
US20210101875A1 (en) 2021-04-08
AU2009311667A1 (en) 2011-06-23
US20150203439A1 (en) 2015-07-23
US9556110B2 (en) 2017-01-31
US20110293703A1 (en) 2011-12-01
JP6431027B2 (en) 2018-11-28
US11414393B2 (en) 2022-08-16
CA3006395A1 (en) 2010-05-14
CN102245559B (en) 2015-05-27
JP2012508235A (en) 2012-04-05
EP2365962A2 (en) 2011-09-21
CN104910025B (en) 2019-07-16
JP2017061563A (en) 2017-03-30
JP2019048839A (en) 2019-03-28
KR101734955B1 (en) 2017-05-12
CA3006395C (en) 2022-05-31
EP2365962A4 (en) 2013-08-14
JP2020063257A (en) 2020-04-23
US20170204075A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
US11414393B2 (en) Aminoalcohol lipidoids and uses thereof
US9006487B2 (en) Amine-containing lipids and uses thereof
US20120009222A1 (en) Modulation of the immune response
EP2640700A1 (en) Amine-containing transfection reagents and methods for making and using same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141010